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Isoflavones, the subclass of flavonoids found in soybeans, may reduce the risk of 
cardiovascular disease (CVD). However, the current evidence is inconsistent. The 
capability to produce the isoflavone metabolite equol in 20-60 % of the population might 
underlie the benefits of isoflavone intake on vascular health. In a retrospective analysis of 
a 12-month intervention containing isoflavones (100 mg isoflavones, as aglycones 
equivalents), postmenopausal women with Type 2 diabetes who were equol producers 
(EPs) had significantly lower diastolic blood pressure (BP), mean arterial BP and arterial 
stiffness (assessed by pulse wave velocity (PWV)) (mean change from baseline ()±SEM; 
-2.2±1.3 mmHg, -1.2±1.3 mmHg, -0.7±0.4 m/s, respectively, P<0.01) than non-EPs. 
Subsequently, an acute crossover double-blind study was conducted where EP and non-EP 
males at elevated heart disease risk were prospectively recruited (n=14 per group) to 
determine whether EP phenotype was associated with differential vascular responses. The 
effects of an isoflavone supplement (80mg; single-dose) on endothelial function, PWV and 
BP were assessed at baseline, and at the anticipated Tmax for plasma isoflavones (6h) and 
equol (24h). After isoflavone intake, EPs had significantly decreased PWV at 24h 
(±SEM: isoflavone -0.2±0.2, placebo +0.6±0.2; P<0.01). However, isoflavone intake had 
no effect on the vascular measures at the 6h and 24h timepoints. To further investigate the 
acute vascular effects of S-equol per se, synthetic S-equol supplements (40 mg) were 
consumed by non-EPs at the anticipated Tmax for plasma S-equol (2h) and this showed no 
significant vascular benefits.  
In conclusion, acute isoflavone intake improved arterial stiffness in male EPs at increased 
CVD risk, with the magnitude of change potentially equating to a 10-12% risk reduction 
in risk of CVD if sustained. Synthetic equol intake had no acute benefit on vascular health 
in non-EPs. These data suggest that the EP phenotype may partly predict the effectiveness 
of soy isoflavones on arterial stiffness. Further long term RCTs with prospectively 
recruited EPs are required to confirm the importance of equol production for 
cardiovascular health.  
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Chapter 1 Literature review: the effect of soy 
isoflavone intake on cardiovascular disease risk factors 
- potential role of equol 
 
1.1 Introduction  
Isoflavones are heterocyclic compounds found in soybeans and belong to the flavonoid 
family that have been studied extensively for their health effects. In particular, soy 
isoflavones may offer benefits on cardiovascular disease risk factors such as blood pressure  
[1], endothelial function [2, 3] and arterial stiffness [4].  
However, the evidence for health benefits is inconsistent [5-16] and the metabolic ability 
to produce the unique isoflavone metabolite equol might lead to differential health effects 
following isoflavone intake [17]. Between 20-60% of populations can produce equol from 
the major soy isoflavone daidzein, with the highest prevalence occurring in Asian 
populations [18]. Equol is of interest because it has higher bioavailability in vivo [19] and 
in vitro it has been shown to have greater antioxidant [20-22] and vascular benefits [23, 
24] compared to its parent compound. In addition, recent observational and retrospective 
analyses of intervention trials support the hypothesis that people who have the ability to 
produce equol may have better cardiovascular health [25-28] and may benefit more from 
isoflavone intakes that target cardiovascular disease risk factors [6].  
This chapter reviews cardiovascular disease development and risk factors, soy isoflavones 
and their effects on cardiovascular disease risk factors, the isoflavone metabolite equol and 
its role in explaining any potential benefits of isoflavones on vascular function, and briefly 
current knowledge on the bioavailability of isoflavone and the gut metabolite equol. 
 
 





1.2 Cardiovascular diseases and atherosclerosis 
Cardiovascular disease (CVD) is the main cause of death worldwide; 17.1 million deaths 
from CVD are estimated each year [29]. CVDs consist of coronary heart disease, cerebro-
vascular disease (i.e. stroke and ischemic heart attack) and peripheral vascular disease, all 
of which develop from atherosclerosis and thrombosis in the arteries [30]. Atherosclerosis 
is a thickening of the arterial lining, which is a consequence of the development of 
atheromatous plaques. Accumulated lipids within the arterial wall form foam cells that can 
progress into mature plaque with proliferation of connective tissue, adhesion of platelets, 
proliferation and migration of smooth muscle cells and infiltration of immune cells (Figure 
1.1). Plaques can grow and significantly reduce the blood flow through an artery and when 
the plaques rupture, thrombus (blood clot) occurs that can occlude the artery [31, 32].  
CVD risk factors include elevated plasma lipid levels [33], endothelium dysfunction [34], 
arterial stiffness [35] and hypertension [36]. Of importance, endothelial dysfunction, 
arterial stiffness and hypertension are demonstrated strong predictors of CVD risk [34, 37-





Figure 1.1 Development of atherosclerosis                                                                                                                                             









1.2.1 Endothelial dysfunction  
 
Endothelial dysfunction is implicated by the loss of sufficient dilation of an artery in 
reaction to endothelial-derived stimulus [41] and is a major early marker of the 
development of atherosclerosis and CVD [41]. Additionally, endothelial dysfunction is 
positively associated with CVD co-morbidities, such as hypercholesterolemia, 
hypertension, and type 2 diabetes mellitus [42]. Human studies have shown that dietary 
and lifestyle interventions such as diet rich in flavonoids could reverse endothelial 
dysfunction and in turn may prevent development of CVDs [43]. 
 
The mechanism by which the dysfunctional endothelium-dependent vasodilation occurs 
has been suggested through an imbalance of endothelium-derived vasodilators and 
contracting factors; particularly a decreased bioavailability of vasodilators and 
antithrombogenic factors such as nitric oxide (NO), and/or increased presence of 
vasoconstrictors and prothrombotic factors [43]. During endothelial dysfunction additional 
impaired activations in the endothelium take place that further lead to atherosclerosis 
progression, in particular decreased anticoagulation, increased levels of pro-inflammatory 
factors (adhesion molecules and cytokines) and elevated smooth muscle proliferation [44].  
 
Endothelial function can be measured at the coronary or peripheral circulation by a variety 
of techniques such as coronary angiography, flow-mediated dilation (FMD) of the brachial 
artery [41, 45], plethysmography of the forearm circulation, and finger plethysmography 
(using EndoPAT) [46]. The main principle for most of these techniques is the measurement 
of the dilatation of the coronary or brachial arteries, in response to a stimulus, either after 
intra-arterial infusion of exogenous vasodilators (acetylcholine or bradykinin), or post the 
occlusion of the artery (when the blood flow increases and creates an amplified tangential 
force or shear stress on the endothelium causing the dilatation of the vessel [47]). The shear 
stress derived hyperaemia reaction and the initiated endothelium-dependent changes in 
vascular tone [48] are most likely the result of the release of the most potent vasodilator in 
the endothelium, NO [34, 41].  
FMD measurement, using high-resolution ultrasound of the artery, is the most commonly 
used method for assessment of endothelium function. However, the limitation of using this 





method is that it is operator dependent, which requires extensive training, and the technique 
does not control for potential tone alterations in the systemic nervous system [49].  
As an operator independent alternative, finger plethysmography (using EndoPAT device) 
is widely used to assess endothelial function by measuring pulse wave profiles, following 
brachial artery occlusion, at a finger artery. The EndoPAT records changes in 
plethysmographic pressure caused by the arterial pulse in the finger and interprets it into a 
peripheral arterial tone (PAT). When using EndoPAT, measurements on the other arm are 
used to correct for any potential simultaneous endothelium-independent changes (for 
details, see Figure 3.5, page 97) [48].  
 
1.2.2 Arterial stiffness  
 
Increased arterial stiffness is positively associated with risk for fatal cardiovascular events 
including myocardial infarction and stroke [35] and it is also correlated with endothelial 
dysfunction and hypertension [38].  
Arterial stiffness is considered an important prognostic factor that has been targeted by 
human studies for protection against CVD development and in terms of the clinical 
importance, it has been shown in meta-analyses that reductions in PWV equal to 1 m/s 
might lead to 13-14% reduction in CVD risk [50]. A recent review reported that dietary 
components could improve arterial stiffness, in particular the flavonoid subclasses: 
isoflavones, anthocyanins and to a lesser extent flavan-3-ols [51]. 
 
During aging and/or development of CVD, the arteries become more stiff and in return 
less compliant, leading to an increase in cardiac muscle contraction to accommodate the 
resistant arteries and this might result in left ventricular hypertrophy (overstretch of cardiac 
walls) and cardiac failure over time [52]. 
Arterial stiffness originates from two different components, structural and dynamic  
alterations in the arterial wall [53] (Figure 1.2). The structural changes occurs in the arterial 
media layer as the collagen to elastin ratio increases, which might be due to elevated 
collagen, elastin fragmentation, arterial calcification, glycation of both elastin and 
collagen, and cross-linking of collagen by advanced glycation end- products (AGE) [53]. 
The cross-linking between collagen and elastin is essential for the strength and elasticity 





to the arteries. However, during ageing, cross-linking of collagen might increase due to 
cross-linking amino acids histidinoalanine and pentosidine in collagen itself, or due to an 
increase in the formation of AGE [54]. AGE are produced by the non-enzymatic glycation 
between the amino groups and sugars in proteins that build bridges between collagen fibres 
and thus decreases the elasticity of the arterial wall [53, 54].  The dynamic changes also 
occur in the arterial media layer and it is related to the tone of smooth muscle cells which 
depends on the release of vasodilators and vasoconstrictors from the endothelium such as 
Nitric Oxide (NO) [53]. This emphasizes the connection between arterial stiffness and 
endothelial dysfunction.  
 
Figure 1.2 The structure of an artery and arterial stiffness causes  
The arterial stiffness could be related structural (increased collagen to elastin ratio) and/or dynamic 
alterations (altered vascular tone induced by vasoactive compounds) in the arterial media layer. 
The media is the middle layer of the artery that is made up of elastic and collagen fibrils, smooth 
muscle cells, and elastic laminae. There are two other layers that compose the artery: the inner 
layer (intima) consisting of collagen fibrils, a single layer of endothelial cells, and a thin basal 
membrane, and the outer layer (adventitia) which is surrounded by loose connective tissue and has 
helically arranged collagen fibrils (figure is adapted from Tsamis et al., 2013 [54]).   
 
Arterial stiffness influences pulse wave reflections [52, 55]. Laurent et al. reviewed the 
most accepted model of the arterial tree: a propagative model that resembles a visco-elastic 
tube that has different elastic properties allowing the generation of a pressure wave which 
travels forward [55]. When the pressure wave travels down through a tube of numerous 





branches of decreased diameter, it is amplified as a result of going through the central 
arteries branching into peripheral arteries that are more muscular and less elastic where the 
resistance increases and creates reflected waves. In healthy arteries, the reflected waves 
arrive during late systole to diastole and subsequently contribute to the magnitude of 
diastole through constructive wave interference [55]. 
During CVD development, central arteries such as the carotid become stiffer and have a 
decreased diameter that repositions points of pulse wave reflections to earlier segments 
along the arterial tree. Thus, reflected waves will arrive to the heart closer to systole, 
augmenting it and delaying the diastole and in turn, this may result in overstretching of the 
cardiac walls and decreased coronary perfusion [38, 55].  
Arterial stiffness can be evaluated by different methods including regional stiffness (pulse 
wave velocity (PWV)), local stiffness (magnetic resonance imaging (MRI)), and arterial 
compliance and wave reflections (pulse wave analysis (PWA)) [38, 55].  The gold standard 
method is the central/aortic PWV that can be estimated between the carotid and femoral 
arteries [38, 55].   
 
1.2.3 Hypertension  
 
Hypertension is a major risk factor for CVD development and mortality [56]. It is highly 
associated with stroke, coronary and peripheral arterial diseases [56]. 
Hypertension is diagnosed in subjects who have persistently high blood pressure; with a 
systolic blood pressure equal or more than 140 mm Hg and/ or diastolic blood pressure 
equal or more than 90 mm Hg [56].  
Hypertension is likely to be reduced by fruit and vegetable-rich diets, particularly due to 
their flavonoid content [57]. A reduction of 2-3 mmHg in diastolic blood pressure in adults 
(50–69 years) could lead to 10-20% reductions in risk of stroke and coronary artery disease 
[58]. 
Two types of hypertension are frequently described: primary hypertension, which is due 
to increased total peripheral resistance, and isolated systolic hypertension, which is caused 
by increased pulse pressure [59]. In both instances, uncontrolled hypertension can cause 
cardiac perfusion and may result in cardiac arrest. High blood pressure can also cause 
aneurysms to develop in arteries that are associated with blood clots and their rupture [56]. 
The cause of hypertension is likely to include dysfunction of either the sympathetic 





nervous system [60], the renal renin-angiotensin aldosterone system [61], endothelial 
dysfunction, and/ or vascular inflammation [61, 62].  
 
As mentioned previously, all the discussed CVD risk factors could be modified by dietary 
factors, which could prevent CVD disease. In particular, intakes of flavonoids might 
provide protection against CVD development [13]. Recent meta-analyses suggest that soy 
isoflavone intake, a subclass of flavonoids, may improve endothelial function [2, 3, 13], 
arterial stiffness [4] and blood pressure [1].  
 
1.3 Isoflavones and cardiovascular disease (CVD) 
1.3.1 Soy isoflavones- Biological properties, chemical structure and soy 
content  
 
During the past 20 years, extensive research has investigated the cardio-protective effects 
of soy isoflavones [63, 64]. Isoflavones are natural heterocyclic phenols, present 
predominantly in soybeans. Research has identified around 370 isoflavones, with 
genistein, daidzein and glycitein as the major ones in soybeans [65]. The basic chemical 
structure of isoflavones consists of two benzene rings (A and B) bound to a heterocyclic 
pyrone ring (C) (Figure 1.3).  
 Isoflavones are classified as a subgroup of phytoestrogens since they have the potential to 
exert both oestrogen agonist and antagonist effects. This might be due to similarity in their 
chemical structure with the 17β oestradiol [66]. As potential selective oestrogen receptor 
modulators (SERMs) [67, 68], it has been suggested that isoflavones might have more 










Figure 1.3 Chemical structures of soy isoflavones  
Chemical structures are shown for major isoflavones in food: daidzein, genistein and glycitein 
existing as aglycones or glycosides that are bound to acetyl or malonyl groups (figure adapted 
from Anupongsanugool et al., 2005 [65]). 
 
Daidzein, genistein and glycitein are the aglycone forms, while daidzin, genistin, and 
glycitin are the glycoside forms that are found mainly in soy food and products, which are 
often bound to acetyl or malonyl groups.  
The soy isoflavone content and composition vary in different soy foods according to the 
cultivation, environmental conditions and processing methods [69]. For instance, 
isoflavone levels may range from 2.66 isoflavones mg/g protein in roasted soybeans to 
0.73 mg/g protein in soy protein concentrate (Table1.1). This loss of isoflavone is due to 











Table1.1 Isoflavone content of soy foods and products 
Soy food and products  Mean total isoflavone content 
(mg/g of food) 
Soybeans (green, raw) 0.49 
Soybeans (mature seeds, sprouted, raw)          0.34 
Soybeans (roasted) 2.66 
Soy flour (textured)                     1.72 
Soy protein isolate                                 0.91 
Soy protein concentrate 0.73 
Miso soup (mix, dry)                                     0.07 
Tempeh                                                 0.61 
Tofu (silken)                                                   0.18 
Tofu yogurt                                                           0.16 
Soy hot dog (frozen, unprepared)                     0.01 
Soy milk (original, vanilla)                                             0.18
Soy sauce                             0.01 
Table adapted from Bhathena et al., 2002 & USDA., 2008 [70, 71].                                                            
 
1.3.2 Epidemiology - Soy isoflavone intake and CVD 
 
In Asian countries the intake of isoflavones has been estimated to range from 25–50 mg 
per day [72, 73], whereas the population in the UK is thought to consume just 1 mg per 
day [74, 75]. This greater habitual intake of isoflavones in Asian countries may be one 
contributor to the low incidence of CVD in this region.  
Some epidemiological research suggests that dietary intake of soy isoflavones may protect 
against CVD initiation and progression [73, 76-79].  A large cohort with 18 years follow 
up has shown that nuts and soy intakes were two of most important independent 
contributors to decreased overall and CVD mortality [76]. It was also reported that higher 
isoflavone intake was positively associated with enhanced endothelial function and better 
clinical atherosclerotic symptoms in patients with coronary artery disease (CAD) or stroke 
[78].  





1.3.3 Randomised controlled trials (RCTs) - the effects of soy 
isoflavones on CVD risk factors  
 
Cardio-protective effects of soy isoflavones have been investigated in human RCTs such 
as improvements in the plasma lipid profile, hemodynamic and endothelial function [5-
16]. In particular, benefits of soy isoflavones on lipid lowering cholesterol levels have been 
reported extensively [64]. Recent meta-analyses suggest that the cardio-protective effects 
of soy intake are related mainly to its constituent isoflavones [3] and they extend beyond 
enhanced lipids to benefits on endothelial function [2, 3, 13], arterial stiffness [4] and blood 
pressure [1]. It has been shown that infusion of 10 to 300 nmol/min of genistein caused 
NO-dependent vasodilation in the brachial artery with comparable efficiency to 17β-
oestradiol in male and female subjects [80]. Subsequently, a meta-analysis of 9 RCTs has 
also shown that isoflavone supplement intake significantly improved endothelial function 
(assessed by FMD) only in postmenopausal women at increased CVD risk having low 
FMD levels, but not in those with high FMD levels at baseline [2].  
Furthermore, a more recent meta-analysis of 17 RCTs providing 33-120 mg/d (as 
isoflavone aglycones) for 4-52 weeks, has shown a potentially clinical relevant increase of 
1.98 % in FMD in women and men by isolated isoflavone intake alone compared to an 
FMD increase of 0.72 % by isoflavone containing soy protein [3].  
Another meta-analysis of 14 RCTs has shown that intakes of 25-375 mg soy isoflavones 
(as aglycone units) for 2-24 weeks significantly improve hemodynamic function 
(estimated decrease of 1.92 mmHg in systolic blood pressure) in subjects with normal 
blood pressure or pre-hypertension [1]. Regarding effects on arterial stiffness, few studies 
have shown improvements on PWV and/or systemic artery compliance (SAC) in response 
to isoflavone supplementation [81-83]. Nestel et al. [82] showed enhanced SAC in 21 peri- 
and post-menopausal women following intake of 80 mg per day  isoflavone (1.3:1:0.1, 
genistein, daidzein, glycitein respectively) for 5 weeks. Similarly, a 6 week intake of 80 
mg per day (red clover isoflavones, precursors for daidzein and genistein) significantly 
increased SAC and lowered PWV in 80 healthy men and postmenopausal women [81].  
Interestingly, few trials investigated effects of isoflavone metabolites, and one of them 
showed that consumption of the isoflavone metabolite trans-tetrahydrodaidzein (THD) (1g 
per day for 5 weeks) significantly decreased central PWV and systolic BP in 25 
postmenopausal women and overweight men [84].  





In contrast, some studies have reported no effects or contradictory findings [15, 16]. A 6 
month intake of dietary soy protein (118 mg as isoflavones aglycone) observed no 
improvements on endothelial function, arterial stiffness or ambulatory blood pressure in 
41 hypertensive men and women [16]. Similarly, a large RCT [15] reported no significant 
change in endothelial function in 202 postmenopausal women after an intervention of soy 
protein (99 mg isoflavones/d for 12 months) and systolic BP increased in the soy group 
compared to the placebo group.  
These equivocal data might be explained by different reasons such as study populations, 
isoflavone dose and source, consumption duration, collection time of endpoints and inter-
individual variability in metabolism in particular the ability to produce a unique isoflavone 
called “equol”.  For instance, the time of collection of study endpoints might be a crucial 
determinant for findings and it is suggested that the vascular benefits of isoflavones could 
be positively related to the bioavailable levels of isoflavones and their metabolites [9]. A 
single dose of 80 mg isoflavones has showed significant increases in FMD and plasma 
Nitric Oxide concentrations (NO) in postmenopausal women at the anticipated peak time 
for the major isoflavones daidzein and genistein [9].  
Additionally, it is believed that the matrix of the consumed isoflavones affects their 
bioavailability and thus isoflavones consumed as pure compounds, or dietary source may 
generate differential health effects [85]. It has been previously reported that isoflavone was 
more bioavailable from a supplement source than from soy based cheese (food source) 
[86]. This might be because the dietary matrix contains lipids, proteins and carbohydrates 
that bind to isoflavones and limit or delay their absorption, or due to isoflavone losses or 
structure conversions through multiple cooking steps like heating and grinding steps [87]. 
Therefore, the source of isoflavone intake may induce significant changes to its 
bioavailability and in turn vascular bioactivity. From the Beavers et al. meta-analysis, it is 
suggested that consumption of isolated isoflavone supplements could improve endothelial 
dysfunction more than isoflavone containing soy protein [3]. However, one recent study 
has shown that whole soy intake significantly reduced plasma levels of lipid and 
inflammation markers among prehypertensive postmenopausal women and these effects 
were not showed after consumption of purified daidzein [88].  





1.3.4 The vascular protective effects of soy isoflavones: mechanism of 
actions and potential biomarkers  
 
From the available evidence, the most beneficial effects of isoflavone interventions tend 
to be improvements in the endothelial dysfunction, which is an early step in the progression 
of atherosclerosis that results from lipid deposition, inflammation and oxidative stress in 
the arteries [34].  
In vivo and in vitro studies have been undertaken to examine how isoflavones exert their 
vasodilation effect, in particular focusing on mechanisms that underlie endothelial 
vasodilation and constriction [39]. The endothelium has crucial functions in blood vessels: 
it modulates immune responses, regulates coagulation and clotting, and controls the 
vascular tone through vasodilation and vasoconstriction [89]. NO is an essential 
endothelial-derived vasodilator that is produced from the conversion of L-citrulline to L-
arginine by endothelial nitric oxide synthase (eNOS) [90]. The maintenance of an adequate 
level of endothelial NO can protect the vessels against atherosclerosis because it promotes 
vaso-relaxation, inhibits migration of adjacent vascular smooth muscle cells (VSMC), 
prevents platelet aggregation and expression of monocyte adhesion and adhesion 
molecules [89]. However, under abnormal physiological conditions, NO is thought to be 
lost through reaction with reactive oxygen species (ROS) to form peroxynitrites (ONOO-) 
[89, 91].  
It has been proposed that the positive effects of chronic and acute exposure to isoflavones 
on endothelial function are explained by elevated bioavailable levels of NO [9, 92] and 
this could be a result of increased expression of eNOS [93, 94] or due to reduced activity 
of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase. NADPH normally 
generates superoxide (O2·−)  that binds to NO and forms peroxynitrite (ONOO−) and thus 
reduces the bioavailable NO [95]. 
Furthermore, some in vitro work has reported that daidzein and genistein induce increased 
prostacyclin (PGI2) production (i.e. a vasodilator and inhibitor of platelet aggregation) 
[96].  Two in vitro and in vivo studies have also shown a significant increase in PGI2 
production in human umbilical vein cells (HUVEC) treated with serum obtained from post-
menopausal women consuming isoflavones (55 mg/ day, for 6 months) compared to 
treatment with baseline serum [97]. An additional proposed mechanism underlying the 





vascular actions of isoflavones might involve inhibition of endothelial-derived 
vasoconstrictors such as Endothelin-1 [11, 98] and angiotensin converting enzyme (ACE) 
[39, 99]; both are part of the Ang II-induced hypertension that occurs in endothelial 
dysfunction and vascular inflammation (Figure 1.4) [61, 100]. 
 
Figure 1.4 Pathway of Ang II-induced hypertensionAng I is converted to Ang II by ACE 
and then Ang II binds to the Ang I receptor that lead to ROS generation through activation of 
NADPH oxidase. NADPH oxidase-derived superoxide (O2·−) reacts with NO to form 
peroxynitrite (ONOO−). Both O2·− and ONOO− increase production of mitochondrial ROS 
leading to mitochondrial dysfunction. The mitochondria release H2O2 that induces ET-1 and 
further activate NADPH oxidase. Collectively, these lead to elevated ROS production and 
reduced NO bioavailability, which contributes to increased endothelial dysfunction and 
vasoconstriction and may result in hypertension. ACE, Angiotensin converting enzyme; Ang, 
Angiotensin; ET-1, Endothelin-1; NADPH, Nicotinamide adenine dinucleotide phosphate 
hydrogen; NO, Nitric oxide, ROS, reactive oxygen species (figure adapted from Fukai., 2009 










Potential effects of isoflavones on insulin resistance 
 
Results from RCTs suggest that consumption of soy isoflavones may have positive effects 
on insulin resistance [14, 101-104]. In such studies insulin resistance is generally estimated 
using the homeostatic model assessment-insulin resistance (HOMA-IR) [105, 106], which 
is considered as an independent predictor of CVD [107, 108]. It is likely that part of the 
insulin sensitising benefits on CVD are related to the role of insulin in vascular function 
[109]. Insulin stimulates vaso-relaxation by NO production via phosphoinositide 3-kinase/ 
protein kinase B (PI3K/Akt) pathway, and in contrast, it induces vasoconstriction by ET-
1 secretion through the mitogen-activated protein kinase (MAPK) pathway (Figure 1.5). 
Insulin resistance creates endothelial imbalance by selectively defect PI3K/Akt pathway 
[110] and/or up-regulation of Ang II-induced pathway [111].  
 
It has also been shown that soy isoflavone reduces insulin resistance in rats, which was 
accompanied by reduced levels of inflammatory markers such as resistin [112].  
Resistin is a cytokine that is secreted by adipose and circulating mononuclear cells [113]. 
It is suggested as an important marker of vascular inflammation and atherosclerosis [114-
117]. Human studies have also reported that plasma levels of resistin are positively 
correlated with severity of coronary heart disease, hypertension [118, 119] and 
development of heart failure even after adjusting for insulin resistance [120]. 
 In vitro work has shown that resistin down regulated eNOS expression via increased 
production of mitochondrial ROS and activation of MAPK proteins in human coronary 
endothelial cells. This down-regulation was reversed by treatment with antioxidants [121]. 
Additionally, resistin has been shown to selectively impair the insulin-induced IRS-1 
(insulin receptor substrate-1) pathway that activates eNOS and vaso-relaxation in 













Figure 1.5 Antagonistic insulin-evoked pathways in endothelium 
Binding of insulin to its own tyrosine kinase receptor; results in activation of IRS-1/PI3K, with 
subsequent phosphorylation of Akt and activation of eNOS leading to increase NO levels. In 
contrast, insulin can activate the Ras/Raf/mitogen-activated protein kinase (MAPK) branch that 
increases the secretion of ET-1.  Akt, protein kinase B; eNOS, endothelial nitric oxide synthase; 
IRS-1, Insulin receptor substrate-1 (IRS-1); MAPK, mitogen-activated protein kinase; NO, Nitric 
oxide; PI3K, phosphatidylinositol 3-kinase (figure adapted from  Potenza et al., 2009 [110]).  
  
Analyses of vascular-related biomarkers in RCTs and differential effects of isoflavones and 
metabolites 
 
Few human studies have been conducted to investigate the effect of isoflavone 
interventions on the previously discussed vascular-related biomarkers such as NO, ET-1 
and resistin (Table 1.2). In two studies, levels of NO have been shown to significantly 
increase following isoflavone consumption, while data were not conclusive on ET-1 and 
resistin. Yet further human studies to investigate related biomarkers that might unravel the 
mechanism of bioactivity of isoflavones in vascular health. 
Different bioactivity of different isoflavones and their metabolites might explain the 
inconsistent health benefits reported in isoflavone supplementing RCTs [123-125]. It has 
also been reported that genistein increases eNOS expression more than that of daidzein in 
vitro [126]. These differential effects might be due to different produced metabolites that 
are suggested to be more physiologically active; such as 3‘-OH-genistein, 3‘-, 6-, and 8-
OH-daidzein and in particular the gut daidzein metabolite equol [127].   





Table 1.2 Effects of isoflavones intake on vascular-related biomarkers in published 
RCTs 
Biomarker Isoflavones RCTs Outcome  
ET- 1   117 healthy postmenopausal women, 50 
mg/d soy isoflavone (genistein-to-
daidzein, 2:1), 8 weeks [10] 
no effect  
 30 healthy postmenopausal women, 50 
mg/d soy isoflavones (genistein-to-
daidzein, 2:1), 8 weeks [11] 
 
no effect 
 79 healthy postmenopausal women, 54 
mg/d genistein, 1 year [98] 
            reduced 
NO   79 healthy postmenopausal women, 54 
mg/d genistein, 1 year [98] 
 
increased 
 22 healthy postmenopausal women, 80 
mg isoflavones of soy bean extract, 
acute phase [9] 
 
increased   
 Resistin   33 men with prostate cancer, 20 g soy 





 75 healthy postmenopausal women, 20 g 
soy protein (160 mg total isoflavones: 
genistein 64 mg, daidzein 63 mg, and 
glycitein 34 mg), 12 weeks [5] 
 
no effect 
ET-1, Endothelin-1; NO, Nitric Oxide; RCT, Randomised controlled trials. 
 





1.4 Potential role of equol on the vascular effects of soy 
isoflavones 
 
1.4.1 Equol - biological importance, and discovery  
  
 Equol is an isoflavone metabolite that has been proposed to be more potent than its parent 
compound daidzein, exhibiting higher binding affinity for the oestrogen receptor [129], 
antioxidant activity [130] and more vascular bioactivity [24, 131].  Equol has shown 
similar oestrogenic activity to genistein and activated transcription of oestrogen receptors 
more strongly than other isoflavones [132].  Furthermore, it has been reported that equol 
and its metabolites (4-hydroxy- and 5-hydroxy- equol) are more potent antioxidants 
relative to daidzein, genistein and their glycosylated forms [133].  
 
Equol was discovered in the urine of pregnant mares in 1932 by Marrian and Haslewood 
during experiments to isolate oestrone [134]. This compound was thought to be a 
contaminant of the hormone hydroxyestrin. Crystallization of the ether-soluble phenolic 
fraction of toluene extracts of the urine by chloroform led to extracting appreciable 
quantities of this compound from the urine of both pregnant and non-pregnant mares. 
Therefore, it was concluded that this compound was not specifically linked to pregnancy 
and not associated with high levels of oestrogenic hormones. Further, multiple analytical 
applications allowed its chemical structuring, and it was called “equol” due to its equine 
source [18, 135]. Further research showed that sheep grazing on clover in South Western 
Australia developed a reproductive disease called clover disease and subsequent analytical 
studies showed that those infertility symptoms were due to significantly high circulating 
levels of equol metabolised from the isoflavone formononetin in the clover plant [18]. 
Formononetin is demethylated by human hepatic enzymes to yield the major soy 
isoflavones genistein and daidzein [136].  In 1982, Axelson et al. was the first to find equol 
in human blood and urine after consuming soy by comparing it to the sample isolated in 
1932 and this discovery led to the valuable scientific finding of soy as a food source rich 
in isoflavones [137, 138]. Afterwards, it was defined that equol is exclusively metabolised 
by the intestinal microflora from the soy isoflavone daidzein. However, there is a high 





inter-subject variability in the levels of excretion of equol in humans. Research has shown 
that only 25%-30 % of Western individuals are equol producers, i.e., can metabolise 
daidzein to equol after soy consumption [6, 139, 140], whereas 50–60% of Asian and 
western vegetarian subjects are equol producers [141]. To accurately assess the equol 
production status it is essential to challenge with sufficient amounts of daidzein and allow 
for a sufficient transit time until the substrate reaches the distal colon and obtains optimal 
intra-luminal redox conditions activating the microbiological reaction [18]. Multiple 
methods have been developed with variable soy challenge periods and cutoffs [17, 142, 
143] such as an urinary detection limit of more than 0.68 nmol/mL [144]. However, this is 
criticized, since low levels of equol appear in the urine of all humans consuming animal-
derived foods like Cow’s milk [145]. Setchell et al. developed a standard method [141] 
that is independent of the amount of daidzein ingested and of different analytical methods 
measuring isoflavones [26, 144].  
                
1.4.2 Equol - Chemical structure and biological properties 
 
Equol is chemically known as 7-hydroxy-3-(4′-hydroxyphenyl)-chroman, 4′.7-
isoflavandiol, or 4′,7-dihydroxyisoflavan, and its formal name is 3,4-dihydro-3-(4-
hydroxyphenyl)-2H-1-benzopyran-7-ol. It has the molecular composition of C15H14O3 
and a molecular weight of 242.27 g/mol [18]. Equol is a non-polar, insoluble and chiral 
molecule with an asymmetric centre at position C-3. Thus, it can exist as two distinct 
optically active isomers R- (+) and S- (-) equol [18] (Figure1.5). It has been shown that 
both equol isomers have higher binding affinity for oestrogen receptor (ER) α and ER β 
than that of the parent compound daidzein [146]. However, these enantiomers have shown 
different biological and chemical effects. S-equol has a more planar shape, which makes it 
structurally more similar to oestradiol, and hence it possesses higher binding affinity to 
oestrogen receptors compared to R-equol and daidzein [147]. An early in vitro study 
showed that S-equol had four times the molar binding affinity of daidzein to oestrogen 
receptors [147]. S-equol also shows higher binding affinity to ERβ than to ERα, while the 
R-equol shows higher binding affinity to ERα than to ERβ. It was reported that the relative 
binding affinities of the S and R-enantiomers were  at around 20 % and 1 % of that of 17 
β-oestradiol for ERβ and 0.47 % and 2 % of that of 17 β-oestradiol for ERα, respectively 





[129]. The oestrogenic binding affinities of the S-equol were also similar to that of the 
most oestrogenic isoflavone genistein. In conclusion, the order of binding affinities to ERs 
is reported to be S-equol≈Genistein > R-equol > Daidzein [146]. S-equol is considered a 
selective oestrogen receptor modulator (SERM) because of its selective affinity to bind 
ERβ. This is of particular importance for postmenopausal health because isoflavones and 
S-equol as SERMs may offer an alternative for synthetic oestrogen replacement therapies 
that have been associated with an increased risk of breast and endometrial cancers [64]. 
On the other hand, R-equol showed chemo-preventative effects in an animal model which 
was not apparent with S-equol [148]. Despite the different biological actions of S-equol 
and R-equol, both were shown to be antagonists for dihydrotesterone which suggest a 
potential role for equol in  androgen-related diseases such as prostate cancer or skin disease 
[125, 149].  
                                                              
        S- (-) equol                                                                         R- (+)-equol                                                                          
Figure 1.6  The two enantiomers of equol, S- (-) equol and R- (+) equol.  
 
1.4.3 Methods for quantification of equol concentrations in biological 
samples  
 
Equol concentration can be quantified in blood and urine by electrospray ionisation liquid 
chromatography-mass spectrometry (LCMS) or gas chromatography-mass spectrometry 
(GC-MS) techniques. First, biological samples are hydrolysed by glucuronidase and 
sulfatase enzymes, extracted, and undergo a preparation method of volatile derivatives in 
the case of GC-MS analysis [127] or injected into LCMS [150].  





S- and R-equol are quantified separately by chiral-phase high performance liquid 
chromatography (HPLC) method; the identification of S- and R-equol depends on the 
retention time of the eluting peak relative to the mass chromatograms of pure standards of 
S- and R-equol analysed under identical conditions [129]. Alternatively, other analytical 
methods have been developed to analyse racemic equol in the urine such as time-resolved 
fluoroimmunoassay [151] and enzyme-linked immunoassay (ELISA) [152].  
Most studies have used the racemic form of equol while each isomer should be studied 
individually, since they possess different biological actions [129]. The form S-equol is of 
more interest because it is more structurally similar to oestrogen and posseses higher 
binding affinity to oestrogen receptors than daidzein and R-equol (as mentioned earlier in 
section 1.4.2, page 27). In addition, S-equol is exclusively found in the urine and plasma 
of equol producer mammals after consuming soy, and it is the only form produced by the 
human intestinal bacteria [129].  
 
1.4.4 Synthesis of S-equol (SE5OH) supplements  
 
Equol can be synthesised from daidzein by catalytic hydrogenation and because of the 
different properties of the two equol isomers experimental methods have been developed 
for the selective synthesis of S-equol and R-equol [153].  S-equol has been found to be 
produced by microbiological reactions. For example, Otsuka Pharmaceutical Co., Ltd has 
developed a natural S-equol supplement, called SE5-OH, which is the standardized soy-
based product of fermentation, sterilisation and drying of a soy germ solution with the 
lactic acid bacterium Lactococcus garvieae (20-92 strain).  In evaluation of toxicity and 
safety of SE5-OH, it has been reported to be not genotoxic and has a no-observed-adverse-
effect-level (NOAEL) of 13 mg equol/kg/day [154]. Therefore, SE5-0H supplements 
would be a source of natural S-isomer equol that could be utilised in human interventions 
to assess the potential effects of equol proposed by in vitro and animal research.  
 
 





1.4.5 Vascular effects of equol and potential mechanisms of action  
 
In cell culture and animal studies, treatment with equol has been shown to induce beneficial 
effects on endothelial function (Table 1.3) and antioxidant status or defence system (Table 
1.4). Moreover, equol showed higher bioactivity, in particular greater vasodilation [23, 24]  
(Table 1.3) and antioxidant effects [20-22], than its parent compound daidzein and other 
major isoflavones (Table 1.4).  
An in vitro study supports evidence of vasodilation effects of equol using endothelial cell 
models e.g. human umbilical endothelial cells (HUVECs) and human aortic endothelial 
cells (HAECs). Treatments of 1-100 nmol/L equol for 2 minutes caused rapid relaxation 
of endothelium intact aortic rings in a dose-dependent manner which was inhibited by pre-
treatment with 100 µmol/L of the NOS inhibitor L-NAME (N-nitro-L-arginine methyl 
ester) [93]. Equol caused a rapid increase in cGMP accumulation which was inhibited by 
L-NAME and subsequently it was proposed that equol stimulated the endothelium to 
release NO at resting cytosolic Ca+2 levels by activation of extracellular signal-regulated 
kinase (ERK) 1/2 and protein kinase B (AKt) [93]. Additionally, equol induced vaso-
relaxation in normotensive rats independent of an intact endothelium, K+ channels, NOS 
activity and gender. Similar findings were obtained for daidzein. This study also compared 
equol and daidzein, showing that equol induced vaso-relaxation during angiotensin II-
induced hypertension, while daidzein did not. Equol also displayed a weak antioxidant 
ability assessed as reduced NADPH-induced superoxide levels in the basilar artery 
compared to negligible ability by daidzein. It was concluded that equol has stronger vaso-
relaxant effect during hypertension compared to daidzein and thus it could be more potent 
therapeutic tool against cerebral vascular disease [23].  
 
In addition, in porcine and human pulmonary arterial endothelial cells equol has been 
shown to reverse detrimental effects induced by HIV protease inhibitor ritonavir  (HIV PI 
RTV) such as increased oxidative stress (expressed by superoxide production), eNOS 
down-regulation and vasomotor dysfunction in arterial rings [155]. Treating fresh porcine 
pulmonary artery rings with 15 µmol/L of RTV for 24 hr significantly reduced the 
endothelium-dependent relaxation induced by bradykinin and this effect was regressed by 
treatment with 0.1, 1, 10 µmol/L of equol in a dose-dependent manner. Using two cultures 





of human pulmonary artery endothelial cells (HPAEC) and the porcine pulmonary arteries, 
it was shown that equol reversed the detrimental effects of RTV including reduction of 
eNOS expression, and production of superoxide anion [155].   
More recently, a putative pathway was proposed to explain the acute vasodilation effects 
of equol [94]. It suggested that equol stimulated the endothelium to release NO by 
activation of ERK 1/2 and AKt, which leads to phosphorylation of eNOS (at serine1177). 
The suggested pathway relates the kinase activation to transactivation of G-protein coupled 
receptor 30 (GPR30)/epidermal growth factor receptor (EGFR). Subsequently, EGFR 
activation leads to ERK 1/2 activation via proto-oncogene c‐Src, whilst mitochondrial 
reactive oxygen species (ROS) facilitate AKt activation via phosphoinositide 3-kinase (PI‐
3K) (Figure 1.7). Furthermore, brachial artery infusion of dehydroequol (a potential 
precursor of equol) metabolite at 3 μmol/min in forearm resistance arteries in six healthy 
men, resulted in a dose-dependent increase in forearm blood flow and these responses were 
diminished by inhibition of eNOS [156].  
 
Figure 1.7 Proposed mechanism underlying vasodilation effects of equol 
Equol induces endothelial vasodilation through kinase activation, and subsequently NO production 
with the involvement of mitochondrial derived ROS. Kinase activation might be related to the 
transactivation of GPR30/ EGFR by equol. Activated EGFR stimulates ERK 1/2 activation via 
activation of proto-oncogene c‐Src. While mitochondrial reactive ROS activates Akt via activation 
of PI‐3K. The two activated proteins ERK 1/2 and Akt then induce phosphorylation of eNOS to 
release NO. AKt, protein kinase B; c-Src, proto-oncogene; EGFR, epidermal growth factor 
receptor; ERK 1/2, extracellular signal-regulated kinase; GPR30, G-protein coupled receptor 30; 
ROS, reactive oxygen species (figure adapted from Rowlands et al., 2011 [94]).  
ERK 1/2 





Equol has also shown antioxidants effects on LDL modification and its implication in 
endothelial cell injury and atherosclerosis development (Table 1.4). Equol has been shown 
to inhibit H2O2-induced apoptosis via reduced levels of intracellular ROS in bovine aortic 
endothelial cells and in human umbilical vein endothelial cells (HUVECs) [157]. Another 
study examining macrophages similarly reported that equol inhibited LDL oxidation and 
modification through reduced superoxide production and increased intracellular NO levels. 
However, this study suggested that these effects may be due to inhibition of NADPH 
oxidase activity instead of an upregulation of eNOS [20].  
One important aspect to note is that almost all of the reviewed in vitro studies have used a 
racemic mixture of equol (50:50) for their investigations and it is worthwhile to investigate 
any differential effects between the two enantiomers S-equol and R-equol.   





Table 1.3 Effects of equol on vascular function in cell culture and animal studies 
Reference Study model Findings  
[24] Ex vivo platelet study Equol had antagonistic effects on the thromboxane A2 (TXA2) receptor (membrane surface 
receptor that is involved in platelet aggregation and vascular smooth muscle contraction). Out of 
all major isoflavones tested, including genistein, daidzein and glycitein, equol was found to have 
the highest binding affinity to the TXA2 receptor. 
 
[93] HUVECs and HAECs Treatments of 1-100 nmol/L equol for 2 minutes caused rapid relaxation of endothelium intact 
aortic rings in a dose-dependent manner, which was inhibited by pre-treatment with 100 µmol/L of 
the NOS inhibitor L-NAME.  
 
[23] Carotid and basilar 
arteries isolated from 
normotensive and 
hypertensive rats 
Equol induced vaso-relaxation independent of an intact endothelium, K+ channels, NOS activity 
and gender and similar findings were obtained for daidzein in normotensive rats. However, in 
hypertension, equol has been shown to induce vasodilation while there was no response following 
daidzein treatement 
AKt, protein kinase B; ERK, extracellular signal-regulated kinase; HAECs, Human aortic endothelial cells; HUVECs, Human umbilical vein 











Table 1.4 Antioxidant effects of equol in cell culture and in vitro studies 
Reference Study model Findings  
[155] Porcine and human 
pulmonary arterial 
endothelial cells 
Equol has been shown to reverse detrimental effects induced by HIV PI RTV such as increased 
oxidative stress, eNOS down-regulation and vasomotor dysfunction  
[157] Bovine aortic endothelial 
cells  
 
Equol has been shown to inhibit H2O2-induced apoptosis via reduced levels of intracellular ROS  
[20] Macrophages Equol inhibited LDL oxidation and modification through reduced superoxide production and 
increased intracellular NO levels 
 





Equol induced activity and protein expression of catalase and total superoxide dismutase (which are 
essential in the antioxidant defence system) to a greater extent than daidzein 
[22] In vitro oxidation of  
lipoproteins in serum 
Equol inhibited lipoproteins oxidation more efficiently than genistein and approximately 10 times 
better than daidzein 
eNOS, endothelial Nitric oxide synthase; HIV PI RTV, HIV protease inhibitor ritonavir; HUVECs, Human umbilical vein endothelial cells; LDL, 
Low density lipoprotein; NADPH, Nicotinamide adenine dinucleotide phosphate.





Potential beneficial effect of equol on insulin sensitivity have been also proposed and 
studied recently using C3H10T1/2 and 3T3-L1 cell lines (i.e. mouse cell models to study 
adipocyte differentiation [158]). It was demonstrated that equol at 1 mol/L significantly 
increased adipocyte differentiation and insulin-stimulated glucose uptake through 
activation of peroxisome proliferator-activated receptor-gamma (PPARγ) [159]. These 
data may explain the potential insulin-sensitizing effects of soy isoflavones because 
PPARγ is a nuclear transcription factor that regulates responsiveness to insulin in adipose 
cells and thus it is a target for anti-diabetic drugs that enhance insulin resistance [160].  
 
Collectively, these in vitro data support further investigations to examine cardio-protective 
effects of equol in vivo. 
 
1.4.6  Cross-sectional studies: equol producer phenotype and CVD 
factors 
 
The previous in vitro studies support the potential role of the isoflavone metabolite equol 
on vascular health and suggest that the capability to produce the bioactive metabolite equol 
might explain benefits of isoflavone intake on vascular function. 
Cross-sectional studies have investigated possible beneficial associations between equol 
producer status and CVD risk factors. Four out of five recent observational studies have 
shown that the equol producer phenotype is associated with reduced levels of various CVD 
risk factors in mostly Asian populations (Table 1.5). When equol producers were compared 
to non-equol producers, they had better cholesterol profiles, lower triglycerides (TG) [25, 
26], free fatty acids (FFA) [25], leptin, leptin/BMI [27], waist to hip ratios [26], free fat 
mass [25] in a variety of populations including healthy subjects, postmenopausal 
prehypertensive, pre-diabetic, or diabetic individuals. Few of these studies investigated 
blood pressure [25, 26, 28] and inflammatory biomarkers such as uric acid [26] and hs-
CRP [25]. Equol producers were reported to have lower blood pressure than non-equol 
producers in two studies [25, 28] while one study showed no difference between the two 
groups [26]. Overall, the available data from observational studies on Asian populations 
suggests positive association between equol producer phenotype and better cardio-
metabolic health and this might be partly related to their high daily intake of isoflavone  
(up to 50 mg [63]).   





1.4.7  Isoflavone interventions: equol producer phenotype and CVD 
factors 
 
A variety of isoflavone RCTs investigated if equol producer phenotype predicts the 
efficiency of soy isoflavones interventions on circulating lipid profile, blood pressure, 
inflammation and metabolic markers; 5 out of 7 studies have reported more profound 
benefits in equol producers than non-equol producers mainly on plasma lipids (Table 1.6). 
All of these studies have followed a retrospective analysis quantifying urinary or plasma 
equol levels to stratify between equol and non-equol producers. Two isoflavone RCTs have 
shown greater benefits on vascular function (FMD, and blood pressure) in equol producers 
compared to non-equol producers and the reported mean concentrations of plasma equol 
were 105 nmol/L [6], and 190 nmol/L [15] in equol producers.  
Kreijkamp-Kaspers et al. [15] showed that 12 month consumption of soy protein (99 mg 
isoflavones aglycone equivalents/day) in postmenopausal women resulted in trends 
towards a decreased systolic and diastolic blood pressure and an enhanced endothelial 
function (assessed by FMD) in the equol producer compared to non-equol producer. 
Additionally, a 4 week intervention of soy germ-rich pasta (33 mg isoflavone 
aglycones/day) induced significant improvements in endothelial function (assessed by 
FMD) in hypercholesterolemia equol producer men and women [6].  Soy germ pasta was 
selected because it is rich in aglycones like fermented soy products that contribute the most 
to the Asian diet and thus it might exert more beneficial health effects based on the 
supporting evidence from observational data (Table 1.6).  
Meyer et al. did not show effects on vascular function including blood pressure and arterial 
compliance. However, only equol producing subjects (women and men, mildly hyper-
cholesterolemic and/or hypertensive) had significantly enhanced lipid profiles, including 
significantly reduced total cholesterol, LDL cholesterol, LDL: HDL-cholesterol ratio, TG 
and lipoprotein (a) after consuming the soy diet (80mg isoflavone aglycones units per day 
for 5 weeks) [161]. Likewise, Wong et al. has also shown significant reductions of LDL-
cholesterol levels after 4 week consumption of soy food (10-73 mg isoflavones aglycones) 
in 43 postmenopausal females and 42 males with high cholesterol profile. Moreover, these 
effects were more profound in equol producers that maintained significantly higher levels 
of HDL-cholesterol compared to non-equol producers [162].  In contrast, two studies 





reported no differential effects of isoflavone interventions on plasma glucose, insulin, lipid 
metabolism and inflammatory biomarkers between equol producers and non-equol 
producers [10, 163]. 
The current literature on RCTs that retrospectively analysed equol producer phenotype 
supports a potential role of equol producer phenotype on the effectiveness of soy 
isoflavones interventions on lipid profile and inflammatory markers. However further 
investigations are required on the vascular function in particular endothelial function, 
arterial stiffness and blood pressure. In addition, there is a need for trials which 
prospectively recruit based on equol producer phenotype to investigate further if equol 
producers benefit more from isoflavone interventions than non-equol producers. 
To date, only one study has been conducted which had prospectively recruited equol 
producers and non-equol producers to study their differential vascular responses after 
isoflavone intake. This clinical study prospectively screened postmenopausal women for 
equol production ability and found that equol producers had significantly lower systolic 
and diastolic blood pressure and mean arterial pressure, and better endothelial function 
than non-equol producers did at enrolment to the study independent of isoflavone intake 
[164-166]. The non-significant responses to isoflavone supplementation in the latter trial 
might (in part) contribute to the study limitations, i.e. use of oestrogen replacement therapy 
and non-matching of equol and non-equol producers for vascular function.  
This variability in previous data can be explained by different study designs such as 
isoflavone dose, source, study populations, consumption duration, equol production 
assessment method, outcome measurement time and inter-individual variability depending 
on their health status. Additionally, the limitations of retrospective analysis that does not 
provide causality between equol producer phenotype and CVD risk, nor answers whether 
there are subtle differences in CVD risk in equol and non-equol producers.   
Consequently, robust RCTs are required to examine if the equol producer phenotype 
explains the potential benefits of isoflavones interventions on vascular function, 
particularly endothelial function and arterial stiffness. Additionally, in order to confirm the 
bioefficacy of equol, it is of interest to investigate its direct health effects per se in vivo 
and the possibility of achieving benefits on vascular function by equol supplements in 
people who lack the endogenous ability to produce equol.  
To date, there have been only few RCTs that reported potential benefits of equol 
supplements. These focused mainly on improving postmenopausal symptoms such as 





intensity and frequency of hot flashes, muscle pain, and bone density loss [167-170].     
Only one study considered metabolic-related markers and one secondary vascular outcome 
(Cardio-Ankle Vascular Index (CAVI)). It has been shown that daily consumption of 10 
mg, 20 mg or 40 mg S-(-)equol (SE5OH) supplements for 8 weeks significantly reduces 
the frequency of hot flushes, intensity of muscle and joint pain more than isoflavone intake 
(48 mg isoflavone aglycones units) in postmenopausal women [170]. Notably, the dose of 
40 mg/day was more beneficial in decrease the frequency of hot flashes than isoflavones 
in women who had more than 8 hot flashes per day. Similarly, a trial showed that daily 
consumption of 10 mg S-(-)equol (SE5OH)  supplements for 12 weeks significantly 
reduces the intensity of hot flashes, neck or shoulder muscle stiffness in non-equol 
producer postmenopausal women [169]. Another RCT of 54 overweight/obese equol and 
non-equol producers showed that the same dose of SE5OH supplements for 12 weeks 
improved metabolic-related biomarkers, including reduced circulating levels of glycated 
haemoglobin (HbA1c), and LDL- cholesterol. In addition, there were decreased levels of 
CAVI, which is a marker of the arterial stiffness of the artery from the aortic valve to the 
peripheries (in the ankle) independent of blood pressure [168].  However, the latter study 
showed greater effects in the female non-equol producer group, but it had a limitation in 
the method used to identify equol producer phenotype that might have been implicated by 
their analysis method and limit of detection of equol [168].  
It is also notable that many of the previously reviewed RCTs have limited their sample 
population to postmenopausal women, and there is a gap in studying other population 
subgroups and in particular the response in males.





Table 1.5 Summary of cross-sectional studies on associations between equol producer phenotype and CVD risk factors 




Confounding factors adjusted 
for 
Outcome 
[26] 100 women and 102 






50% None EPs showed lower serum uric acid, TG, and 
waist/hip, higher HDL cholesterol than 
non-EPs, and no difference on BP 
[28] 633 women and 758 
men, Korean, healthy, 
average 53 y 
 
habitual intake 70% Area, sex, age, smoking and 
alcohol consumption 
EPs showed lower diastolic BP than non-
EPs 
[144] 100 women and 100 






60% BMI  No association between plasma lipids or 
uric acid and EP phenotype 
[25] 595 postmenopausal 
women, Chinese, pre-
hypertensive, 48-70 y 
 
7 day daidzein 
challenge 
53% Age, menopausal year, physical 
activity, dietary energy, 
isoflavone and fat intake (for  
BP and body composition) and 
BMI (for TG, FFA and hs-CRP) 
 
EPs had lower systolic and diastolic BP, 
serum TG, FFA, hs-CRP and higher fat free 
mass than non-EP 
[27] 34 men and 45 women, 
Japanese, pre-diabetic 
or diabetic patients, NA 
for age 
 NA NA NA EPs showed lower leptin and leptin/BMI 
than non-EPs in women only. 
BP, Blood pressure; BMI, Body mass index, EP, Equol producer; FFA, Free fatty acids; HDL, High density lipoprotein, hs-CRP; high sensitivity-C-
reactive protein; NA, No available data (abstract access only); TG, Triglycerides.  





Table 1.6 Summary of interventional studies that investigated beneficial effects of isoflavone and equol producer phenotype on CVD 
risk factors 







[171] 97 postmenopausal 
women, healthy,  
>60 y 
Serum equol, retrospective  
analysis, no challenge, >20 
nmol/l 
 
49% 105 mg, soy protein 
and/ isoflavone 
aglycones units, 12 mo 
EPs showed significantly reduced total 
Cholesterol/HDL-C, LDL/HDL-C from 
baseline at 12 mo but data were not 
significantly different from non-EPs.  
 
Plasma: 190  
[15] 202 women, 
postmenopausal, 
healthy, 60–75 y 
plasma equol, retrospective  
analysis, no challenge, >83 
nmol/L 
 
30% 99 mg, soy protein 
powder, 12 mo 
EPs showed trends towards decreased 
systolic and diastolic BP, and increased 
FMD, and these data were in the 
opposite direction in non-EPs 
 
NA 
[161] 10 women and 13 
men, mildly hyper- 
cholesterolemic 
and/or 
hypertensive, 54 y 
(mean) 
 
plasma equol, retrospective  
analysis, no challenge, if 
detected in plasma/urine 
35% 80 mg, soy 
milk/yogurt, 5 wk 
EPs had significantly reduced total 
Cholesterol, LDL-C, LDL/HDL-C, TG 
and lipoprotein (a) after soy intervention 
compared to placebo, and there was no 






women, 60 y (mean) 
 
Urine equol, retrospective 
analysis, ≥1000 nmol/d and 
log 
 equol: daidzein ratio of > -
1.75 
35% 10-73 mg, soy food, 4 
wk 
EPs and Non-EPs had similarly reduced 
LDL-C, and EPs had maintained high 
HDL-C compared to significantly 
reduced levels in non-EPs 
Urine: 1334 
creatinine 




Serum equol, retrospective 
analysis, log equol: daidzein 
ratio of > -1.75 
69% 33 mg, soy germ pasta, 
4 wk  
EPs showed significantly reduced 
plasma LDL-C, total cholesterol, and 
hsCRP; and greater FMD than Non-EPs 
Plasma: 105  






















analysis, log equol: 
daidzein ratio of > -
1.75 
33% 70-80 mg, isoflavones 
and soy protein, 6 wk 
EPs did not show significant 
differences in response from non-EPs 
on plasma lipids 
NA 
[10],  117 postmenopausal 
women, healthy,45-70 y 
Urinary equol, 
retrospective, >936 
nmol/L or serum 
equol >39 nmol/L  
28% 50 mg, soy enriched 
cereal bar, 8 wk 
EPs did not show significant 
difference in response from non-EPs 
on inflammatory biomarkers, blood 
pressure; plasma TC, LDL-C, HDL-
C, total:HDL-C, TG, NEFA, glucose, 
insulin, or HOMA-IR. Only 
differences in Lp(a) and % small 
dense LDL concentrations were 
shown in equol producers.  
Urine: 2.61 mg/ d 
BP, Blood pressure; EP, Equol producer; FMD, Flow mediated dilatation; HDL-C, High density lipoprotein-Cholesterol; HOMA, Homeostatic model 
assessment of insulin resistance; hs-CRP; high sensitivity-C-reactive protein; LDL-C, Low density lipoprotein-Cholesterol; Lp(a), Lipoprotein (a); NA, 
No available data; NEFA, Non- esterified fatty acids; TG, Triglycerides.





1.4.8 Potential factors affecting equol producer phenotype 
 
Differences in equol producer phenotype frequency  
In contrast to animals, the excretion of equol is highly variable in humans. As mentioned 
earlier, not all healthy humans possess the ability to convert daidzein to equol. It was 
reported that daily ingestion of 500 ml of soy milk for 3 days resulted in mean 
concentration of 139 nmol/L and 12574 nmol/L, of equol in serum and urine respectively 
[141]. Generally, it is estimated that around 30-50 % of humans can produce equol from 
daidzein [18, 172]. However, there is evidence that the prevalence of equol producers is 
higher among Asian populations than western populations [173]. One study has found that 
38 % and 58% of Japanese women and men had serum equol higher than 20 nmol/L, in 
comparison with 2.2% and 0% of British women and men [140]. However, this result 
might be in part due to the habitual intake of soy in Asian populations. In addition, the 
chemical form of isoflavone intake was considered as a possible factor. The Asian diet is 
rich in fermented soy products, which is rich in isoflavone aglycones that are suggested to 
be more rapidly and easier to absorb than glycosides and thus attain higher bio-availability 
than the non-fermented soy and in turn yield more equol [6]. However, it has also been 
suggested that equol might be produced more from isoflavone glycosides as they possess 
longer transit time in the intestine, allowing for more bacterial metabolic reactions to take 
place [174, 175]. Another study by Song et al. found that the prevalence of equol 
production status was 51% in Korean American females compared to 36% in Caucasian 
American females and reported no dietary association between regular soy intake and the 
equol production phenotype [139]. Collectively, there is a research gap regarding the 
reasons behind the high prevalence of equol producer phenotype in Asian populations and 
research has been conducted to investigate factors that might influence the equol producer 









Gut microbiota and equol producer phenotype 
   
In the 1980s, it was found that equol production depends on the intestine microflora from 
studies on germ-free animals and antibiotic use [137, 138]. Further research suggested that 
the ability to produce equol is determined by the intestinal microflora profile (Table 1.5). 
In vitro work has suggested that the equol production capability is most probably 
accredited to specific strains of the intestinal microflora; in support of this, it has been 
shown that faecal flora extracted from equol producers, had the capacity to metabolise 
incubated daidzein to equol whereas faecal flora of non-equol producer did not [176].  
 
Research has been conducted to identify the intestinal bacteria species that are able to 
metabolise equol and develop probiotics that might induce this ability in non-equol 
producers.  In vitro culture of human faecal flora after soy intake identified three bacteria 
species which showed ability to convert daidzein to equol; the gram-negative Bacteroides 
ovatus spp, the gram-positive Ruminococcus productus spp and Strepotococcus 
intermedius spp [17]. In addition, a mixture of the faecal bacteria Lactobacillus sp. Niu-
O16 and Eggerthella sp. Julong 732 have been found to transform daidzein to 
dihydrodaidzein and dihydrodaidzein to S-equol respectively [177]. Another nine strains 
of equol-producing bacteria (Adlercreutzia equolifaciens gen. nov, sp. nov) were isolated 
from human faecal microflora and classified as obligately anaerobic, asaccharolytic and 
gram-positive coccobacilli. Seven of these new strains could produce equol from daidzein 
via dihydrodaidzein and the left two (FJC-A10 and FJC-A161) are able to metabolize only 
dihydrodaidzein to equol similarly to the previously identified Julong732 [178]. Recently, 
another daidzein-metabolising bacterium was isolated; the NATTS strain which found to 
be a Gram-positive, non-spore-forming rod bacterium and belong to the genus Slackia sp. 
Interestingly, 40% of the Japanese population have a mean of 106 cells of Slackia sp per 












Table 1.7 Microflora species associated with equol producer phenotype 
Bacteria  Ref 
Slackia isoflavoniconvertens [180] 
Slackia equolifaciens [181] 
Adlercreutzia equolifaciens [178] 
Lactococcus garvieae [182] 
Lactococcus sp. strain 20-92 [183] 
Lactobacillus sp. Niu-O16 and Eggerthella sp. Julong 732 [177] 
FJC-A10 and FJC-A161 [178] 
NATTS strain  (Slackia) [179] 
 
 
An alternative hypothesis proposed that a mixture of bacterial strains could be responsible 
for equol production because of the complex composition of intestinal microflora. Decroos 
et al. (2005) prepared a mixed culture of intestinal bacteria (EPC4; consisting of 
Lactobacillus mucosae EPI2, Enterococcus faecium EPI1 and Finegoldia magna EPI3 and 
Veillonella sp strain EP) that efficiently metabolises daidzein into equol [184].  EPC4 was 
also supplemented with propionate and butyrate, which are major short chain fatty acids 
produced by microflora fermentation of complex carbohydrates such as non-starch 
polysaccharides in dietary fibers and resistant starch [185]. This supplementation increased 
the equol production, suggesting a positive influence of a diet rich in complex 
carbohydrates. In contrast, treatment with fructo-oligosaccharides inhibited equol 
production. Interestingly, the equol-producing ability of EPC4 was preserved when added 
to a faecal bacterial culture of non-equol producer [184]. Further experiments reported that 
EPC4 was also successful in converting the faecal profile of non-equol producers to equol 
producers, after being administered to stimulator of the human intestinal microbial 
ecosystem (SHIME, a model for a gastrointestinal tract of an adult human) which was fed 
soy germ powder and inoculated with faecal samples of non-equol producers [186]. In 
contrast, studies have failed to change equol producer status by probiotic consumption 
(including Lactobacillus acidophilus and Bifidobacterium bifidus which are not 
specifically equol producing bacteria but found to be highly associated with equol producer 
phenotype) [187, 188].   
Overall, it seems that the literature includes some data about specific colonic bacterial 
species that are capable of producing equol from daidzein and these information are useful 
for future research. In particular, there is still a lack of human RCTs providing probiotics 




that are specifically designed for equol-producing strains or alternatively faecal transplant 
studies to investigate the possibility to change a non-equol producer to equol producer.  
 
Effects of antibiotic administration on equol producer phenotype 
 
Studies since the 1980s administering antibiotics have shown that equol production 
depends on the intestine microflora [18, 137, 138]. More recent studies have suggested 
using antibiotics to aid in identifying the specific strains of equol-producing bacteria. Blair 
et al. [189] performed a 1 month antibiotic treatment to female monkeys and showed 
variable effects of antibiotics on metabolism of equol, isoflavones and their metabolites. It 
has been shown that vancomycin, kanamycin, and a mixture of vanomycin and kanamycin 
induced significant reduction in plasma equol levels whereas doxycycline treatment did 
not influence plasma equol [189]. In accordance, plasma concentrations of daidzein were 
increased by kanamycin, and a mixture of vancomycin and kanamycin but also, 
surprisingly, by deoxycycline and this might be attributed to variable influence of different 
antibiotics like effects on metabolism of isoflavones or on their absorption [189]. Similar 
in vitro results were found for metronidazole and kanamycin in faecal inoculates from 
equol producers and non-producers incubated with daidzein [190]. It is suggested that 
equol production is a permanent capability except during administration of antibiotic – 
“once an equol producer, always an equol producer” [17, 172].  In contrast, some studies 
reported equol-producer “cross-overs” (i.e. their equol-producer status was altered from a 
non-producer either to a producer or vice versa) [191, 192]. 
 As a conclusion, there is a lack of solid knowledge on the collective specific strains of 
intestinal bacteria, required conditions, dietary factors, possibly other determinants such 
as genetic factors; that might be cumulatively responsible for metabolising daidzein to 
equol.  
However, it should be noted that research on this matter is challenging because the colon 
is a highly complex and metabolic organ that is inhabited by a huge variety of bacteria 
strains that change along the different intestinal regions and other environmental factors 
such as diet [193]. 
  
Effects of diet on equol producer phenotype 
Diet may contribute to the association between the intestinal microflora and the ability to 
produce equol. Diet can influence the dominance of intestinal microflora species [194] and 




thus studies have investigated whether diet changes including altered prebiotic intakes 
induce the equol-producing ability. Studies have found that equol producers had 
significantly higher energy intake of carbohydrates [195, 196], lower energy intake of fat 
[196] and fibre intake [195] than those of non-equol producers. Another study of healthy 
postmenopausal women has shown that urinary equol production was positively associated 
with high PUFA intake [197]. However, most of these studies are cross-sectional and they 
do not provide causality.  
Feeding studies have also been conducted to investigate whether equol production ability 
can be influenced by certain dietary interventions such as prebiotics through changing the 
intestinal microflora profile. However, results of animal and human studies were 
equivocal; a 1 month intervention of fibre (16 g of wheat bran) with soy protein did not 
influence equol production [198]. In contrast, it was shown that feeding resistant starch 
(12% supplemented diet) to ovariectomized mice for six weeks significantly increased 
urinary equol concentration and, interestingly, it showed markedly higher caecal ratio than 




















1.5 Metabolism and bioavailability of soy isoflavones and 
equol 
 
1.5.1 Metabolism and absorption 
 
In order to understand bioactivity of isoflavones and their metabolites, there is a need to 
understand their metabolism and absorption in the body. Isoflavones are found as ß-
glycosides, and might also be bound to acetyl and malonyl glucosides (Figure 1.3) in soy 
food and products [200].  The levels of ß-glycosides, acetyl or malonyl glycosides vary 
between food and supplements following preparation and processing methods [201]. 
Isoflavone metabolites exhibit biphasic appearance in the blood; the first phase reflects 
these glycosides being partially hydrolysed along the proximal small intestine by ß-
glucosidases (e.g. lactase phlorizin hydrolase (LPH)) in order to release aglycones that can 
be absorbed [172, 200]. Afterwards, isoflavones undergo metabolism phase II reactions of 
glucuronidation and to a lesser extent sulfation by glucuronosyl-transferases (UDP-
glucuronyltransferase) and sulfotransferases in the intestine and/or liver [17]. These 
conjugates get transported to the tissues by circulation and then get excreted by the 
kidneys, or disposed into the bile and return to the intestine. In the large intestine, they can 
undergo de-conjugation and their aglycones can be reabsorbed and excreted through the 
kidneys, or returned to the liver for re-conjugation and more enterohepatic circulation. 
These recycling steps also contribute to the biophasic pharmacokinetics of isoflavones 
[202].  
A substantial part of the ingested isoflavones that are not hydrolysed in the small intestine 
reaches the colon, along with the returned part of conjugated isoflavone from the 
enterohepatic circulation and aglycones that are not reabsorbed [172]. Isoflavones 
conjugates then undergo intestinal metabolic reactions including dehydroxylation, 
demethylation, C-ring cleavage, and reduction to produce different metabolites [17, 172, 
196, 200]. These previous metabolic steps seem highly variable between subjects [172, 
203] and thus may explain the high inter-individual variability of plasma concentrations of 
isoflavones and their metabolites upon consumption of the same isoflavone dose [176].  
Glycitin is the minor isoflavone in soy food. It is quickly hydrolysed to glycitein and is 
considered metabolically inert [204]. However, there is a recent study that identified 




glycitein metabolites such as dihydroglycitein [205]. Genistein is converted to p-ethyl 
phenol and 4-hydroxy-phenyl-2-propionic acid. Daidzein is metabolised more intensively. 
It undergoes up to two different metabolic pathways, which might result in the formation 
of equol via dihydrodaidzein and tetrahydrodaidzein [200](Figure 1.8) or O-
desmethylangolensin (ODMA) via dihydrodaidzein, and 2'-Dehydro-O-
desmethylangolensin. In a review, it has been suggested that only little percentage of 
daidzein is metabolised 4% for equol and 7% for O-DMA [202].  
Little is known about the metabolism of equol [183]. It was previously thought that equol 
is an inert metabolic product [17]. However, further research discovered six aromatic 
hydroxylated metabolites (phase I) with 39-hydroxy-equol and 6-hydroxyequol as main 
products [172]. Overall, isoflavones are found in plasma mostly as glucuronide conjugates 
(75%), and to less extent as sulphates (24%), and less than 1% as aglycones [172].  The 
main metabolites for daidzein and genistein are 7-O-glucuronides, 4'-O- glucuronides, and 
to a lesser extent 7,4’-O-diglucuronide, genistein 7,4’-O-disulphate [188].  
 





















Figure 1.8 Metabolic pathways of daidzein and equol production in the intestine  
(Figure adapted from Cassidy et al., 2012 [201]). 





1.5.2 Pharmacokinetics of soy isoflavones and equol 
 
Isoflavone consumption plasma concentrations of daidzein and genistein attain a first peak 
at 1 to 2 h, followed by a second peak at 6-8 h and then start to decrease after 12 h [65, 
175, 206, 207] (Figure 1.9). Different isoflavone compounds and metabolites have 
different bio-availabilities [208]. For instance, plasma genistein levels have been shown to 
peak more rapidly than those of daidzein (5.2 h; 6.6 h, respectively; [174]). They also had 
a lower urinary excretion rate than daidzein [206] and this suggests further metabolism of 
daidzein and conversion to equol [17]. Genistein and daidzein had elimination half-lives 
of 7 and 9 h after aglycone administration [174] and 3-9 h, 8-11 h after glycoside 
consumption or food consumption, respectively [174, 202].  After isoflavone intake (soy 
germ, total isoflavone: 1.20 mg/kg body weight), maximum concentrations (Cmax) of total 
isoflavones reached ~2.7 μmol/L in the blood (at 6 h) [208]. In a review of Nielsen et al. 
2007, it has been show that urinary recovery of isoflavones follows daidzein > glycitein > 
genistein [209]. 













Figure 1.9 Pharmacokinetics of soy isoflavones daidzein and genistein (an example)  
Overview of the pharmacokinetics of isoflavones in 12 postmenopausal women following an intake of soy extract capsule (daidzin: genistin, 7.79:22.57 
mg) or soy based beverage (daidzin: genistin, 9.27:10.51 mg), A) for daidzein and B) for genistein, plasma concentrations presented as mean±standard 
deviation, (figure reproduced from Anupongsanugool et al., 2005 [65]). 
  
A) B) 




S-equol is negligible in plasma until 8 h and peaks around 24 h after soy consumption in 
humans [174, 175, 210] (Figure 1.10). Oral administration of synthetic equol displays 
different pharmacokinetics with higher bioavailability and rapid absorption than the parent 
isoflavone, e.g. 50% of equol circulates freely in the plasma compared with only 18.7% as 
free daidzein [174, 175]. Moreover, Tmax of equol has been shown at 1-1.5 h after 
consuming 10 mg/30 mg of SE5-OH (S-equol containing tablets) and attained plasma Cmax 
of 2 and 5 mol/L that are much higher than that of endogenously produced equol (see 





Figure 1.10 Pharmacokinetics of equol in humans  
(A) Plasma Cmax of synthetic S-equol at 2 h after 10mg of S-equol (SE5OH) supplement ingestion 
12 women  (figure adapted from  Setchell et al., 2009 [211]). (B) Plasma Cmax of endogenously 
produced S-equol at 24 h after isoflavone capsule ingestion as aglycone (♦) or glucoside (□) in 15 
women (figure adapted from Zubik et al., 2003 [175]). 
 
A) 




Table 1.8 Plasma levels of equol when consumed as supplements or endogenously 
produced after daidzein consumption 




[211] 10 mg,  30 mg (SE5-OH) supplements 
 
1 h 1907, 4953 
[211] 20 mg S- (C13) equol supplements 
 
3 h 991 
[141] 14 mg daidzein (500 ml soy milk) day 4 
(3 days challenge) 
139  
[165] 38 mg daidzein (52 g soy protein 
powder) 
After 2 months 144  
[212] 30 mg daidzein (100 mg soya isoflavones 
concentrate) 
day 1 300  
Data represented as means. Tmax, Peak time; Cmax; Peak concentration.  
 
1.5.3 Factors affecting bioavailability of soy isoflavones 
 
The extent of metabolism and absorption of isoflavones appear to be highly variable 
between individuals. A daily consumption of 50 mg isoflavones has been shown to achieve 
plasma concentrations of 50-800 ng/ml [174]. Current human and animal studies propose 
isoflavone bioavailability of around 20-30% [39] and this can be highly influenced by 
many factors including delivery medium, different isoflavones sources, food matrix, food 
processing, diet, dose and frequency of ingestion, age, gender and gut microflora [174, 
196, 207, 209, 213]. The chemical composition of isoflavone intake as glycosides or 
aglycones affects their absorption. It is reported that the absorption of isoflavone 
glycosides is higher than that of their aglycones and this might be related to the stability 
and water-solubility of glycosides that might facilitate faster delivery to LPH [209]. In 
contrast, fermented soy food (rich in aglycones), showed higher bioavailability than non-
fermented soybeans (rich in glycosides). However, this was linked in part to the food 
medium rather than the attaching sugars per se [85, 207, 214]. 
 Previous studies have not found any correlations between age and bioavailability of 
isoflavones except for equol during the first months compared with adulthood, which is 
most likely due to the undeveloped intestinal microflora. Further food processing and 




storage conditions affect bioavailability, and therefore it is important to measure the 
isoflavones prior to consumption in trials. 
 
1.6 Summary - identifying research gaps 
 
Multidisciplinary research suggests that consumption of soy isoflavones might reduce 
CVD risk factors and in particular hemodynamic and vascular-related markers; however, 
a number of RCTs have reported equivocal data. One potential explanation for the variable 
response to isoflavones may be metabolic differences, particularly the ability to metabolise 
the soy isoflavone daidzein to equol. Some in vivo studies have shown associations 
between the equol producer phenotype and reduced endothelial dysfunction and arterial 
stiffness, and lower blood pressure and this has been supported by in vitro work that has 
identified potential underlying mechanisms, particularly elevated production of the 
endothelial-derived vasodilator NO.  
Despite these notable findings, there is a lack of data to demonstrate: 1) the potential role 
of equol producer phenotype in the benefits of isoflavone intake on vascular function 
particularly data derived from RCTs that prospectively recruit equol and non-equol 
producers, 2) the effects of S-equol supplement intake per se on vascular health, 
specifically in non-equol producers, 3) the biological markers of vascular function that 
may explain the underlying mechanisms for the vascular protective effects of isoflavones, 
and 4) the differential efficacy of isoflavones consumption as isolated compounds or 










1.7 Hypothesis and objectives  
The hypothesis of this thesis was that the ability to produce the isoflavone metabolite equol 
influences the effectiveness of isoflavone intake on vascular function in humans. This 
research was designed to investigate primarily whether equol producers have greater 
benefits on vascular function markers (in particular arterial stiffness, endothelial function 
and blood pressure) in response to an isoflavone intervention than non-equol producers. 
Our secondary aims were to study: a) the effects of isoflavone containing intervention on 
circulating biomarkers of vascular and hemodynamic function that might explain the 
underling mechanisms for vascular bioactivity of soy isoflavones and the metabolite equol, 
b) if non-equol producers have acute benefits on vascular function following an intake of 
S-equol supplements, and c) the efficacy of isoflavone intake in different food matrices on 
vascular function (food versus supplements, providing the same dose).  
 
Figure 1.11 summarises the research objectives and approaches in this thesis. We 
conducted the followings:    
 
1) a retrospective analysis from a previously completed trial to evaluate whether equol 
production capability were associated with enhanced vascular function in 
postmenopausal type 2 diabetic women after a chronic flavonoid intervention. 
Outcomes included arterial stiffness (PWV), blood pressure (primary outcome 
measures), and biomarkers of vasodilation (NO) and vasoconstriction (ET-1 and 
ACE), and insulin resistance assessed by HOMA-IR and resistin (secondary 
outcome measures) (Chapter 2). 
2) an acute study for which we prospectively recruited equol and non-equol 
producers, to further establish the role of equol producer phenotype on arterial and 
endothelial function responses to a single dose of soy isoflavone in a male 
population at elevated risk of CVD. Non-invasive clinical vascular markers such 
as endothelial function (reactive hyperaemia reaction (RHI)), and arterial stiffness 
(PWV) (primary outcome measures), augmentation index (AI)), and blood pressure 
were studied (secondary outcome measures) (Chapter 3).   
3) An additional study arm to investigate whether a single intake of S-equol 
supplements induces acute benefits on vascular markers including RHI, and arterial 




stiffness measurements (PWV) (primary outcome measures), AI and blood 




































Figure 1.11 Thesis project approaches and vascular-related outcomes 
Upper diagram represents chapters' content; lower diagram represents clinical and biological markers of vascular and hemodynamic function. ACE, 
Angiotensin converting enzyme, AI, Augmentation index; BP, Blood pressure; EP, Equol producer; ET-1, Endothelin-1; c-fPWV, carotid-femoral Pulse 
wave velocity; HOMA-IR, Homeostatic model assessment of insulin resistance; MAP, Mean arterial pressure; NO, Nitric Oxide assessed as nitrite and 
nitrate; RHI, Reactive hyperaemia index.
 
2) Acute prospective isoflavone study: 
recruiting EPs and non-EPs- vascular 
responses to isoflavone treatment 
(Chapter3) 
1) Retrospective analysis: 
association EP phenotype 
and vascular health 
(Chapter 2) 
3) Acute equol administration study: 
vascular responses to S-equol 
supplement treatment in prospectively 












Clinical vascular measures 














Chapter 2 Establishing the association between 
equol producer phenotype and vascular function: 




Soy isoflavones are polyphenol compounds that may have potential health benefits [64]. 
In particular there is a significant interest in the effects of soy isoflavone intake on 
cardiovascular disease risk factors but the available data are inconclusive [5, 6, 8-16]. Inter-
individual differences in metabolism might offer an explanation [17]. The equol producer 
phenotype is present in only a third of the Western population, who possess the ability to 
convert the precursor compound, daidzein, into the unique metabolite equol in the large 
intestine after consuming soy [18]. Equol showed higher bioavailability in human studies 
[211], greater antioxidant activity [20, 21], and was suggested to be more anti-
atherosclerotic than daidzein in vitro [23, 24]. Additional in vitro and animal work has 
shown beneficial vaso-relaxant activity of equol suggesting its potential for the prevention 
and treatment of hypertension [23, 92-94, 155].  
Few recent observational studies of Asian populations have shown positive associations 
between the equol producer phenotype and cardiovascular risk factors; including blood 
pressure [25],  plasma lipid profiles  [25, 26] and inflammatory biomarkers [25, 27].  
Using a retrospective analysis approach, several isoflavone interventions have investigated 
associations between the equol producer phenotype and cardiovascular disease risk factors. 
Two studies showed benefits of isoflavone intake on vascular function including enhanced 
endothelial function [6], and a trend towards lower blood pressure [15] in equol producers. 
Conversely, two other studies have reported no difference between equol and non-equol 
producers on vascular reactivity [215] or carotid artery intima-media thickness [12]. 
However, these studies had major limitations in their methodology for identifying equol 
producers [12, 215] which impacts upon the confidence in the results; in addition, the small 





sample size of equol producers was a limitation in the dataset [215]. Overall, further data 
are required to determine whether the equol producer phenotype might affect the vascular 
bioactivity of isoflavone interventions.  
Furthermore, there is also currently a lack of data regarding the underlying biological 
mechanisms by which isoflavone intake and the metabolite equol might influence CVD 
risk factors, in particular endothelial dysfunction, hypertension and arterial stiffness, with 
an overview provided in Figure 2.1. It has been suggested that the vascular bioactivity of 
isoflavone intake could be explained by elevated levels of the potent vasodilator Nitric 
Oxide (NO) [9, 92] which has been shown to play an important role in the regulation of 
endothelial function, arterial stiffness and development of hypertension. The literature also 
suggests a potential inhibition of vasoconstrictors such as Endothelin-1 [11, 98] and 
angiotensin converting enzyme (ACE) [39, 99] (Figure 1.4) by isoflavones. In diabetic 
populations, isoflavone intake might induce benefits on insulin resistance [112] and this 
might be correlated with improvements on vascular function [110]. It has been shown that 
the homeostatic model assessment of insulin resistance (HOMA-IR) [107] is positively 
associated with premature stiffening of small and large arteries [216] and hypertension 
[217]. Notably, isoflavones effects on the previously mentioned potential biomarkers have 
been investigated mostly in cell lines and animal models, while further research is required 
in human studies.  
In order to help address gaps in the current understanding of equol producer phenotype  on 
vascular and hemodynamic functions, and understand the underlying biological 
mechanisms, we conducted a retrospective analysis using data from a previously 
completed study in postmenopausal women with type 2 diabetes who had consumed a 
flavonoid enriched chocolate (containing 100 mg isoflavone as aglycones units and 90 mg 
epicatechins) for 1 year. The hypothesis of this retrospective analysis was that the equol 
producers had greater improvements in vascular and hemodynamic markers than non-
equol producers, after the isoflavone-containing intervention. The primary outcome 
measures of our analysis included change from baseline in blood pressure, and arterial 
stiffness following the flavonoid intervention.  
 
 





In addition, secondary outcomes included change from baseline in circulating levels of 
biomarkers of endothelial function (in particular, NO metabolites, ET-1, ACE, and insulin 












Figure 2.1 Potential correlated biological and clinical risk factors that explain the 
underlying mechanisms by which isoflavones might protect against the CVD 
development  
Hypertension and arterial stiffness are established predictors of CVD mortality [29, 218]. Under 
hypertensive stimuli, functional and structural changes in the blood vessels take place and may 
cause arterial stiffening [219]. Endothelial dysfunction can explain hypertension and arterial 
stiffness prior to CVD development [41] and thus the potential benefits of isoflavones/equol on 
endothelial function by regulating biomarkers of vasoconstriction and vasodilation, may reduce the 
susceptibility to developing CVD. ACE, Angiotensin converting enzyme; CVD, Cardiovascular 
disease; ET-1, Endothelin-1; HOMA-IR, Homeostatic model assessment of insulin resistance; 
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2.2.1 Study design, subjects and intervention dose 
 
This analysis included data and biological samples collected from a previously conducted 
study (www.clinicaltrials.gov; NCT00677599).  
Briefly, the study was a double-blinded RCT with a parallel design. It included 118 
postmenopausal women (at least one year since last menstruation) with type 2 diabetes, up 
to 75 years old, using statins for at least 12 months.  On the other hand, exclusion criteria 
included:  
 those who were smokers/ex-smokers within less than 1 year ago 
 taking hormone replacement therapy 
 clinically diagnosed with vascular disease, or cancer, hypertension with systolic 
BP ≥ 160 mm Hg, prescribed aspirin for a period of less than 12 months prior to 
recruitment 
 having antibiotic medications or with planned vaccinations, or those consuming 
flavonoid/vitamin supplements (within 3 months prior to the study). 
  
Participants were randomly allocated into a flavonoid or placebo arm (n=59 for each 
group) where they were required to consume flavonoid-rich chocolate containing 100 mg 
isoflavones as aglycone units, and 90 mg epicatechins (850 mg total flavan-3-ols) or 
matched (appearance and nutrient content) placebo daily for 12 months. Intake was divided 
in 2 doses a day to sustain sufficient circulating levels of metabolites based on their known 




Outcomes included hemodynamic and endothelial function in particular blood pressure 
measurements (ambulatory systolic, diastolic blood pressure (BP), and mean arterial blood 
pressure (MAP)) and arterial stiffness assessment (central pulse wave velocity (PWV)) that 
were assessed at baseline, 6 months and 12 months of flavonoid consumption in the 
previously conducted study [220]. Fasting plasma/serum samples were additionally 





analysed for biomarkers of hemodynamic and vascular function such as NO, ACE, ET-1, 
HOMA-IR, and resistin.  
Anthropometric measurements  
 
Body weight was measured by digital electronic weighing scale to the nearest 0.1 Kg and 
the body height was measured using a stadiometer to the nearest 1 cm following the 
standard procedure (participants adapted a head position according to the Frankfort plane). 
Body mass index was calculated (Kg/m²). All anthropometric measurements were carried 
out following standard operating procedures by research nurses blinded to intervention 
allocation. 
In addition, body composition was estimated by bioelectrical impedance analysis (BIA) 
using Tanita, Model TBF-305. The machine follows leg-to-leg BIA, where a weak current 
is passed through the lower body part.  BIA determines the electrical resistance of different 
body tissues to calculate an estimate of whole body fat, and trunk fat [221]. 
 
Clinical hemodynamic and vascular function measurements  
 
Ambulatory pressure measurements were obtained over a 2 h daytime observation period 
using a non-invasive ambulatory monitor (Spacelabs SL902072) approved by the British 
Society of Hypertension.  
 
The monitor automatically inflated every 10 minutes. An appropriately sized cuff 
(pneumatic bag 20% wider than the diameter of the upper arm; standard adult (24-32 cm), 
large adult (32-42 cm) or extra large adult (42-55 cm)) was placed on the least dominant 
arm at the heart level. For each recording, mean of blood pressure was calculated from 
average measurements obtained every 10 minutes (in total 12 measurements). Central 
PWV was measured between 2 recording sites: neck (Carotid) and femoral (thigh) ateries 
using validated non-invasive device (Vicorder, Skidmore Medical Ltd, Bristol, UK) and 
appropriate sized cuffs. All measurements were done in triplicate and subjects were in a 
relaxed supine position and controlled conditions (dim light, quiet atmosphere and suitable 
temperature between 21° and 24° C). Valid PWV data was only available for a subgroup 
analysis due to problems with the equipment. It was reviewed by two-blinded independent 





researchers for validity and inclusion based on quality assessment criteria and guidance 
from manufacturer. 
The central PWV is derived from the transit time (Δt) between the carotid and femoral 
pulse waves and the estimated distance between the two sites (ΔL). The pulse wave 
velocity (m/s) is calculated from the ratio of the estimated distance travelled by the pulse 
(ΔL in meters) during the pulse transit time over the measured pulse transit time (ΔT in 




Figure 2.2 Clinical measurement of the central pulse wave velocity (PWV) 
The figure shows the arterial tree on the right. Top wave is measured at the carotid artery and the 
bottom wave is measured at the femoral artery. PWV is calculated from the ratio of the estimated 
distance travelled by the pulse during the pulse transit time over the measured pulse transit time.  
Δt, transit time; ΔL, estimated distance travelled by the pulse  (figure reproduced from  [55]). 
 
Analyses of vascular function related biomarkers 
 
Collected blood samples were immediately centrifuged and then the resulting plasma was 
stored until analysis at -80 ºC. Stored plasma was thawed at room temperature and used 
for quantification of the vascular biomarker concentrations. To obtain reliable and precise 
results, researchers were blinded, all samples were analysed in duplicate, any repeated 
thaw-freeze cycles were avoided, and aliquots of human quality controls were used in 
every assay. In addition, samples which had showed a coefficient of variation (CV) % of 





higher than 10%, were re-run or excluded in order to obtain an adequately precise data 
[222, 223].  
 Plasma fasting samples were analysed for insulin, ET-1, ACE, and resistin in duplicate by 
commercially available ELISA kits (Table 2.1).  For every analysis, approvals for COSHH 
forums and scheme of work for handling human tissues and body fluids were obtained and 
standard operating procedures (SOPs) were prepared following guidelines from the 
manufacturers and UEA safety officer.  
Fasting plasma glucose concentrations were determined in the pathology labs of Norfolk 
and Norwich University Hospitals (NNUH) and provided to calculate HOMA-IR, which 
is a reliable, accurate index for measurement of insulin resistance and has been shown to 
correlate to the gold standard method euglycemic-hyperinsulinemic clamp. HOMA-IR is 
calculated from fasting plasma glucose (mmol/L) × fasting serum insulin (mU/L) divided 
by 22.5 [107]. For NO analysis, defrosted plasma samples were filtered to remove proteins 
> 10kDa and total nitrate and nitrite (NO) concentration was analysed in triplicate by a 
colorimetric assay using a Nitric Oxide Quantitation kit (nitrate/ nitrite colorimetric assay, 
Caymen Chemical). Quantification of the nitrite and nitrate concentrations in plasma, 
serum and urine, is the most feasible mean to assess NO production in vivo [224] because 
of the short half-life of circulated NO  (<0.1 second) that is oxidised to nitrate by oxy-
haemoglobin in red blood cells and undergoes autoxidation in haemoglobin-free media to 
nitrite [224]. This assay includes two steps: first, conversion of nitrate to nitrite by a nitrate 
reductase and second, a Griess reagent is added that converts nitrite to an azo compound 













Table 2.1 Summary of biomarker assays used to determine vascular-related 
functions. 












kit (QuantiGIo),  
R&D systems, UK 
 
5%, 3% 0.06 pg/ml 
ACE ELISA Human ACE ELISA, 
USCNK, China 
 
12%, 7% 0.11 ng/ml 




7%, 2% 0.16 ng/ml 
NO Nitrate/ nitrite 






3%, 3% 2.3 mol/L 
ACE, Angiotensin converting enzyme; ET-1, Endothelin-1; ELISA, Enzyme linked immunsorbent 
assay; NO, Nitric Oxide assessed as nitrate/ nitrite.  
 
Identification of equol producer phenotype 
 
Urinary concentrations of the isoflavone daidzein, genistein and equol were analysed by 
HPLC using an in-house validated method in the institute of food research (Norwich, UK).  
Compliance to intervention was confirmed by flavonoid excretion in 24 h urine and 
counting of returned chocolate bar wrappers. Subjects were then defined as equol 
producers by having urinary log10 S-equol/ daidzein > -1.75 [141]. 





2.3 Statistical analysis 
All variables were first evaluated for their normal distribution and equality of variances 
between groups using Levene’s test and sphericity for homogeneity of variance. Data were 
log transformed when normal distribution assumption was violated.  
Independent t-test was used to check any differences in baseline measures between equol 
producers and non-equol producers. χ2 test was used for categorical variables and Mann-
Whitney test was used for data identified as not normally distributed. 
Univariate tests were used with equol production phenotype as a fixed factor and baseline 
level as a covariant. Data were analysed as changes from baseline levels at 6 month and 
12 month observations. A Mann-Whitney test was used for analysis of skewed data that 
could not be transformed to a normal distribution. For variables that showed a significant 
effect of equol producer phenotype, Pearson’s test was used to test correlation of levels of 
vascular endpoints and urinary concentrations of equol.  For analysis of urinary excretion 
of isoflavones, data were not normally distributed and could not be transformed to normal 
distribution, thus a non-parametric test was used (Kruskal-Wallis test) to examine any 
significant differences of urinary excretion between equol and non-equol producers at 
baseline, 6 months and 12 months. 
Additionally, statistical analyses were conducted to investigate interaction effects of time 
(baseline, 6 and 12 months) and equol production phenotype on the analysis variables (i.e. 
vascular markers). These analyses were carried out using a mixed model that included 
repeated-measures ANOVA to investigate the effect of time (within subject factor), and 
effect of equol production phenotype (between subject factor). 
 
 All results are expressed as mean±SEM (standard error of mean) and a P value<0.05 was 
considered statistically significant. SPSS software (PASW, version 18, SPSS) was used. 
On a blinded review of the data, all outliers of values > mean±3standard deviation (SD) 
were excluded and for lab analyses, and all data showing coefficient of variation CV% > 
10% were excluded. The number of participants in the analysis was for equol producers= 
17, non-equol producers= 30 for most variables (check table footnotes for participant 
numbers).  






The number of participants included in the analysis was limited to the participants who 
only completed the flavonoid arm, which included 17 equol producers, and 30 non-equol 
producers. The subjects allocated to the placebo arm could not be included because they 
did not have any isoflavone intake or soy challenge to assess their equol producer 











Figure 2.3 Number of enrolled subjects in the 12 month flavonoid intervention   
 
2.4.1 Baseline differences between equol producers and non-equol 
producers – general health and metabolic characteristics, and vascular 
function markers  
 
There were no significant differences in baseline levels of general health and metabolic 
related characteristics between equol and non-equol producers (Table 2.2). Similarly, there 
were no significant differences in the clinical vascular measures, i.e., ambulatory blood 
pressure or PWV at baseline (Table 2.3). In contrast, the levels for most analysed vascular-
related biomarkers were significantly different between equol and non-equol producers 
162 clinically screened  
 
118 Eligible, randomly allocated 
to either arms- matched for age, 
BMI, insulin use, & menopause 
years 
Flavonoid arm 
N= 59 at baseline 
N= 49 at 6 month 
N= 47 at month 12 
Placebo arm 
N= 59 at baseline 
N= 50 at 6 month 
N= 46 at month 12 
Drop outs N=25 due to different reasons such 












with a healthier profile in the equol producers. In particular, plasma concentrations of the 
vasodilator biomarker NO were significantly higher in equol than non-equol producers 
(61.1±6.5 vs 43.0±4.2 µmol/L, respectively, P<0.01). Consequently, the baseline ratio of 
NO to ET-1 was also significantly higher in equol than non-equol producers (37.29±4.66 
vs 33.59±6.22, respectively, P<0.05). In addition, baseline plasma levels of the 
vasoconstrictor ACE were lower in the equol than non-equol producers (102.89±33.01 vs 
163.79±104.82 ng/ml, respectively, P<0.05). Lower baseline levels of fasting plasma 
insulin (mU/L) in equol producers than non-producers (6.1±0.9vs 8.8±1.1 mU/L, 
respectively, P= 0.05) were indicative of a greater insulin sensitivity.  
 
Table 2.2 Differences in baseline levels of health and metabolic related 
characteristics of equol and non-equol producers 
Baseline characteristics Non-equol producer (N1)  Equol producer (N2)  P- 
value 
Mean±SEM   Percent % Mean±SEM Percent%  
Age (years)  62±1  62±1  0.67 
Diabetes duration (years)  7±1  10±2  0.27 
*Years since menopause 14±2  13±2.  0.97 
*Weight (Kg)  87.6±3.9  84.5 ± 5.3  0.65 
*BMI (kg/ m²)  32.8±1.29  32.5±2.01  0.84 
Trunk fat % 38.3 ± 1.4  36.1±1.8  0.35 
Insulin use  NO  87 
 
 
                         
71   
0.18 YES  13  29 
Blood Pressure medicated  NO  43  35 
0.59 
YES  57  65 













0.84 YES  73  71 
N1=30, N2=17. Data presented as mean±SEM. P- values of independent T-test represent statistical 
significance of differences in baseline measures between equol producers and non-producers. χ2 
test was used for categorical variables. *Data found not normally distributed and Mann-Whitney 
test was used. BMI, Body Mass Index. 
  





Table 2.3 Differences in baseline levels of hemodynamic and vascular function 
markers between equol and non-equol producers 
Baseline endpoints Non-equol producer (N1) Equol producer (N2) P value 
 
AMBP systolic BP 
(mmHg)  
135 ±2 1131±2 0.16 
 
AMBP diastolic BP 
(mmHg)  
77 ±2 74±2 0.25 
 
AMBP  MAP 
(mmHg) 
98±2 95±2 0.21 
PWV (m/s)  9.1 ± 0.6 8.6±0.5 0.50 
 
*Fasting plasma 
insulin (mU/L)  













43.0±4.2 61.1±6.5  <0.01 
*Plasma ET-
1(pg/ml)  
1.64±0.17 1.65±0.16  0.181 
*NO/ET-1  33.59±6.22 37.29±4.66  <0.05 
*ACE (ng/ml)  163.79±104.82 102.89±33.01  <0.05 
The number of participants in the analysis was: N1=30, N2=17 for AMBP systolic and diastolic 
BP, N1=30, N2=16 for PP, N1=29, N2=17 for MAP, N1=29, N2=16 for resistin, insulin and 
HOMA-IR; N1=8, N2=5 for ACE; N1=19, N2=13 for ET-1 and NO/ET-1. Data presented as 
mean±SEM (Standard Error of the Mean). P values of T-independent test represent statistical 
significance of differences in baseline measures between equol producers and non-producers. χ2 
test was used for categorical variables. * Data found not normally distributed and Mann-Whitney 
test was used. ACE, Angiotensin converting enzyme; AMBP, Ambulatory blood pressure; BP; 
Blood pressure; ET-1, Endothelin-1; HOMA-IR, Homeostatic model assessment of insulin 
resistance, MAP, Mean arterial pressure; NO, Nitric oxide assessed as nitrite/ nitrate ; PP, Pulse 
pressure; PWV, Pulse wave velocity. 
 





2.4.2 Urinary concentrations of isoflavones and equol producer 
frequency 
 
17 volunteers (36%) were identified as equol producers following soy isoflavone 
intervention. There were no equol cross-overs (i.e. equol producers becoming non-equol 
or vice versa) identified from the data at either 6 or 12 months.  
As expected, after 6 and 12 months consumption of intervention, the urinary excretion of 
daidzein and genistein (P<0.01) significantly increased compared to baseline in equol 
producers and non-producers. Results indicated good compliance to the flavonoid 
intervention with significantly increased levels of isoflavones in urine (P<0.01 for all 
analytes) and 88% wrappers returned. It is notable that non-equol producers excreted 
significantly more daidzein at 6 months than equol producers (P<0.01) but this relationship 




Figure 2.4 Urinary concentrations of isoflavones (µmol/L) after 6 and 12 months of 
flavonoid intervention  
P values represent significant difference of urinary excretion of isoflavones between equol and 
non-equol producers. P values for daidzein, genistein, and *equol in were, P> 0.05 for all at 
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2.4.3 Effects of equol production phenotype on blood pressure and 
arterial stiffness after flavonoid consumption  
 
There were no significant differences in the levels of blood pressure (Systolic BP, Diastolic 
BP, MAP or pulse pressure), and arterial stiffness (PWV) between equol and non-equol 
producers following intervention (including baseline, 6 months and 12 months, see 
Appendix B, page 178, Table I) for P values of repeated measure ANOVA for interaction 
effect of time and equol production phenotype. 
After 6 months of flavonoid consumption, there were no observed effects of equol producer 
phenotype on blood pressure or arterial stiffness (Table 2.4, Figure 2.5, Figure 2.6, Figure 
2.7). However, after 12 months of flavonoid consumption, diastolic blood pressure was 
significantly decreased in equol producers (change from baseline: -2.2±1.3 mmHg in equol 
producers versus 1.0±0.9 mmHg in non-equol producers, P<0.01, Figure 2.5). Mean 
arterial pressure (MAP) was also significantly lower in equol producers (change from 
baseline: -1.2±1.3 mmHg in equol producers versus 2.2±1.1 mmHg in non-equol 
producers, P<0.01, Figure 2.6). Similarly, arterial stiffness assessed by PWV was 
significantly decreased in equol producers compared to no change in non-equol producers 
(change from baseline: -0.7±0.4 m/s in equol producers, versus 0.3±0.6 m/s in non-equol 
producers, P<0.01, Figure 2.7) after 12 months. There were no differences in systolic blood 
pressure and pulse pressure between equol and non-equol producers after 12 months of 
flavonoid consumption (Table 2.5).  
 





Table 2.4 Effects of equol producer phenotype on blood pressure levels after 6 month flavonoid consumption 
Endpoint Non-equol producers (N1) Equol producers (N2) P value 






135±2 137± 2 1.6±2.1 131±2 132±4 1.9±3.1 0.49 
PP (mmHg) 58.3±1.8 60.2±2.0 1.9±1.4 56.4±2.2 56.8±2.8 0.3±1.4 0.40 
N1=30, N2=17 except for PP N1=30, N2=16. P value for univariate analysis. BL, Baseline; BP, Blood Pressure; PP: pulse pressure. Blood pressure 
medicated was used as covariant.  
 
Table 2.5 Effects of equol producer phenotype on blood pressure levels after 12 month flavonoid consumption 
Endpoint Non-equol producers (N1)   Equol producers (N2) P value 










PP (mmHg) 58.3±1.8 60.8±1.8 2.5±1.4 56.4±2.2 59.1±2.6 2.6±0.9 0.98 
N1=30, N2=17 except for PP N1=30, N2=16. P value for univariate analysis. BL, Baseline; BP, Blood Pressure; PP, pulse pressure. Blood pressure 
medicated was used as covariant.






Figure 2.5 Change in diastolic BP in equol and non-equol producers after 
consuming flavonoids for 6 or 12 months.   
Data presented as mean±SEM. P value for univariate analysis. Medicated blood pressure status 
was used as covariant. BP, blood pressure. 
 
 
Figure 2.6 Change in MAP in equol and non-equol producers after consuming 
flavonoids for 6 or 12 months.   
Data presented as mean±SEM. P value for univariate analysis. Blood pressure medicated was 









































12 months - baseline, P= 0.008
6 months- baseline, P= 0.67































12 months - baseline, P= 0.01
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Figure 2.7 Change in PWV in equol and non-equol producers after consuming 
flavonoid for 6 or 12 months.  
Data presented as mean±SEM. P value for univariate analysis. PWV, Pulse Wave Velocity. 
 
2.4.4 Effects of equol producer phenotype on circulating levels of 
vascular function and insulin resistance related biomarkers after 
flavonoid consumption 
 
Plasma level of NO significantly decreased in equol and non-equol producers (P<0.01) 
during the intervention (Appendix B, Table I, page 178). Specifically, after 6 months, only 
plasma NO levels decreased significantly in equol producers compared to non-equol 
producers (change from baseline: -17.8±-19.6 vs 0.8±3.9 µmol/L, P= 0.05, respectively, 
Table 2.6) and there was no difference at 12 months (Table 2.6). There were no significant 
differences in the other analysed biomarkers of hemodynamic and vascular function 
between equol and non-equol producers following flavonoid intake neither at 6 month nor 
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Table 2.6 Effects of equol producer phenotype on  vascular function and insulin resistance related biomarkers after consuming 
flavonoids for 6 months 
Biomarker Non-equol producers (N1) Equol producers (N=2) P value 
















2.74±0.34 2.40±0.23 0.34±0.2 2.13±0.33 2.07±0.28 -0.06±0.30 0.85 
N1=30, N2=17 for NOx; N1=29, N2=16 for resistin, Insulin and HOMA-IR; N1=8, N2=5 for ACE. Data presented as means ±SEM, P values of univariate 
analysis and baseline values were used as covariant. *Data appeared not to follow normal distribution and presented as mean±SEM and analysed by Mann-
Whitney test. BL, Baseline; HOMA-IR, Homeostatic Model Assessment of Insulin Resistance; NO, Nitric Oxide assessed as nitrite/nitrate. Note: ACE 













Table 2.7 Effects of equol producer phenotype on vascular function and insulin resistance related biomarkers after consuming 
flavonoid for 12 months 
Biomarker Non-equol producers (N1) Equol producers (N2) P value 




























2.74±0.34 2.49±1.89 -0.25±-0.10 2.13±0.33 1.89±0.26 -0.23±0.09 0.49 
N1=30, N2=17 for NOx; N1=29, N2=16 for resistin, insulin and HOMA-IR; N1=8, N2=5 for ACE; N1=19, N2=13 for ET-1 and NO/ET-1. Data presented 
as means ±SEM. P values of univariate analysis and baseline values were used as covariant. *Data appeared not to follow normal distribution and presented 
as mean±SEM and analysed by Mann-Whitney test was used. ACE, Angiotensin Converting Enzyme; BL, Baseline; ET-1, Endothelin-1; HOMA-IR, 
Homeostatic Model Assessment of Insulin Resistance; NO, Nitric Oxide assessed as nitrite/nitrate.






In addition, flavonoid intervention for 12 months or equol producer phenotype did not 
significantly affect body weight, BMI or trunk fat % (P>0.05). When analysing the 
association between equol excretion and parameters of vascular function in the equol 
producer group alone, there was a weak trend for a correlation between change in diastolic 
blood pressure from baseline and urinary concentrations of equol at 12 months (r= -0.44, 
P= 0.07). Changes in MAP and in arterial stiffness (PWV) were not correlated with urinary 
equol (µM) (P>0.05). In addition, diastolic BP, MAP and PWV were not associated with 
age, BMI, trunk fat percentage, diabetes duration, insulin use or years at menopause 
(P>0.05). 






This retrospective analysis of a previously completed study [220] showed that the equol 
producer phenotype was associated with enhanced clinical markers of hemodynamic 
function and arterial stiffness in postmenopausal women with type 2 diabetes, following 
long-term isoflavone containing intervention. In particular, equol producers had 
significantly lower diastolic blood pressure, mean arterial pressure and central pulse wave 
velocity than non-equol producers after completing a one year intervention.  
However, we cannot conclude that these observed vascular and hemodynamic benefits 
were in response to the 12 month flavonoid intervention, because there was no control arm 
included in the analysis. Intermediate assessment at 6 months observed no effects of the 
equol producer phenotype on the analysed clinical and circulating markers of 
hemodynamic and vascular function except for plasma levels of the endothelial vasodilator 
NO (measured as plasma nitrite/ nitrate levels) which were surprisingly reduced in equol 
producers compared to non-equol producers. Collectively, these findings could suggest 
that long-term flavonoid intakes might be more beneficial in postmenopausal diabetic 
equol producers. 
Using a similar retrospective analysis, another large RCT of postmenopausal women has 
shown trends towards improvements in systolic and diastolic blood pressure and an 
enhanced endothelial function (assessed by FMD) in the equol producers (n=25) while 
these measures deteriorated in the non-equol producers (n=63) after consuming 
isoflavones (99 mg as aglycones /day) for 12 months [15]. Another parallel-designed RCT 
of soy germ-rich pasta intervention (33 mg isoflavones/day as aglycones) for 4 weeks has 
reported significant improvements from baseline levels of endothelial function (assessed 
by brachial artery FMD) in hypercholesteraemic equol producers (n=9) compared to non-
equol producers (n=20) [6].  
In contrast, in a recent 2.7 year RCT of 350 postmenopausal women, there were no 
significant differences on atherosclerosis progression (carotid artery intima-media 
thickness (CIMT)) in equol and non-equol producers in the soy group (91 mg isoflavone 
as aglycones/ day) versus placebo group. But this analysis is conflicted by the comparison 
to the placebo group who were not assessed for their equol producer phenotype [12]. 
Another 6 week study similarly showed no differential responses to isoflavone plus soy 
protein (107 mg as aglycone + 25 mg protein) between postmenopausal equol producers 





(n=10) and non-equol producers (n=18) on endothelial function (assessed by FMD). 
However, this intervention showed significantly better vascular reactivity than that after 
placebo intake (total milk protein), to similar extent in both equol and non-equol producers 
[215]. Yet, it is worth to note that the observed number of equol producers was small 
(n=10).   
In our study, it is difficult to explain the significant better improvements in the equol 
producers on PWV, diastolic blood pressure, mean arterial blood pressure, but not on 
systolic blood pressure and to what extent these observed hemodynamic changes were 
related to the decreased arterial stiffness assessed from PWV. These findings may be 
related to the fact that the equol producer group had a mean PWV of 8.6 m/s at baseline 
(Table 2.3) which falls within the normal expected range for this age group [225]. 
Subsequently, one could hypothesise that the reflected pulse waves in these subjects might 
be returning close to the diastole and therefore, the decreased diastolic blood pressure 
might be related to the decreased PWV, while the systolic blood pressure was not affected. 
Consistent with our findings, it was previously shown that arterial stiffness indices, such 
as augmentation index and PWV, were strongly correlated to diastolic blood pressure, but 
not to systolic blood pressure. However this study sample was limited to young males [226] 
and further research is needed on other population groups such as our study sample, type 
2 diabetic postmenopausal women.  
The plausible underlying biological mechanism of the significant better hemodynamic and 
arterial stiffness in the equol producers might be related to higher vaso-relaxant activity of 
equol compared to daidzein, as it has been shown by in vitro work [23]. Previously, it has 
also been shown that infusion of dehydroequol has increased blood flow in forearm 
resistance arteries in humans and this effect diminished by inhibition of eNOS [156]. Most 
studies suggest that the underlying mechanisms of vascular bioactivity of equol involve 
phosphorylation of eNOS and thus increasing bio-available NO [94, 155]. However, the 
current study did not find increased levels of plasma NO metabolites in equol producers, 
compared to non-equol producers after 12 months of flavonoid consumption. However, 
these results could have been conflicted by the limitations of the griess reagent method for 
analysis of NO derivatives (nitrite and nitrate). Specifically, this method is not considered 
sensitive enough to measure nitrite (NO-2) levels in biological samples and nitrate (NO-3) 
levels could have been influenced by dietary factors [227], in particular because this trial 
did not restricted their intake of nitrate.  





ET-1 is an another important biomarker and  predominant vasoconstrictor peptide that 
constricts vascular smooth muscle and is responsible along with NO for vascular tone in 
the endothelium and therefore NO/ET-1 ratio is suggested as a marker of coronary artery 
disease development [228, 229]. Previous short term RCT of soy enriched cereal bar has 
showed significant increases in plasma NO/ET-1 ratio in healthy postmenopausal women. 
On the contrary, our analysis did not show significant changes on NO/ET-1, but the 
hypotensive effects observed after 12 months intervention might be explained in part by a 
trend towards a decreased plasma ET-1 (change from baseline, -0.08±0.22 pg/ml in equol 
producers, P= 0.09, Table 2.7). Other potential plausible underpinning mechanisms could 
be related to effects of isoflavone and equol on the vasodilator prostacyclin (PGI2) and/or 
platelet function [24]. In vitro work showed that daidzein and genistein induced increased 
PGI2 production [24, 96, 97] and equol inhibited platelet activation and aggregation that 
were induced by thromboxane 2 analogs [24].   
An in vitro study has shown that equol treatment increased relaxation of endothelium in 
aortic and porcine pulmonary artery rings [155] in a dose-reponse manner [93]. Therefore, 
the bioactivity of equol per se could be related to the observed hemodynamic benefits in 
our study. This hypothesis can be tested by styding the effects of equol supplements intake 
on endothelial and hemodynamic functions in human studies and to our knowledge, the 
literature lacks such studies.  
The urinary concentration of isoflavones significantly increased after 6 and 12 months of 
consumption of study intervention (P values<0.001 for all analytes).  Our data did not show 
any equol producer cross-overs (i.e. their equol-producer status was altered), which agrees 
with the literature reviewing equol production as a permanent capability except during 
administration of antibiotic [17, 172, 230]. In contrast, some studies have reported 
significant cross-overs in equol producer phenotype over longer periods [191, 192, 231, 
232]. It has been suggested that equol producer phenotype might significantly change and 
antibiotic use influences it inconsistently [191, 192]. 
Our results suggest that the positive associations between equol producer phenotype and   
the flavonoid intervention on hemodynamic function and arterial stiffness are more 
profound after long term exposures (12 months rather than 6 months). These findings might 
explain the epidemiological data on better profiles of cardiovascular risk factors, including 





lower blood pressure and plasma lipids [25, 28] in equol producers compared to non-equol 
producers in Asian populations that have daily dietary intakes of high isoflavones.   
Another interesting data was observed at baseline, where equol producers had significantly 
higher plasma levels of vasodilation markers NO and NO/ET-1 (P<0.01, 0.05, 
respectively), lower plasma levels of the vasoconstrictor marker ACE (P<0.05), and better 
profile (but not statistically significant) for almost all studied vascular markers than non-
equol producers, Table 2.3. The literature lacks information about plausible explanation 
for association between equol producer phenotype and better vascular health independent 
of soy supplementation. It has been suggested that the gut bacterial flora might have an 
effect on the oestrogen metabolism [200]. Specifically, inter-individual differences in 
intestinal microflora species may contribute to variation in disease vulnerability through 
effects on metabolism and subsequent exposure to phytoestrogens. It might be postulated 
that the capacity to produce equol is a marker for other mechanisms that may have an effect 
on the vascular function. For instance, the equol producer phenotype has been studied in 
assessment of breast and prostate cancer risk [125].   
Our analysis had strengths in its double-blinded randomised design, long duration of 
intervention, good compliance to intervention, reproducible and robust clinical methods 
such as ambulatory blood pressure that produces more representative data than blood 
pressure measured in clinics [233]. Some baseline characteristics of equol and non-equol 
producers showed no statistical difference, such as years at menopause, diabetes duration, 
percentage of women who used blood pressure medications, insulin, and past history of 
smoking. On the other hand, it is notable that equol producers showed non-significant 
better profiles for blood pressure, PWV, HOMA-IR, and fasting insulin and significant 
higher levels of baseline plasma NO, NO/ET-1, and ACE than non-equol producers, which 
might have masked beneficial effects of flavonoid intake in equol producers compared to 
non-equol producers.  
This trial was not designed to determine the responsiveness to soy interventions in equol 
producers and a formal sample size calculation was not considered a priori. For instance, 
our data of PWV included only 7 equol producers, and there was not a standard method of 
soy challenge to properly evaluate equol producer phenotype prior to intervention in the 
subjects allocated to the control group. The soy challenge is important because soy intakes 
are not part of the habitual diet of the study general population. Using standard soy 





challenge would have enabled us to include the participants in the placebo (control) group 
in the analysis and investigate the effects of the flavonoid intervention in equol and non-
equol producers. We would have also had a larger sample size to study the baseline 
differences in vascular function between equol and non-equol producers independent of 
isoflavone intake.  
Additional weakness of this analysis lie in the supplementation that included flavan-3-ols 
in addition to isoflavones which also suggest effects of flavan-3-ols supplementation that 
might have masked the differential responsiveness of equol producers to isoflavones. The 
lack of a controlled low-nitrate diet constitutes a limitation of assessment of NO activity 
measured as plasma nitrite/ nitrate as it is stated that the circulatory concentration of these 
NO metabolites (nitrate/ nitrite) reflects constitutive eNOS activity in vivo, but only under 
















2.6 Conclusion  
In summary, our retrospective analysis showed that equol producers had improved 
hemodynamic markers and arterial stiffness, particularly reduced diastolic BP, MAP and 
central PWV in comparison to non-equol producers at increased risk of developing CVD 
after 12 months of isoflavone containing food intake. These effects were not apparent after 
6 months intervention, which might reflect the importance of longer-term chronic 
interventions. However, the observed hemodynamic benefits in equol producers could not 
be imputed to the 12 month flavonoid consumption because the control arm was not 
included in the analysis (due to the absence of soy challenge prior to the intervention).  
Consequently, studies with prospective analysis for equol producer phenotype would 
provide better research tool that follows hypothesis-driven controlled design, has powered 
sample size and they should follow a standard method for identification of equol producer 
phenotype independent of analysis procedure and daidzein intake.   






Chapter 3 The effect of soy isoflavone intake on 
vascular health – potential differential effects in 
prospectively recruited equol and non-equol producers 
 
3.1 Introduction  
There is growing research on the potential health benefits of the equol producer phenotype, 
which is apparent in 20-30% of Western and 50-60% of Asian populations [141].  In 
particular, the ability to produce equol has been associated with a reduction in 
cardiovascular risk factors. In observational studies on Asian populations exposed to 
isoflavones through their habitual soy intake, equol producers had a more favourable blood 
pressure profile [28], significantly improved plasma lipids [25, 28], and inflammatory 
biomarkers [25, 26] compared to  non-equol producers. In two intervention trials on 
Caucasian postmenopausal women, equol producers had lower arterial stiffness, improved 
endothelial function, lower blood pressure [165, 166] and higher circulating concentrations 
of the most potent vasodilator nitric oxide (NO) [220]. In support of these findings, equol 
has also been shown to possess higher bioavailability with a longer half-life and higher 
circulating concentrations than the major isoflavones daidzein, genistein and glycitein. In 
vivo [19] and in vitro studies have also shown that equol has a greater antioxidant [20-22] 
and vasodilator activity [23, 24] compared to its parent compound, daidzein. 
Retrospective analysis of randomised controlled trials (RCT) which have intervened with 
soy-based foods, or supplements, for between 4 weeks to 12 months [6] [15, 220], have 
shown significant reductions in risk markers of cardiovascular disease (CVD) in equol 
producers. In particular, effects on blood pressure [15, 220], arterial stiffness [220] and 
endothelial function [6] have been reported. 
Despite these promising data, there is limited evidence from isoflavone RCTs to explain 
the potentially beneficial associations between equol producer capacity and vascular 
function. Almost all previous research on the role of equol producer phenotype on the 
vascular health is derived from observational studies or retrospective analyses of RCTs. 
To our knowledge, only one published study to date has prospectively recruited equol 





producing versus non-equol producing postmenopausal women [166]. These data 
suggested that hemodynamic function and arterial stiffness were not affected by 8 week 
exposure to isoflavone intake (52 g of soy protein drink containing 112 mg of isoflavones). 
However, this lack of effect may have been due to at least two factors; I) significant 
differences in vascular function which were observed at baseline between equol and non-
equol producers and II) the use of the oestrogen replacement therapy Tibolone by the study 
population, that is known to affect vascular function [235]. It is also notable that most of 
the previous RCTs have been limited to postmenopausal equol producers and there is a gap 
in studying equol producer males. It has also been suggested that the stage of disease 
development may be related to the bioactive effects of isoflavones; one meta-analysis has 
shown that chronic isoflavone intake was associated with greater improvements in 
endothelial function in subjects with initial endothelial dysfunction (i.e. those at elevated 
CVD risk) [2]. 
In terms of study design, an important factor, related to bioavailability, is the time of 
collection of vascular measures and biological samples. It has been suggested that the 
vasodilation induced by isoﬂavones could be positively correlated to the bioavailable 
levels of flavonoids [236-239], isoflavones [9] and potentially their bioactive metabolite 
equol. Therefore, vascular measurements are likely to be related to the peak levels of 
isoflavones, highlighting the importance of investigating the effects of isoflavone 
consumption on vascular function at peak concentrations of equol.  
There is also some evidence to suggest that food matrix may impact on the absorption of 
isoflavones and that isolated forms may be more bioactive [85, 86, 213]; studies are now 
required to further understand the importance of food matrix on vascular function and to 
determine the effects of isoflavone intake in prospectively recruited equol producers. 
In this chapter, we aimed primarily to examine the acute effects of isoflavone intake on 
vascular function in prospectively recruited equol and non-equol producer males at 
moderately elevated risk of heart disease and secondarily to investigate any differential 
effects of isoflavone matrix on the vascular response. 
Particularly, we hypothesised that a single dose of isoflavone intake would induce greater 
improvements on vascular function related measurements in equol producers than in non-





equol producers, at the anticipated peak times of plasma isoflavones (6 h post intervention) 
and equol (24 h post intervention).  
Our primary outcome measures were endothelial function (Reactive hyperaemia index 
(RHI)) and arterial stiffness measurements (assessed by Pulse wave velocity (PWV)), 
while blood pressure assessments and Pulse wave analysis (PWA) were secondary 
outcome measures.  
 
3.2 Methods 
3.2.1 Study design  
 
28 healthy subjects were recruited and completed our double blinded randomised 
controlled acute isoflavone intervention trial. Written informed consent was obtained from 
all subjects before participation. The national research ethics committee (REC) approved 
the study (REC number: 11/EE/0233). The study was conducted at the Clinical Research 
& Trials Unit (CRTU) at the University of East Anglia (United Kingdom) and followed 
the principles of the Declaration of Helsinki. It was registered at www.clinicaltrials.gov, 
NCT01530893 (note: this study was part of a bigger trial - the FASTCHECK study) 
consisting of different acute studies on isoflavones, flavanones and anthocyanins). 
Scientist contribution and all trial documents (i.e. poster, participant information sheet, 
health and lifestyle questionnaire, and consent form) are provided in Appendix C, page 
183.  
 
Sample size  
 
Our aim was to prospectively recruit 14 equol producers and 14 non-equol producers. Our 
sample size calculations included 80% statistical power at 5% significance levels. It 
assumed expected mean differenceSD of 0.50.4 for RHI (endothelial function 
assessment) [46] and 1.51.2 m/sec for PWV [240] (arterial stiffness assessment), 
respectively. According to these calculations, we required 12 participants per group 
(Sample size= 16 (σ2/ Δ2) +1, σ= standard deviation of variable as estimated, Δ= expected 





mean difference, [241]) to complete study.  Assuming 15% drop out, we recruited 14 
subjects per group. These calculations were based on clinical treatments/studies (not 
nutrition related interventions) and thus the sample size might be under-powered. 
Nevertheless, it was deemed appropriate to carry out the study due to the limited study 
budget and the fact that similar sample sizes (n=10) were used in previous acute cross over 
flavonoid RCTs showing beneficial effects on vascular function [236-239].  
 
Inclusion and exclusion criteria 
 
The study included men aged 50-75 years, with a 10-year risk of CVD of 10-20% (based 
on age, lipid profile and systolic blood pressure [36]) and excluded those who were 
smokers/ ex-smokers for at least 3 months prior to study start, those clinically diagnosed 
with vascular disease, diabetes, cancer, hepatic, renal, digestive, haematological, 
neurological and/ or thyroid disorders, those prescribed anti-hypertensive, statin, antibiotic 
medications or with planned vaccinations, those consuming flavonoid supplements (within 
3 months prior to the study), or having a soy allergy.  
 
Recruitment and eligibility  
 
Participants were recruited through local advertisements (i.e. poster and electronic mail 
out) including Norwich research park (NRP), local media including newspapers, and radio 
and targeting potential local groups/ societies (e.g. Parish councils), advertising in public 
events such as science fairs, and through GP practices (posters and hardcopy mail-outs). 
The primary eligibility of those showing interest in participating in the study was assessed 
after completion of a health and lifestyle questionnaire (H&LQ). Eligible subjects then 
attended a consent visit where they were provided with three soy bars and a urine collection 
pot to assess their equol producer phenotype (described in more details in 3.2.5). 
Participants, who had provided consent, attended a clinical screening visit during which 
blood pressure (BP), pulse, anthropometric measurements and fasted blood samples were 
collected. Age, systolic BP, and ratio of total cholesterol to HDL-cholesterol were 





incorporated into the Cardiac risk assessor (by Joint British Societies' Cardiac Risk 
Assessor Computer Program) to assess the subject 10 year CVD risk.  
 
Soy challenge for identifying equol producers 
 
Participants undertook a soy challenge to determine their ability to produce equol. A 
standard method was followed; each volunteer consumed a 63 g soy protein bar providing 
161 mg soy isoflavones as aglycone equivalents; 63.5 mg daidzein, 63.9 mg genistein and 
33.7 mg glycitein (commercial soy bars, Revival. CO, Kernersville, USA) for 3 
consecutive days and collected a mid-stream urine sample (50 - 80 ml) from the first urine 
voided on the 4th day. Participants were provided with the necessary 3 soy bars, instructions 
for soy bar intake, urine collection container at the end of the consent visit and returned 
the urine sample when attending the clinical screen. A questionnaire was administered to 
determine whether the soy bars were consumed. Urinary isoflavones are stable at room 
temperature [206]. On receipt, the urine was frozen at -80◦C until quantification of 
isoflavone concentrations.  
 
Blinding and randomisation    
 
Samples from eligible volunteers were quantified for their urinary concentrations of equol 
and daidzein by HPLC-MS/MS (analysis was done externally by HFL sport science, 
Fordham, Cambridgeshire, UK), following in-house developed method [150]. The results 
were sent to an independent researcher at UEA (who was not involved in the study 
conduction or outcome analysis) to identify equol producers as having urinary log10 S-
equol/ daidzein of greater than -1.75 [141]. All researchers involved in conducting the trial 
and participants taking part were blinded to the intervention order and equol producer 
phenotype until the end of analysis stage.  
A UEA staff member who was not involved in the study conduction or outcome analysis 
assigned labels A, B, and C to the three study interventions and this information was stored 
in a protected locked place. The intervention order were randomised using the random 





function in MS office Excel to create the three random intervention labels A, B, and C 
(interventions are described in Table 3.1, page 90) and the intervention order was provided 
to the research nurse giving the intervention foods who was not involved with the data 
collection/ analysis.  
 
 Intervention allocation 
 
14 equol-producers were identified and then 14 non-equol producers were matched with 
the identified equol producers for factors that might majorly affect vascular function 
including body mass index (BMI) and blood pressure. Two volunteers dropped out after 
the first visit and were replaced by two additional participants (Figure 3.8). Following a 
randomised crossover design, groups attended 3 assessment visits (isoflavone rich food 
assessment, isoflavone supplement assessment, and one placebo assessment). A wash out 
period of 1 week between each acute study day was selected based on other acute phase 
studies with flavonoids and polyphenols [242-246] and bioavailability studies on 




Figure 3.1 Randomisation to study interventions  
This figure describes the study design of cross-over randomisation to isoflavone supplement, 
isoflavone enriched cereal bar or placebo separated by at least 7 d in a randomised order. BP, Blood 
pressure; CVD, Cardiovascular disease; EP, Equol producers. 
 







An isoflavone dose of 80 mg was chosen because previous studies have reported enhanced 
endothelial function following consumption between 50 and 100 mg isoflavone (as 
aglycone units) per day [9, 63, 81, 220] and there have been no reported side effects for 
this intake. 
The isoflavone interventions included an:  
 isoflavone enriched protein bar (a 40 g soy protein bar, providing 80 mg aglycone 
equivalents of total isoflavone, prepared from SoyLife extract (40%) which  has a 
typical soy germ ratio of genistein : daidzein : glycitein which is 15 : 50 : 35). 
 isoflavone supplement (matched for isoflavone content, also containing 80 mg 
aglycone equivalents of total isoflavone, prepared from SoyLife extract (40%) 
which has a typical soy germ ratio of genistein : daidzein : glycitein which is 15 : 
50 : 35). 
 placebo supplement (matched for colour and containing carboxy-methylated 
cellulose (CMC)) and placebo bar (matched for micro and macronutrient content, 
flavour and texture) (Table 3.1).  
 





Food based intervention Supplement intervention  Placebo intervention  
Isoflavone enriched bar 
(80 mg aglycone 
equivalents of daidzein, 







(80 mg aglycone equivalents of 
daidzein and genistein and 
glycitein) 
Placebo bar 
(no  isoflavone) 
+ 
Placebo supplement 





Lifestyle and dietary control  
 
In order to control for potential confounders (e.g. dietary intake, alcohol consumption and 
physical activity) that might interfere and affect our analyses, participants were asked to: 
1. maintain their habitual lifestyle during the study (e.g. alcohol and dietary intake, 
physical activity) 
2. stop taking flavonoid containing dietary supplements 1 month prior to start of trial  
3. maintain typical intake of non-flavonoid supplements (i.e. fish oils, multivitamins) 
during study duration 
4. follow a low flavonoid diet for three days prior to commencing each study day  
Phenol explorer 2.0 database was used to identify foods that contain one or more of 4 
flavonoid subclasses (flavanols, anthocyanins, flavanones and isoflavones) that might 
have vascular and hemodynamic effects [13, 237, 239]. For each food, the portion size, 
which provided 10% of the intervention dose of any of the four flavonoids above, was 
calculated. Participants were asked to avoid the consumption of foods where one 
portion provided ≥10% of the intervention dose, and to restrict their intake of foods, 
where eating ≤12 portions of these foods provided ≥10% of the intervention dose, to 
one portion for the three days before study assessment. Alternative foods were 
suggested using dietary restrictions tables, for restricted food including foods if 
consumed more 12 portions provide 10%. In addition, we also asked participants to 
restrict the intake of food that contained other compounds [242] which, in previous 
publications, have been shown to have vascular effects i.e. such as oily fish.  
5. refrain from strenuous exercise for 48 hours before each study assessment 
6. abstain from alcohol consumption, and caffeinated products (including decaf coffee/ 
tea due to their flavonoid content) for 24 hours before each study assessment  
7. avoid nitrate and nitrite rich foods such as leafy green vegetables, broccoli, radishes, 
carrots, sausages, other processed and cured meats and bottled waters containing high 
levels of nitrate. Consumption of these foods elevate circulating NO metabolites 
concentrations [247]. 
8. eat a standardised evening meal consisting of a ready meal of low flavonoid and low 
nitrate/ nitrite content and bottled water (Buxton; containing <0.1mg/L nitrate) in order 





to control for any effect of recent background dietary intake on the biological 
assessments  
9. fast for 10 h prior to the clinical visit and advised to consume only the provided bottled 
water for 10 h prior to the assessment visit.  
  
Analysis of 24 dietary recalls 
 
Compliance to the dietary restrictions was monitored by 24hr food recall conducted by 
telephone 1-2 days prior to the assessment visit. In addition, 24h dietary recalls were used 
to calculate daily intakes of macronutrients. All data were analysed using software for 
nutritional analysis of dietary intakes (WISP version 4.0, Tinuviel software, Anglesey, 
UK).  
The food coding procedure was conducted following a standardised operating procedure 
conducted by two scientists and 10% of total food entries were re-entered to check 
accuracy of data analysis. Analysed data were reviewed for data below or above 3 Standard 
deviation (3SD) of average daily intakes of macronutrients. Food portion sizes were 
decided based on food standard agency (FSA), 3rd edition [248]. 
For unusual food entries, a decision tree was made to look for similar food items with best 
matching macronutrient percentages of energy>fat>protein>fibre content and all decisions 
made were justified, kept in a log and reviewed by two additional scientists.   
Assessment visits schedule  
 
Subjects underwent a baseline assessment i.e. anthropometric measurements (height and 
weight), blood pressure measurement, blood sampling, arterial stiffness and endothelial 
function measurements (Figure 3.2).  All measurements were taken in a temperature 
controlled (22-24°C) and dimly lit clinical room after at least a 15 minute resting period in 
a supine position.  
After the baseline measurements were completed, the intervention was administered by a 
research nurse (who was not involved in the blinding and randomisation procedure). Blood 
sampling and study assessment measurements were repeated at 2, 6 and 24 h after 
intervention administration, which corresponded to the anticipated peak plasma 





concentration of the isoflavones of interest (i.e. daidzein, genistein, glycitein and equol) 
from published literature [175, 201].  
 A standard lunch comprising of two cheese sandwiches and a vanilla flavoured yogurt 
(consisting of 31 g of protein, 96 g of carbohydrates and 27 g of fat providing 753 kcal) 
was administered after the 2 h assessment was finished. Participants were also provided 
with a standard pasta dinner (Brake Bros Ltd, Kent, UK) and asked to fast for at least 10 h 
before returning to the facility for the 24 h study assessment (Figure 3.2).  
 
Figure 3.2 Schedule of baseline and study assessments and time scale for visits  
Top panel represents timeline and schedule of each study day. Bottom panel represents + collection 
of blood samples and/ or clinical measurements that were collected at baseline, 2, 6 and 24 hours 
after intervention administration. BP, Blood pressure. 
 
3.2.2 Endpoints  
 
For each time point clinical vascular (CV) markers of endothelial function, arterial stiffness 
and blood pressure were assessed and blood sampling was conducted in an identical 
manner at each time point (0, 2, 6 and 24 h) for the analysis of isoflavone concentrations.  
Prior to the trial start, there were many training and test sessions for all staff involved in 
the conduction of the study measurements including anthropometrics, blood pressure, 
arterial stiffness (PWV, and PWA assessed by Vicorder) and endothelial function (RHI 
assessed by EndoPAT) assessments. In addition, there were training sessions provided by 
the manufacturer (for Vicorder) and dry runs of the study assessment.  However, the intra-
observer coefficient of variation in reproducibility tests were not collected.  





Blood pressure measurements 
 
Ambulatory blood pressure measurements were obtained over a 24 h observation period 
using a non-invasive ambulatory monitor (Spacelabs SL902072) approved by the British 
Society of Hypertension. The monitor automatically inflated every 10 minutes during the 
daytime and once/ hour between 22:00 pm and 6:00 am to minimally disturb participants 
at night. Participants were asked to keep their arm relaxed and still down by their side when 
the cuff inflated until deflation.  An appropriately sized cuff (pneumatic bag was 20% 
wider than the diameter of the upper arm; standard adult (24-32 cm), large adult (32-42 
cm) or extra-large adult (42-55 cm)) was placed on the non-dominant arm at the heart level. 
One off measurement was made at each start of baseline assessment at supine position. 
The monitor was then attached during the measurement gaps between baseline and 2 h 
assessments, 2 h and 6 h assessments, and 6 h and 24 h assessments. However, it was 
detached during CV measurements. Blood pressure measurements included systolic BP, 
diastolic BP and MAP. Participants were provided with a diary sheet to record any unusual 
events, their sleeping hours, error messages and times when they removed the ambulatory 
device. In addition, before each assessment battery, systolic and diastolic BPs were 
measured in triplicate using a validated Omron device 705IT (Omron Healthcare Co., 
Kyoto, Japan).   
Arterial stiffness 
 
Measurements of arterial stiffness were conducted by carotid- femoral pulse wave velocity 
(c-f PWV) and augmentation index (AI) using the Vicorder device (Skidmore Medical Ltd, 
Bristol, UK). 
Pulse wave velocity (PWV) 
 
Measurement of PWV is a non-invasive, researcher independent and reproducible method 
[55]. The aortic (carotid - femoral) PWV is considered the gold standard for assessment of 
arterial stiffness and greater arterial stiffness is associated with an increased cardiovascular 
mortality in adults with hypertension and coronary heart disease. PWV has been 
recommended for the assessment of individual CVD risk and therapy by the European 
Society of Hypertension [35] [55]. 





PWV was measured using the Vicorder equipment, which allowed simultaneous 
oscillometric measurements of the carotid and femoral pulse waves [249, 250]. C-f PWV 
was assessed by placing BP cuff around the neck at the carotid artery level and placing 
another BP cuff around the upper thigh at the femoral artery level. Good quality waveforms 
were recorded simultaneously for 7 seconds by a volume displacement technique. The 
upstroke to upstroke transit time was calculated using an in-built algorithmic equation. 
Path length was defined as the distance from the middle of the carotid cuff to the middle 
of the femoral cuff. PWV (m/s) was calculated from the ratio of the estimated distance 
travelled by the pulse (ΔL in meters) during the pulse transit time over the measured pulse 
transit time (ΔT in seconds) (Figure 3.3).  
 
 
Figure 3.3 Carotid femoral pulse wave (PWV) output using Vicorder  
An example of PWV from collected data during the study. The upper wave represents the pulse 
wave at the carotid artery and the lower one represents the pulse wave at the femoral artery. ΔT is 











Pulse wave analysis (PWA) 
 
PWA studies the arterial pressure wave and consists of the wave produced by left-
ventricular contraction and the reflected wave from the peripheral arteries [55]. 
PWA was undertaken using the Vicorder by placing a cuff around the brachial artery to 
estimate AI and cardiac output (CO). Aortic waveform and central BP were then calculated 
using the inbuilt brachial-to-aortic transfer function. The AI was calculated from difference 
in amplitude between the first and second systolic peaks divided by pulse pressure × 100, 
while pulse pressure is the difference between aortic systolic and diastolic BP. The cardiac 
output (CO) was calculated by multiplying the stroke volume by heart rate (Figure 3.4).  
 
 
Figure 3.4 Pulse wave analysis (PWA) output using Vicorder  
An example of PWA from collected data during the study. PWA represent estimate the aortic pulse 
wave (red) from the pulse wave at the brachial artery (blue). AI= augmentation pressure (difference 
the first and second systolic peaks)/ pulse pressure × 100, and CO= stroke volume x heart rate. BP, 
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Endothelial function was assessed using a non-invasive method, whereby a beat-to-beat 
plethysmographic recording of peripheral arterial tone (PAT) [46, 239] was assessed using 
finger cuff s by the EndoPAT 2000 equipment (Itamar Medical Ltd, Israel). Each 
measurement included 5 min baseline, 5 min occlusion (using a minimum 60 mmHg above 
the systolic blood pressure) and 5 minutes post-occlusion recordings [46, 239] (Figure 3.5). 
Reactive hyperaemia (RHI) was induced after release of brachial artery occlusion and the 
other arm was used as control for any confounding effects of the sympathetic system. RHI 
is calculated using an inbuilt automated algorithm (EndoPATTM 2000, software 3.5x). 
Consistently, all PAT measurements were conducted on one arm and the blood collection 




Figure 3.5 Reactive hyperaemia index (RHI) calculations by EndoPAT  
A= Mean PAT amplitude between 90-150 seconds post occlusion, and B= Mean PAT amplitude 
from the baseline period of the assessed arm. C= Mean PAT amplitude between 90-150 seconds 
post occlusion and D=Mean PAT amplitude from the baseline period of the control arm. Figure 
reproduced from (http://www.itamar-medical.com/). PAT, peripheral arterial tone; RHI, reactive 
hyperaemia index.  
 
3.2.3 Analysis of isoflavones in blood samples  
 
Plasma concentrations of the isoflavone metabolites of daidzein, genistein, glycitein, and 
equol were analysed using LC-MS based on a previously developed method [150, 251] 
and details are described below. With the exception of the plasma samples collected at 
baseline, all samples were analysed individually. For each participant, the plasma samples 





collected at baseline were pooled together before analysis. The baseline sample pooling 
was done to reduce the required time and consumables for analysis including enzyme 
hydrolysis, and solid phase extraction of study samples (which were done manually 
because the 96 well plate extraction was not feasible in our laboratory).  
The pooling was done only to the baseline samples because these samples were expected 
to have negligible concentration of all isoflavones and equol (the participants were on a 
controlled diet). If any pooled sample had shown substantial isoflavone/equol levels, the 
individual samples would have been analysed again to identify the outlier. This was not 
the case and all baseline plasma samples showed negligible amounts of isoflavones (Table 




Daidzein, genistein, glycitein, taxifolin, β-glucuronidase type HP-5, and sulfatase type HP-
1 from Helix pomatia were purchased from Sigma (Sigma-Aldrich Ltd, Dorset, UK). S-
equol was purchased from Caymen chemical company (Cambridge Bioscience Ltd, 
Cambridge, UK).  Stock standards were prepared at 50 mmol/L in dimethyl sulfoxide 
(DMSO), from which sub-aliquots were stored at -80°C to use when preparing mixture of 
standards.  
 
Sample collection and preparation  
 
Blood samples were collected in Sodium heparin tubes. Within 30 min, samples were 
centrifuged at 3300 g for 10 min at 4°C and plasma was stored in aliquots at -80°C until 
further analysis. Sample preparation for the analysis of isoﬂavones in plasma was 
performed following the method developed by [251]. Briefly, plasma (200 μL) was thawed 
before addition of 25 μL of each β-glucuronidase type HP-5 (100,000 U/mL) and sulfatase 
type HP-1 (1,000 U/mL) from Helix pomatia, 200 μL phosphate buffer (pH 5), and 1.2 μL 
of internal standard taxifolin (1 mg/mL in matched-matrix human serum). Isoflavone 
conjugates were hydrolysed by incubation at 37°C for 3 h. Thereafter, 200 μL cold 
methanol was added to each tube, tubes were mixed and left for 20 min at room temperature 
for equilibration of the two phases. Samples were then spun for at 12,000 rpm for 15 min 





at 0°C and then 200 µL supernatant were transferred into solid phase extraction (SPE) 
cartridges (Strata-XTM, 1 mL, 30 mg, Phenomenex) for extraction of aglycones. 700 μL of 
methanol, followed by 700 μL 30% methanol (aqueous) were used to condition the SPE 
cartridges as stated in the manufacturer's instructions. Samples were then loaded onto the 
cartridges and washed twice with 600 μL 40% methanol. Afterwards, the aglycones were 
eluted using 600 μL acetonitrile/ methanol (1:1 v:v). The eluates were dried in Speedvac® 
centrifugal evaporator (Savant, USA) and reconstituted in 100 μL 40% methanol and 
stored at −80°C until injection in the LC-MS. A blank was prepared and used to control 
for the levels of isoflavones found naturally in the β-glucuronidase and sulfatase. 
Calibration standards were prepared in matched-matrix of fasted human serum, which was 




Following hydrolysis and SPE, sample analysis was performed on an Agilent 1200 series 
HPLC coupled to an AB Sciex 3200 series Q-trap LC/MS/MS system, with samples 
injected onto a Kinetex pentafluorophenol (PFP) RP-HPLC column (2.6 µm, 100 x 
4.6 mm) with PFP Security Guard cartridge (4 x 2.0 mm) from Phenomenex, UK. The 
column temperature was set at 37°C, and samples were stored in the autosampler at 4°C 
prior to injection. The system was controlled by Analyst software (v. 1.5, Applied 
Biosystems/MDS Sciex). 
 
 For analysis of daidzein, genistein and glycitein 
 
Daidzein, genistein and glycitein were eluted from the column using a flow rate of 1 
mL/min over a 22 minute gradient elution as detailed in Table 3.2. A binary solvent system 
was used consisting of 0.1% formic acid in MilliQ water (solvent A), and 0.1% formic acid 











Table 3.2 Solvent gradient for analysis of genistein, daidzein, glycitein, and taxifolin 
Time (min) % A      %B         
0 99.9 0.1 
14 60      40 
15 0 100 
17 0 100 
18 99.9 0.1 
22 99.9 0.1 
 
Quantification was conducted in negative mode using multiple reaction monitoring 
(MRM), with the compound parameters optimised for each standard with m/z of the parent 
(Q1) and daughter fragments (Q3) as shown in Table 3.3. The MS/MS source parameters 
included curtain gas 40 psi, ion spray voltage -4000V, temperature 700 °C, nebulizer gas 



























Table 3.3 Optimised MRM compound parameters for the target analytes  
Analyte Q1 
(m/z) 
Q3 (m/z) Time (ms) DP (V) EP (V) CE (V) CXP (V) 
Genistein* 269 133 100 -100 -10 -35 -2 
Genistein 269 107 100 -100 -10 -35 -2 
Genistein 269 181 100 -100 -10 -35 -2 
Genistein 269 224 100 -100 -10 -35 -2 
Daidzein* 253 91 100 -97 -10 -51 -1.19 
Daidzein 253 133 100 -97 -10 -45 -1.19 
Daidzein 253 208 100 -97 -10 -40 -1.19 
Daidzein 253 224 100 -97 -10 -35 -1.19 
Glycitein 283 184 100 -80 -8 -55 -3.6 
Glycitein 283 196 100 -80 -8 -55 -3.6 
Glycitein 283 211 100 -80 -8 -55 -3.6 
Glycitein 283 240 100 -80 -7 -35 -3.6 
Glycitein* 283 268 100 -80 -7 -26 -3.6 
Taxifolin 303 285 50 -50 -5 -17 0 
Taxifolin 303 151 50 -50 -5 -30 0 
Taxifolin* 303 125 50 -32 -5 -26 0 
* refers the predominant precursor ions/MS2 fragments used for single reaction monitoring (SRM) 
quantification. CE, collision energy corresponding to MS2 fragment; CXP, collision cell exit 
potential; DP, declustering potential; EP, entrance potential; MS, Millisecond; Q1, precursor ion; 
Q3, MS2 fragments; V, Volts.  






Figure 3.6 Multiple reaction monitoring (MRM) chromatograms of major 
isoflavones  
Standards of daidzein, genistein, and glycitein were spiked in extracted (SPE) fasted serum at 5 
M.   
 
 For analysis of S-equol 
 
The method described previously was found to be unsuitable for the analysis of S-equol 
due to its poor ionisation in acidic conditions (pKa of S-equol = 9.94), which were required 
for optimum ionisation of the other analytes. Figure 3.7 illustrates the improvement in the 
method sensitivity when S-equol was eluted in the absence of any acid modifier within the 
mobile phase. Therefore, S-equol was eluted using the same conditions as described 
previously, but with a mobile phase consisting of MilliQ water (solvent A) and acetonitrile 









Table 3.4 Solvent gradient for analysis of S-equol 
Time (min) % A %B          
0 75 25 
5 0 100 
7 0 100 
8 75 25 
10 75 25 
 
Quantification of S-equol was conducted in a negative mode, using multiple reaction 
monitoring (MRM), with the compound parameters optimised for each standard with m/z 
of the parent (Q1) and daughter fragments (Q3) as shown in Table 3.5.  The MS/MS source 
parameters were as described previously. 
 
Table 3.5 MS compound parameters for analysis of S-equol 
Analyte Q1 (m/z) Q3 (m/z) Time (ms) DP (V) EP (V) CE (V) CXP (V) 
S-equol 241 93 100 -63 -2 -42 -1 
S-equol* 241 119 100 -63 -2 -34 -1 
S-equol 241 121 100 -63 -2 -20 -1 
S-equol 241 135 100 -63 -2 -26 -1 
Taxifolin 303 285 100 -50 -5 -17 0 
Taxifolin 303 151 100 -50 -5 -30 0 
Taxifolin* 303 125 100 -32 -5 -26 0 
Dwell time of 100 ms was constant across all transitions. * refers the predominant precursor 
ions/MS2 fragments used for single reaction monitoring (SRM) quantification. CE, Collision 
energy corresponding to MS2 fragment; CXP, Collision cell exit potential; DP, Declustering 

















Figure 3.7 Multiple reaction monitoring (MRM) chromatograms showing the ion 
pairs used for quantification of S-equol  
S-equol standard spiked in extracted (SPE) fasted serum. A) shows ionisation of S-equol (50 M) 
in  0.1% formic acid in MilliQ water (solvent A), and 0.1% formic acid in acetonitrile (solvent B). 
B) shows ionisation of S-equol (5 M) in MilliQ water (solvent A) and acetonitrile (solvent B).  
 





Method validation  
 
Analytes were quantified using Analyst software (v. 1.5, Applied Biosystems/MDS Sciex). 
Their identities were confirmed by retention time (using standards) and three ion 
transitions. The HPLC-ESI-MS/MS method was validated for linearity and precision 
across all analytes, based on the United States Food and Drug Administration's (U.S. FDA) 
guidelines for analytical method validation. Six point standard curves ranging from 0.039 
to 5 µmol/L were constructed. The inter-assay and intra-assay precisions had overall means 
of 12% and 11%, respectively (with a range between 6.7% to 18.0%; data were calculated 
from 4 standard curves and quality controls that were analysed regularly) and linearity of 
the standard curves was established as R2= 0.9916-0.9999 (CV%= 12%) across all analytes 
and for both methods. The recovery (extraction efficiency) of the method was evaluated 
by comparing the analytical results for samples spiked with the analytes prior to extraction, 
to samples spiked with the analytes post extraction. The extraction efficiencies for the 
analytes of interest ranged from 81% to 92% (prepared in triplicate). The limit of detection 
of the method were established by calculating the concentration of the analyte yielding a 
signal to noise ratio of 3:1, and were established as 0.003 µmol/L for genistein, 
0.001µmol/L for daidzein and glycitein, and 0.002 µmol/L for S-equol.  
 
3.2.4 Statistical analysis  
 
All data are presented as mean±standard error of mean (SEM).  Results were considered 
statistically significant at P< 0.05. Only volunteers who completed all interventions were 
included in the analysis. Statistical analyses were performed using SPSS software 
(version 22). Primary outcomes were the change in endothelial function (RHI) and arterial 
stiffness (PWV) following isoflavone intervention intake in equol and non-equol 
producers. Secondary outcomes included effects of interventions on BP, AI and biological 
markers of CVD risk. 
Before start of analysis, a statistical plan was prepared. During the statistical analysis, we 
were blinded to treatment and equol producer phenotype. For each variable/outcome, 
outliers (mean±3.5 SD) have been identified and then the case report forms were reviewed 
for any unusual comments/errors that could explain the outlier result. There were no 
unusual errors or comments that could explain the outliers and thus all results were 





included in the analysis. Shapiro-Wilk test was used to assess normality of data. Levene’s 
test and Mauchly’s test were applied to check equality of variances for use of univariate 
analysis and homogeneity of variance for use of repeated measures analysis of variance 
(ANOVA), respectively. Baseline characteristic health data were evaluated for statistical 
differences using Student’s independent t test. In addition, baseline data for outcome 
variables were evaluated for statistical differences between the intervention/ equol 
producer groups using univariate analysis.  
Given the cross-over design of our study in prospectively recruited equol and non-equol 
producers, the most suitable statistical model  is mixed general linear model with repeated 
measures analysis [252].  
First, we conducted our analysis following a repeated measures general linear model that 
included two within subject factors (treatment at three levels A, B, C and time point at 4 
levels baseline, 2 h, 6 h and 24 h) and one between subject factor (equol producing status 
at 2 levels 1 and 2).  The model investigated significant differences of outcomes at baseline, 
2 h, 6 h, and 24 h after consuming A, B, C in equol producers and non-equol producers (by 
including interaction of treatment, time and equol producing status factors). Posthoc tests 
using Bonferroni correction were done to test pairwise comparisons between groups, time 
points and treatments and highlight where statistically significant differences occurred. 
There were no statistical differences for any variables/outcomes and it was difficult to 
interpret results due to the 4 time points included in the analysis.   
Subsequently, we adopted the second option in the statistical plan, which was to separate 
the analysis based on time points, which enabled us to relate our results to the peak times 
of major isoflavones daidzein and genistein (outcomes measured at 6 h) or metabolite 
equol (outcomes measured at 24 h).  Outcomes were analysed as changes from baseline to 
2 h, 6 h or 24 h post-intervention. Three models were used to investigate significant 
differences in change from baseline to 2 h, 6 h or 24 h after consuming placebo, isoflavone 
supplement, or isoflavone rich cereal bar in equol and non-equol producers (by including 
interaction between intervention and equol producer phenotype factors). Each model 
included one within-subject factor (repeated ANOVA for intervention at 3 levels: placebo, 
isoflavone rich cereal bar and isoflavone supplement) and one between-subject factor 
(equol producer phenotype at two levels: equol vs. non-equol producers). Bonferroni 
correction was used to test post hoc comparisons and to highlight where statistically 
significant differences occurred.  





Our statistical analyses included different possible confounding factors such as age, BMI, 
and treatment order. Including BMI and treatment order did not make a difference to the 
outcomes and it was decided to include only age in the model as it was statistically different 
between the two groups of equol and non-equol producers. 
LCMS data was analysed using univariate analysis in equol and non-equol producers 
separately to investigate differences in plasma concentrations of daidzein, genistein, 
glycitein and S-equol following intakes of the three different interventions (placebo, 
isoflavone rich cereal bar and isoflavone supplement). Additional analyses were run for 
differences in concentrations between baseline and the different time points. Our plasma 
analyses revealed that circulating levels of isoflavones after consumption of the isoflavone-
enriched cereal bar were not significantly different from circulating levels of isoflavones 
after consumption of placebo, suggesting that the purchased bars did not contain a 
sufficient amount of bioavailable isoflavones. Unfortunately, we did not independently test 
the isoflavone content of the bar prior to commencing the study. Therefore, we amended 
our statistical analysis on vascular bioactivity to include only data collected after placebo 
or isoflavone supplement intervention and all presented data are related to a comparison 
of these two arms of the study. For ambulatory blood pressure data, participant data with 
less than 70% of the expected number of recordings were excluded [253]. In addition, 
ambulatory blood pressure measurements were analysed as mean±SE of systolic blood 
pressure, diastolic blood pressure and mean arterial blood pressure collected at the 
following time intervals: 2 to 6 h (relating to significant plasma levels of isoflavones) and 
8 to 24 h excluding night time data (relating to significant plasma levels of equol) post-
intervention. 
Spearman nonparametric test was used for bivariate correlations between plasma equol 
concentrations and the vascular endpoints because the plasma concentrations of equol were 











3.3 Results  
3.3.1 Baseline characteristics of equol and non-equol producers  
 
During the recruitment phase of the trial, 190 volunteers were screened, from which 42 
participants were identified as eligible to take part in the study based on our 
inclusion/exclusion criteria. These participants undertook the soy challenge, and 14 (33%) 
were selected as equol producers and were matched to an equal number of non-equol 
producers based mainly on criteria related to our primary vascular endpoints, BMI and 

















Figure 3.8 Participant recruitment and enrolment 
This figure explains the number of participants recruited and enrolled in the study, eligibility 
according to CVD risk, identification of eligible equol producers and matching them to non-equol 
producers. 
 
Our study population ranged in age from 50 to 70 years old, BMI of 19 to 35 kg/m2 and 54 
% of them were classified as having phase I pre-hypertension and at 10% to 20 % risk of 
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developing CVD over the next 10 years (Table 3.6). Baseline characteristics were similar 
between equol producers and non-producers; except for age - equol producers were 
approximately 5 years younger than non-equol producers. However due to the limited time 
frame for completion of the study, it was not feasible to continue recruitment for age-
matched groups (Table 3.6). 
In addition, the estimated daily dietary macronutrient intakes were similar between the two 
groups. Equol and non-equol producers showed dietary intakes consisting on average of 
18.6± 1.1 %, 18.6±0.9 % protein; 47.6±1.7 %, 46.1±2.6 % carbohydrates; and 34.2±1.6 %, 
35.7±2.1 % fat, respectively (Table 3.7). 
 
Table 3.6 Baseline characteristics for the participants who completed the trial 





Age (range in years) 54-70 50-69  
Height (m) 1.77±0.01 1.80±0.02  
BMI (kg/m2) 25.0±1.0 26.4±0.9  
LDL-C (mmol/l) 3.82±0.20 3.86±0.21  
TG- (mmol/l) 1.24±0.15 1.49±0.20  
Systolic BP (mmHg) 133±2 131±3  
Diastolic BP (mmHg) 80±1 81±2  
CVD risk (%) 16±1 14±1  
All values presented as mean±SEM, with the exception of age (presented as a range). All P> 0.05 
(Student’s independent t test), except age P=0.01. BMI, Body mass index; BP, Blood pressure; 















Table 3.7 Daily macronutrient intakes calculated from 24 h dietary recalls 





Energy (kcal/d) 1622±100 1777±119 0.36 
Protein (g/d) 76.0±6.1 80.3±4.0 0.54 
Carbohydrate (g/d) 194±15 200±13 0.74 
Sugars (g/d) 77.8±6.3 73.6±7.5 0.67 
Starch (g/d) 114±11 124±10 0.47 
Total Fat (g/d) 61.9±5.1 73.2±8.66 0.27 
Saturated fatty acids  (g/d) 23.7±2.3 29.7±3.2 0.14 
Monounsaturated fatty acids (g/d) 20.2±1.7 23.5±3.0 0.34 
Polyunsaturated fatty acids (g/d) 8.99±0.73 10.4±1.5 0.40 








Carbohydrates  47.6±1.7 46.1±2.6 0.62 
Fat  34.2±1.6 35.7±2.1 0.56 
Data presented as mean±SEM, P value for Student’s independent t test. 
 
3.3.2 Isoflavone concentrations in plasma  
 
Plasma concentrations of genistein, daidzein, and glycitein (post-hydrolysis quantified as 
aglycones) significantly increased 6 h after intake of isoflavone supplement compared with 
placebo (for all analytes, P< 0.01) with concentrations (mean±SEM) of 301±40, 
1692±269, 291±48 nmol/L in non-equol producers and 200±33, 1688±215, and 237±36 
nmol/L in equol producers, respectively (Table 3.8). Total plasma concentrations of 
isoflavone concentration decreased 24 h after consumption of the isoflavone supplement 
group but remained significantly higher than placebo (P< 0.01) (Table 3.8).  
In equol producers, plasma concentrations of equol showed a similar pattern, reaching a 
significantly higher mean concentration (236±81 nmol/L) at 24 h following intake of 
isoflavone supplements than that after placebo (range:12 nmol/L-1000 nmol/L) (Table 
3.8).  





Plasma concentrations of isoflavones after intake of the isoflavone-enriched cereal bars 
were low and ranged for daidzein from 0 to 238 nmol/L compared to a range from 253 to 
3436 nmol/L after isoflavone supplement intake. They were not significantly different 
from the placebo data (Table 3.8, and for P values see Appendix B, Table IV) and therefore 
we excluded this arm of the study from all subsequent analysis. A validated LCMS method 
was used for the plasma analysis (for further details section 3.2.3, page 97) and all study 
samples were extracted, and analysed in random order. In addition, prior to the sample 
analysis at the method development stage for the isoflavone analysis in plasma, these bars 
were used in experiments to develop LCMS methods that would quantify isoflavone 
metabolites and these tests failed three times repeatedly to identify any isoflavones or 
metabolites in the samples. The company had assured us that their cereal bars were 
isoflavone rich, and provided us the content (40 g soy protein bar, providing 80 mg 
aglycone equivalents of total isoflavone, prepared from SoyLife extract (40%) consisting 
of  a ratio, 15 : 50 : 35 of genistein : daidzein : glycitein). Unfortunately, these data were 
not independently confirmed prior to commencing the trial. It is therefore likely that there 
was an error in the preparation procedure of the cereal bar and/or used soy germ extract 
used to produce the bars.  The method development experiments and plasma data support 
no isoflavones in the soy bars. 





Table 3.8 Plasma concentrations of total isoflavones at baseline, 6 h and 24 h in non-equol and equol producers (n=28) after intake 
of either placebo or isoflavone intervention (80 mg isoflavone as aglycone equivalents) 
    
                                                            Intervention 
 
  





BL 6 h 24 h  BL 6 h 24 h   BL 6 h 24 h  
P value  P  value  
(6 h)  (24 h) 
Non-equol  Genistein 4±3 15±9 7±5 4±3 301±40 72±37 4±3 45±17 1±1 <0.001 0.093 
producers Daidzein 4±2 16±7 8±4 4±2 1692±269 170±46 4±2 54±16 6±4 <0.001 0.002 
(n=14) S-equol ND ND ND ND ND ND ND ND ND NA NA 
 Glycitein 21±7 20±13 3±2 21±7 291±48 54±12 21±7 28±10 ND <0.001 <0.001 
Equol  Genistein ND ND 3±3 ND 200±33 28±15 ND 7±3 ND <0.001 0.11 
producers Daidzein 1±1 3±2 4±2 1±1 1688±215 190±31 ND 39±11 4±2 <0.001 <0.001 
(n=14) S-equol ND ND ND ND ND 236±81 ND ND 11±5 <0.001 0.007 
  Glycitein 19±6 7±4 6±4 19±6 237±36 35±9 18±6 23±7 2±2 <0.001 0.009 
All values presented as mean±SEM. Univaraite analysis used. Presented P values for difference between placebo and isoflavone supplement intervention 
at 6 h timepoint (6 h), and at 24 h timepoint (24 h). Isoflavone or S-equol concentrations were significantly different from baseline at 6 h and/or 24 h after 
consumption of isoflavone supplement, while these concentrations were not significantly different from baseline at 6 h or 24 h after consumption of placebo 
(P values are shown in Appendix B, Tables II&III). BL, Baseline; NA: Not applicable; ND, non-detectable or below limit of detection. Note: isoflavone 
concentrations were not significantly different between isoflavone enriched bar and placebo in both equol and non-equol producers at 6 h and 24 h (P 
values are shown in Appendix B, Table IV).





3.3.3 The role of the equol producer phenotype in explaining the 
potential acute effects of isoflavone intake on vascular function 
 
There were no significant differences in the assessed vascular measures between equol and 
non-equol producers at baseline (Table 3.6) or 2 h after isoflavone consumption (Appendix 
B, Table V).  At 6 h after isoflavone intake, there were no effects of isoflavone supplement 
intake on the assessed vascular measures; including endothelial function (assessed by 
peripheral arterial tone (RHI)), arterial stiffness (PWV, and AI), or systolic and diastolic 
BP in either equol or non-equol producers (Table 3.9).  
At 24 h after isoflavone  supplement intake, arterial stiffness assessd by PWV significantly 
decreased in equol producers 24 h after intake of isoflavone supplement (change from 
baseline in PWV: -0.2 ± 0.2 m/s after isoflavone intake, versus 0.6 ± 0.2 m/s after placebo 
intake, P= 0.002, Figure 3.9). Notably, these changes in PWV were significantly correlated 
with plasma equol concentrations 24 h post-isoflavone supplement consumption (r= -0.36, 
P = 0.01, Figure 3.9). However, there were no additional observed effects on RHI, AI, CO, 
systolic and diastolic BP (Table 3.10). No significant changes were observed in non-equol 
producers 24 h after intake of isoflavone supplement (change from baseline in PWV: 0.3 
± 0.2 m/s after isoflavone, versus -0.1 ± 0.2 m/s after placebo intake, P= 0.21, Figure 3.9).  
After plotting the hourly means for all collected ambulatory BP dataset (Figure 3.10), it 
was noticeable that the systolic BP in non-equol producers had decreased levels between 
14:00 and 18:00 pm after isoflavone consumption while this pattern seems reversed in 
equol producers. However, when the average of systolic BP measurements collected 
between 2 and 6 h after isoflavone consumption (≈12:00 to 18:00 pm) were compared, 
there were not significantly different between equol and non-equol producers (Table 3.11). 
Overall, there were no significant effects on ambulatory systolic, diastolic BP and MAP 
assessed from the average of measurements collected between  2 and 6 h (Table 3.11), and 
8 and 24 h (Table 3.12) after intake of isoflavone supplements in either equol and non-
equol producer groups.   










Intervention Time (h) RHI** 
    
CO (L/min)  AI (%)  PWV (m/s)  Systolic BP   Diastolic BP  
(mm Hg) (mm Hg)  
 Non-equol 
Placebo 
0 2.57±0.15 128±2 76±2 4.30±0.18 26±2 9.9±0.2 
producers 6 2.92±0.20 126±3 72±2 4.54±0.24 24±1 9.8±0.3 
(n=14) 6-0* 0.39±0.22 -2±3 -4±2 0.18±0.15 -2±1 -0.1±0.2 
 80 mg 
isoflavone 
supplement 
0 2.58±0.15 128±3 76±2 4.32±0.17 26±1 9.7±0.3 
 6 2.51±0.16 122±3 70±2 4.39±0.23 25±2 9.6±0.3 
  6-0* -0.05±0.26 -7±3 -5±2 0.03±0.24 -2±1 -0.3±0.2 
 Equol  
Placebo 
0 2.72±0.16 122±6 82±3 3.92±0.21 24±1 9.9±0.3 
producers 6 2.39±0.17 120±4 78±4 4.40±0.20 21±1 10.1±0.3 
(n=14) 6-0* -0.38±0.23 -3±3 -5±2 0.54±0.15 -3±1 0.2±0.2 
 80 mg 
isoflavone 
supplement 
0 2.62±0.17 123±6 83±3 4.09±0.21 25±1 10.0±0.3 
 6 2.19±0.21 121±5 77±4 4.61±0.32 22±1 10.4±0.4 
  6-0* -0.46±0.27 -3±3 -6±2 0.56±0.24 -3±1 0.5±0.2 
P value                                    0.816                0.227            0.544               0.654                0.970           0.311 
Data presented as Mean±SEM. *Adjusted means, age used as covariate. For RHI**, equol producers (n=13), and Non-equol producers (n=14). P value for 
the interaction of intervention and equol producer phenotype factors (mixed general linear model, repeated ANOVA for intervention). AI, Augmentation 
















Intervention Time (h) RHI** 
    
CO (L/min)  AI (%)  PWV (m/s)  Systolic BP   Diastolic BP  
(mm Hg) (mm Hg)  
 Non-equol 
Placebo 
0 2.57±0.15 128±2 76±2 4.30±0.18 26±2 9.9±0.2 
producers 24 2.75±0.16 130±3 78±2 4.27±0.21 25±1 9.9±0.3 
(n=14) 24-0* 0.05±0.19 2±3 2±1 -0.06±0.18 -1±1 -0.1±0.2 
 80 mg 
isoflavone 
supplement 
0 2.58±0.15 128±3 76±2 4.32±0.17 26±1 9.7±0.3 
 24 2.59±0.13 130±3 77±2 4.48±0.21 24±1 10.1±0.3 
  24-0* -0.07±0.18 2±3 0±2 0.23±0.17 -2±1 0.3±0.2 
 Equol  
Placebo 
0 2.72±0.16 122±6 82±3 3.92±0.21 24±1 9.9±0.3 
producers 24 2.80±0.24 124±5 85±4 4.20±0.23 23±1 10.4±0.3 
(n=14) 24-0* 0.22±0.20 2±3 3±1 0.31±0.18 -1±1 0.6±0.2 
 80 mg 
isoflavone 
supplement 
0 2.62±0.17 123±6 83±3 4.09±0.21 25±1 10.0±0.3 
 24 2.87±0.12 124±5 83±4 4.27±0.23 22±1 9.7±0.4 
  24-0* 0.33±0.18 2±3 0±2 0.11±0.17 -3±1 -0.2±0.2 
P value                                   0.552            0.993               0.558                  0.076                0.952          0.007 
Data presented as Mean±SEM. *Adjusted means, age used as covariate. For RHI**, equol producers (n=13), and Non-equol producers (n=14). P value for 
the interaction of intervention and equol producer phenotype factors (mixed general linear model, repeated ANOVA for intervention). AI, Augmentation 
index; BP, Blood pressure; CO, Cardiac output; PWV, Pulse wave velocity; RHI, Reaction hyperaemia index. 






Figure 3.9 Acute effect on 24 h PWV after isoflavone consumption on PWV and 
plasma equol concentrations in equol and non-equol producers 
Data presented as mean±SEM. For PWV data, an overall P value for mixed general linear model 
for interaction effect between intervention and equol producer phenotype was 0.007, as shown in 
Table 3.10. Further analysis using repeated ANOVA for intervention effect only showed P= 0.002 
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Table 3.11 Acute effect of isoflavone consumption on average ambulatory blood 
pressure measurements  (time interval between 2 and 6 h post treatment) in equol 
and non-equol producers 
EP phenotype Intervention 
Systolic BP 
(mmHg)   
Diastolic BP 
(mmHg)        
 MAP 
























127±5 84±3 96±4 
P value    0.882 0.729 0.957 
Data presented as Mean±SEM. P value for the interaction of intervention and equol producer 
phenotype factors (mixed general linear model, repeated ANOVA for intervention). Participant 
data with less than 70% of the expected number of recordings were excluded as explained in the 
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Table 3.12 Acute effect of isoflavone consumption on average ambulatory blood 
pressure measurements  (time interval between 8 and 24 h post treatment) in equol 
and non-equol producers 
EP phenotype Intervention 
Systolic BP 
(mmHg)   
Diastolic BP 
(mmHg)        
 MAP 
























128±6 82±3 95±4 
P value    0.225 0.117 0.180 
Data presented as Mean±SEM. P value for the interaction of intervention and equol producer 
phenotype factors (mixed general linear model, repeated ANOVA for intervention). Participant 
data with less than 70% of the expected number of recordings were excluded as explained in the 
statistical analysis section 3.2.4. Night data were excluded too because most volunteers turned the 
ambulatory blood pressure monitor off during sleep time (data collected through night time were 




Figure 3.10 Acute effect of isoflavone consumption on 24 ambulatory blood pressure 
measurements in equol and non-equol producers.  
Non-equol producers (n=11), Equol producers (n=10). Participant data with less than 70% of the 
expected number of recordings were excluded as explained in the statistical analysis section 3.2.4




3.3.4 The acute effects of isoflavone intake on vascular and hemodynamic function 
 
Overall, there were no significant acute effects of isoflavone intake on vascular function after either at 6 h assessments (Table 3.13 shows 
data for 6 h timepoint). 
Table 3.13 Acute effect of isoflavone consumption 6 hours on hemodynamic and vascular measures 







CO (L/min) AI (%) PWV (m/s) 
Placebo 
0 2.64±0.11 79±2 125±3 4.11±0.14 25±1 9.9±0.2 
6 2.73±0.15 82±2 129±3 4.31±0.20 23±1 10.0±0.3 
6-0* 0.02±0.17 -4±1 -2±2 0.36±0.10 -3±1 0.0±0.1 
80 mg isoflavone supplement 
0 2.60±0.11 79±2 126±3 4.21±0.14 25±1 9.9±0.2 
6 2.55±0.12 79±2 125±3 4.13±0.15 24±1 10.0±0.2 
6-0* -0.25±0.18 -6±1 -5±2 0.30±0.17 -2±1 0.1±0.2 
P value   0.271 0.334 0.188 0.695 0.429 0.807 
Data presented as Mean±SEM.*Adjusted means, age used as covariate. Total n=28 except for RHI* n=27. P value for repeated ANOVA for intervention 
effect. AI, Augmentation index; BP, Blood pressure; CO, Cardiac output; PWV, Pulse wave velocity; RHI, Reaction hyperaemia index.  
 




This study investigated the acute effects of isoflavone supplement intake on vascular 
function in prospectively recruited equol and non-equol producer males at moderately 
elevated risk of cardiovascular disease. Although the acute intake of 80 mg isoflavone 
supplement did not significantly affect endothelial function (assessed by EndoPAT) or 
blood pressure in either equol nor non-equol producers equol producers, it did show an 
improved response in PWV at 24 hours after isoflavone supplement intake. This significant 
decrease could be related to the peak plasma concentrations of equol at 24 hours. 
Human studies have been conducted to investigate the vascular effects of isoflavones in 
equol producers, but the most commonly used approach has been retrospective data 
analysis of studies, which were not appropriately designed to address the subject. 
Interestingly, our previous analysis (presented in Chapter 2) observed similar 
improvements on PWV in postmenopausal equol producers after 1 year of a combined 
isoflavone and flavan-3-ols intervention. Additionally, a previous parallel-designed RCT 
of soy germ-rich pasta has shown positive association between equol producer phenotype 
and endothelial function after 4 week isoflavone intake [6], in particular FMD significantly 
improved in hypercholesteromic equol producers compared to non-equol producers. On 
the other hand, contrasting data was shown in one study, where supplementation with 
isoflavone soy protein had no effect on atherosclerosis progression [12]. However, this 
study used retrospective analysis and included subjects that were not analysed properly for 
their equol producer phenotype. The current study was novel in its prospective recruitment 
design and also the investigation of the acute effects of isoflavone consumption on vascular 
function at 24 hours, which related to the peak plasma concentration of equol [175, 210].  
Our acute study showed no benefits on blood pressure in equol producers, while in our 
retrospective analysis (presented in chapter 2), equol producers showed significantly lower 
blood pressure following long-term isoflavone intervention (12 months). Similarly, 
another acute study providing a single dose of isoflavones (80 mg) did not report changes 
on blood pressure 6 h post-intervention [9]. In addition, a study showed significant 
reductions in diastolic blood pressure after intake of orange juice or hesperidin (another 
subgroup of flavonoids) for 4 weeks and this hemodynamic benefit was not apparent 
following acute intervention intake despite there were microvascular endothelium 
reactivity [254]. A recent review suggested that isoflavone supplement interventions that 
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are longer than 3 months showed greater benefits on reducing blood pressure [1] however 
further data are required to investigate the plausible underlying mechanisms. In addition, 
gender-dependent responses could have played a role and equol may induce greater 
benefits for vascular function in females than males because of its suggested selective 
oestrogen receptor modulator (SERM) activity [255].  
Our analysis of isoflavone concentrations in plasma confirmed the peak plasma levels of 
equol at 24 h post supplement intake. Vedrine et al. [212] had reported comparable 
maximum plasma concentrations of 1.68 mol/L for daidzein after consumption of 100 
mg isoflavone (containing up to 40 mg daidzein that is similar to our provided dose of 
daidzein). In addition, their maximum plasma concentration of equol reached 0.31±0.27 
µmol/L which is comparable to the equol concentrations of 0.24±0.81 µmol/L observed in 
our study 24 h post intake of isoflavone supplement (Table 3.8). We observed high inter-
individual variability in equol concentrations (between-subject range of plasma 
concentrations of equol at 24 h was 0.012- 1.029 µmol/L; CV= 27%) which also agrees 
with previous pharmacokinetic studies on  isoflavones and equol [141, 174, 176, 212] (e.g. 
CV for plasma concentrations of equol was 110% in equol producers [176]).  Additionally, 
concentrations of total isoflavones significantly increased at 6 h after supplement intake 
and these levels were decreased at +24 hours but remained higher than placebo. This 
observed pattern agrees with isoflavone pharmacokinetics reported in the literature [174, 
212, 213]. 
Interestingly, Vedrine et al. [212] also showed that the peak concentrations of equol 
increased threefold after 30 days of isoflavone consumption and this might be a result of 
an adaptation of the gut microbiota that is responsible for equol production [28]. This could 
be one of the reasons for our null findings after single exposure on the assessed vascular 
endpoints such as endothelial function, augmentation index and blood pressure; therefore 
a longer duration intervention could potentially result in higher and sustained plasma 
concentrations of equol and presumably increased benefits on vascular function.  
Only at the 24 h time point post-intervention, there was a significant decrease in PWV,  
while we found no significant changes 6 h post-intervention, at a time when equol levels 
were negligible. It has previously been shown that equol appears in the blood only ~8 h 
after ingestion as daidzein requires time to reach the intestine and be metabolised to equol 
by the microbiota (212). A plausible explanation for our observed improvement in pulse 
wave velocity following soy supplementation in the equol producers might be related to 
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higher vascular bioactivity of equol compared to daidzein, which has been suggested by 
previous in vitro work [23, 24].  
Studies have suggested that the underlying mechanisms of vascular bioactivity of equol 
involve phosphorylation of eNOS and consequent increased levels of bio-available NO 
[93, 94]. Moreover, it has also been shown that infusion of dehydroequol (equol precursor) 
increased blood flow in forearm arteries in humans and this effect was diminished by 
inhibition of eNOS [156].  
Arterial stiffness is linked to structural changes induced by increased collagen to elastin 
ratio or dynamic changes in the tone of smooth muscle cells induced by decreased release 
of NO [53]. Thus, the possible underpinning mechanisms for our positive findings on 
reduced PWV in equol producers with the lack of effect on blood pressure, could be related 
to increased levels of NO that caused peripheral changes in vascular resistance and 
consequently reduced PWV.  In support of this hypothesis, it has been shown previously 
that inhibition of eNOS resulted in a significant acute increase in PWV independent of 
changes in blood pressure [256].  
Central PWV is a direct measurement of arterial stiffness of the thoracic and abdominal 
aorta. It is the gold standard method for assessment of arterial stiffness and it is non-
invasive, simple, quick, and reproducible [35]. Interestingly, it has been reported that 
reductions in PWV of 1 m/s might result in a reduction in heart disease risk of 13-15%) 
[50]. Thus our results could be clinically important if sustained, as the equol producers 
showed central PWV reductions of -0.8 m/s after isoflavone consumption compared to 
placebo consumption, and thus our results might lead to 11-12% reduction in CVD risk.  
Our study, with prospective recruitment of equol producers, provides a better insight on 
the potential effect of equol production compared to other previous retrospective studies 
because its hypothesis-driven design, use of reliable standard method for analysing equol 
producer phenotype correctly, matched equol and non-equol producers, and assessment for 
vascular function at a time correlating to equol bioavailability. Our study participants had 
similar characteristics and profiles of CVD risk factors at baseline and the prevalence of 
equol producer phenotype in our recruited sample was found to be 33% which is a similar 
proportion to previous trials [18].  
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Our study subjects were men because many of the previously conducted RCTs have been 
limited to postmenopausal women [10, 15, 171, 220]. However, further studies are required 
to include both males and females and investigate any gender related variations in the 
effects of isoflavone intake and equol producer phenotype on CVD risk.  
 
Our study had a number of limitations, one of which could be the use of the EndoPAT 
system to analyse microvascular reactivity/ endothelial function, instead of using a more 
robust common standard method such as ultrasound flow mediated dilatation (FMD). 
EndoPAT have recently been reviewed [49, 257, 258] and there is some suggestion that 
EndoPAT assessed endothelial function does not significantly correlate with CVD risk 
score (Framingham score) or with flow mediated dilatation (FMD) [49, 257].  
Another limitation is the lack of independent verification of the isoflavone content in the 
soy bars prior to commencing the trial, which resulted in unusable data and an inability to 
investigate the impact of food matrix on the effectiveness of acute isoflavone intake on 
vascular function. The LCMS method used for analyzing our samples followed a validated 
method [150] and our extraction and preparation steps were the most commonly used for 
isoflavone analysis in biological samples. Moreover, our LCMS method identified 
significant levels of isoflavones in the plasma samples collected after ingestion of 
isoflavone supplement at 6 h and 24 h and the resulting plasma concentrations were 
comparable with previous bioavailability studies that used a similar dose [212]. Therefore, 
it is most likely reason that the cereal bars did not contain isoflavones and it might be due 
to a processing or preparation error in the production phase.  
NO metabolites in plasma samples were not analysed due to lack of PhD time and it is a 
research gap that could be done in the future to investigate more on the underlying 
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3.5 Conclusion  
In summary, we showed that the acute intake of isoflavones improved central PWV in 
equol producers and this improvement coincides with the peak 24 h equol plasma 
concentration. These results suggest that equol might be more effective in modifying 
vascular function than parent compounds and/or the endogenous capacity of producing 
equol may play an additional role in the effectiveness of soy isoflavones on arterial 
stiffness. This finding supports further investigations on the direct effects of equol 
supplement intake on vascular function in non-equol producers and also provides 
preliminary data for longer term interventions to further understand the efficacy of 
isoflavone intake on endothelial function, arterial stiffness and hemodynamic function in 























Chapter 4 The effect of S-equol (SE5OH) 
supplement intake on vascular health in non-equol 
producers 
 
4.1 Introduction  
There has been recently a research interest in the benefits of the isoflavone metabolite 
equol on various health aspects, such as postmenopausal symptoms [64, 167], metabolic 
syndrome [27, 168], cancer [125] and cardiovascular disease  (CVD) [63]. Equol is a gut 
metabolite of the isoflavone precursor daidzein and it has a similar chemical structure to 
oestrogen. This structural similarity might explain the results from in vitro studies that 
have observed a higher binding affinity of equol to oestrogen receptor α, and β than 
daidzein [146]. Additionally, equol has similar binding affinity to the major bioactive 
isoflavone, genistein, to both oestrogen receptors, more preferably β than α.  Equol has 
also been shown to activate oestrogen-receptor dependent transcription activity more 
strongly than other isoflavones [132]. Equol has additionally showed higher vascular [20, 
23, 24] and antioxidant bioactivity [20-22] compared with its parent compound daidzein.  
 
Equol, out of all major isoflavones tested including; genistein, daidzein and glycitein, was 
found to have the highest antagonistic effects to the thromboxane A2 (TXA2)  receptor that 
is implicated in endothelial dysfunction [24]. In addition, equol has been shown to induce 
vasodilation in carotid arteries isolated from hypertensive rats whilst there was no response 
to daidzein [23]. In a liver cancer cell model (HepG2 human hepatocellular carcinoma 
cells), equol stimulated activity and protein expression of potent antioxidant proteins, 
catalase and total superoxide dismutase more than daidzein [21]. Equol also induced 
greater oxidation inhibition of serum lipoproteins than genistein and approximately 10 
times greater than daidzein [22].  
Notably, equol has shown vasodilation effects in cell culture models. Treatments of equol 
caused rapid relaxation in human endothelial cells in a dose-dependent manner and this 
effect was inhibited by pre-treatment with eNOS inhibitor (L-arginine methyl ester (L-
NAME)) [93, 94]. 
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In support of these in vitro findings, several recent observational studies have shown that 
the ability to metabolise isoflavones to equol is associated with reduced levels of 
cardiovascular risk factors such as lower blood pressure [28], improved plasma lipids and 
lower  inflammatory biomarkers [112], lower arterial stiffness and improved endothelial 
function [166]. Likewise, retrospective analyses of several isoflavone randomized 
controlled trials (RCTs), which quantified equol levels reported improvements in blood 
pressure [15, 220], endothelial function [6], and arterial stiffness [220] in equol producers 
after 4 weeks to 1 year of daily isoflavone consumption compared with non-equol 
producers. In addition, as detailed in chapter 3, when we prospectively recruited equol and 
non-equol producers, we observed an improvement in arterial stiffness after isoflavone 
intake only in the equol producers at the time of the expected peak plasma concentration 
of equol. Collectively, these data further suggest that equol could be the key to the efficacy 
of isoflavone interventions on vascular function and one explanation for this may be that 
equol affects vascular function causing higher vasodilation in the endothelium [23, 156]. 
To date, there have been few RCTs that have investigated the direct effects of equol 
supplements and those that have been published, have predominantly focused on the 
potential benefits in relation to postmenopausal symptoms [167, 169, 170]. Overall, the 
current data suggest that daily consumption of between 10 mg and 40 mg S-equol 
supplement for durations between 4 weeks and 12 months significantly reduces the 
frequency of hot flushes, neck and shoulder muscle stiffness [167, 169] and bone density 
loss in postmenopausal women [170]. Notably, the dose of 40 mg/day was more efficient 
in reducing the frequency of hot flushes than soy isoflavones in postmenopausal women 
experiencing more than 8 episodes per day [167]. To our knowledge, only one study 
considered effects of administered equol on metabolic syndrome-related and secondary 
cardiovascular biomarkers. This study showed that daily intake of 10 mg/d of synthesised 
S-equol supplements by overweight/obese subjects for 12 weeks, significantly improved 
glycaemic control (decreased glycated haemoglobin HbA1c levels) and secondary  CVD-
related outcomes such as circulating LDL concentrations and arterial stiffness (measured 
by cardio-ankle vascular index (CAVI) scores) [168]. However, this study had limitations 
in both study design (i.e. lack of a wash-out period) and the method used for assessing 
equol producer phenotype (i.e. not following the standard method suggested by Setchell et 
al. [141]). Therefore, ‘fit-for-purpose’ research is required to establish the effects of equol 
supplements on vascular function in non-equol producers and to identify plausible 
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explanations for the previously reported beneficial effects of isoflavone intake on vascular 
health in equol producers. 
Thus, we conducted a study where we fed an equol supplement to non-equol producers 
and hypothesised that equol intake would have beneficial effects on vascular function.  
Based on the assumption that vasodilation induced by isoﬂavones is correlated to their 
bioavailiability, we related our study assessment timing to the previously published data 
on the pharmacokinetic profile of S-equol in blood following equol supplement intake 
(Tmax: 1-1.5 h, T1/2: 7.4- 8 h, Cmax/dose: 50-191 nmol/L per mg, [19]) and we followed an 
acute phase design. Our study aimed to assess the effects of an equol supplement on a 
range of biomarkers for CVD risk (including endothelial function (reactive hyperaemia 
index (RHI), arterial stiffness measurements (PWV) (primary outcomes), augmentation 
index (AI), and blood pressure (secondary outcomes)), measured at around the anticipated 
Tmax of equol in middle-aged males who were non-equol producers and at elevated 
cardiovascular risk.  
 
4.2 Methods  
4.2.1 Subjects and study design  
 
This study was an additional study arm to the clinical trial (described in detail in section 
3.2, page 86). It followed the same study design as a randomized, double-blind, placebo-
controlled, crossover study and was conducted at the Clinical Research & Trials Unit 
(CRTU) at the University of East Anglia (United Kingdom), with approval from the local 
Ethics Committee (www.clinicaltrials.gov; NCT01530893). The same subjects that were 
recruited for the isoflavone study (Chapter 3) were asked to complete this additional study 
arm and all investigations were conducted according to the Declaration of Helsinki 
(Appendix C, page 183). 12 non-equol producers were required to complete study and 14 
subjects were recruited assuming 15% dropouts (Details for the sample size calculations 
are presented in Chapter 3, see page 86). 
 
The participants included 42 men aged 50-75 years who had a 10-20% risk of CVD over 
the following 10-years (same as described in detail in section 3.2.1, page 87) [36]. 
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16 prospectively recruited non-equol producers were identified using a standard soy 
challenge, out of which 14 subjects completed the study (as described in page 88), Figure 
4.1.  
Briefly, a 63 g soy protein bar providing 161 mg soy isoflavones as aglycone equivalents 
(63.5 mg daidzein, 63.9 mg genistein and 33.7 mg glycitein (commercial soy bars, Revival. 
CO, Kernersville, USA)), was consumed daily for three consecutive days. Urinary 
concentrations of equol and daidzein were then quantified in a fasted urine sample 
collected on the fourth morning using a validated LC-MS/MS methodology [150]. Non-
equol producers were defined as the ones having a urinary log10 S-equol/daidzein ratio < 
-1.75 [141] (as described in chapter 3 in more details). 
The non-equol producer participants were afterwards cross-over randomised to a  
6.6 g SE5-OH  supplement (containing 40 mg of S-equol as aglycones equivalents), or a 
matched placebo dose with a wash out period of minimum 1 week.  
Participants followed the same dietary and exercise restrictions as described in chapter 3, 
section 3.2.1, page 91. Briefly, before the study visit participants were asked to follow a 
number of dietary and lifestyle restrictions; maintaining intake of non-flavonoid 
supplements, excluding intake of flavonoids (for 72 h) and strenuous exercise (for 48 h), 
and avoidance of caffeine and alcohol (for 24 h). We also controlled for other potential 
factors including nitrate/ nitrite intake that might affect circulatory levels of NO 
metabolites [247], therefore subjects were asked to avoid nitrite/ nitrate rich foods (for 24 
h) and drink only low nitrite / nitrate containing bottled water (Buxton, Nestle Ltd UK). In 
addition, the same standardised pasta meal (Brake Bro Ltd, Kent, UK) was consumed for 
dinner before the assessment visit. Habitual dietary intakes were also assessed by 24 h 

































Figure 4.1 Study design and assessment schedule 
A) This study included only non-equol producers (the same subjects recruited to study in Chapter 
3), who were crossover randomised to S-equol supplement (intervention group) or matched 
placebo (placebo group). Only one volunteer attended the first visit for this study arm from the 
2 participants who dropped out and it was not included in the analysis because of the used 
statistical analysis (the repeated measures ANOVA requires completed datasets for each 
volunteer).  
B) + represents collection of blood samples and/ or clinical measurements that were collected at 
baseline, and 2 h after intervention administration. BP, blood pressure.  
At least 7 day wash out period 
Matched placebo + placebo 
cereal bar  
S-equol (SE5OH) supplements  
(Containing 40mg S-equol) + placebo 
cereal bar 
14 Non-equol producers 
  
14 identified EPs 
16 non-Eps 
 
N=2 drop outs 




for the study 
42 Eligible  
190 Screened  Medical 
screening and 
CVD risk based 
on plasma lipid, 
age and systolic 
BP  
Soy challenged:  
3 d intake soy protein 
bar (64 mg daidzein) and 
urine sample on 4th day 
for EP phenotype 
analysis 
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4.2.2 Study interventions  
 
The study interventions were 6.6 g SE5-OH given in gelatine capsule (Otsuka 
Pharmaceutical Co. Ltd., Japan) which delivered a total of 40 mg of S-equol as aglycones 
equivalents, or a matched placebo dose (6.6 g) of carboxyl-methyl cellulose (CMC) in a 
gelatine capsule.  
The dose of 40 mg of S-equol was chosen as this dose has been previously reported to be 
bioactive [167]. Although it is important to note that this dose was found effective on 
postmenopausal symptoms in an 8 week intervention, unlike our study that investigated 
the effects of a single dose of equol on vascular function in  men.   
Due to the lack of available literature for an effective dose of S-equol on vascular function 
derived from human trials when we set up our study design, we considered a priori that 40 
mg would achieve physiological plasma concentrations comparable with previous in vitro 
work. These studies have reported NO-dependent relaxation in endothelium intact aortic 
rings following a dose-response relationship at concentrations between 0.1-10 µmol/L 
[93]. In addition, data from a human study has shown NO-dependent vasodilation in 
brachial arteries following infusion of 3 µmol/L dehydroequol (a potential equol precursor 
found in human urine) [156].   
 
Table 4.1 Content of isoflavones and S-equol in SE5OH supplements 
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4.2.3 Endpoints- clinical markers of vascular function and plasma 
isoflavones 
 
Assessment schedule and vascular function measurements 
 
Subjects attended the CRTU in the morning after fasting for ≥ 10 h whilst consuming 
nitrate-low mineral water only (Buxton mineral water co, Buxton, UK). After a 15 min 
supine rest in a standardized quiet, light and temperature monitored clinical room (21–
24°C), baseline blood pressure (BP) measurements were taken in triplicate (3 min between 
assessments) using an automated sphygmomanometer (Omron Healthcare Ltd, UK). 
Subsequently, carotid-femoral pulse wave velocity (c-f PWV) and augmentation index 
(AI) were assessed using a Vicorder according to manufacturer’s instructions (Smart 
Medical, UK) as indices of arterial stiffness. Endothelial function was also measured using 
an EndoPAT 2000 device (Itamar Medical, Israel), whereby the response to a 5 min 
restriction of arterial blood flow (brachial artery), inducing reactive hyperaemia, was 
monitored using peripheral arterial tonometry (PAT) of the index finger. In the contra 
lateral arm to that used for all vascular measures, blood samples were taken and the isolated 
plasma stored in cryovials at -80 °C until subsequent analysis of biomarkers of vascular 
function and circulatory isoflavone levels. Interventions were then administered by a 
research nurse that was not involved in the study analysis, and subsequently all vascular 
measurements and biological sampling procedures were repeated 2 h after intervention 
administration (around the time of peak equol concentration in plasma 1-1.5 h after intake). 
The 2 h assessment was chosen to allow time for study assessments to be conducted on 
other volunteers on the same day (each battery of vascular measurements took around 60-
90 minutes and after the baseline assessment, there was around 90 minutes break that was 
enough for another volunteer study assessment, for details refer to Table 4.2). The vascular 
measurement equipments, research nurses and clinical room facilities were shared among 
our study, and other clinical trials taking place in the CTRU.   
Plasma isoflavones and equol were analysed by HPLC-ESI-MS/MS (Agilent1200 series 
HPLC (Agilent Technologies UK Ltd., Stockport, UK) coupled with a 3200 QTRAP® 
LC/MS/MS System (AB Sciex UK Ltd, Warrington, UK)) using a previously validated 
method as described in Section 3.2.3. Note: the plasma concentrations of isoflavone and 
equol in non-equol producers 2 h after consuming placebo were not analysed due to the 
time restriction and study funds. 
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Table 4.2 Study assessment times and order 
Example time Time taken Assessment  
8:30-8:45 am 15 minutes Baseline anthropometric measurements 
8:45-9:00 am 15 minutes  Baseline relaxing period 
9:00-9:10 am 10 minutes                            Baseline blood pressure measurement (by Omron)  
9:10- 9:25 am 5-10 minute                        Baseline blood collection 
9:25- 9:55 am 15-25 minutes                     Baseline arterial stiffness (by Vicorder) 
9:55- 10:20 am 20-25 minutes Baseline endothelial function (by EndoPAT) 
10:25 am 5 minutes Treatment administration 
12:00 am 90 minutes Break 
12:00-12:15  am 15 minutes                             Relaxing period   
12:15- 12:25 am  10 minutes  Blood pressure measurements (by Omron) 
12:25- 12:40 am 5-10 minute                        2 h blood collection 
12:40-13:10 am 15-25 minutes                     2 h arterial stiffness (by Vicorder) 
13:10- 13:40 am  20-25 minutes 2 h  endothelial function (by EndoPAT) 
Note: equipment used for vascular measurements (Vicorder and EndoPAT) were shared for study 
assessments of at least two participants a day.   
 
4.2.4 Statistical analysis  
  
Data are presented as means ± standard error of means (SEM).  Results were considered 
to be statistically significant at P< 0.05. Only volunteers who completed the trial were 
included in the analysis. Statistical analyses were performed using SPSS software (version 
22, IBM Corporation, Armonk, NY, USA).  The primary outcomes were the changes in 
endothelial function (reactive hyperaemia index (RHI)) and arterial stiffness (c-f PWV)) 
post-intervention. Secondary outcomes included the effects of the intervention on blood 
pressure, AI and isoflavone concentrations in plasma.  
Shapiro-Wilk test was used to assess normality of data. Levene’s test and Mauchly’s test 
were applied to check equality of variances for use of univariate analysis and homogeneity 
of variance for use of repeated measures analysis of variance (ANOVA), respectively. 
Baseline data for all outcome variables were evaluated for statistical differences between 
the intervention groups using Student’s paired t-test. 
For the main data analysis, similar analysis plan was followed as in the study arm in 
Chapter 3 (for details refer to Statistical analysis section, page 105); a repeated measures 
ANOVA model was used with one within-subject factor (intervention at 2 levels: placebo, 
and SE5OH supplement). Data was analysed as change from baseline at 2 h post-
intervention and age was included as a covariate.  
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LCMS data was analysed using univariate analysis to investigate differences in plasma 
concentrations of daidzein, genistein, glycitein and S-equol following intakes of the         
SE-5OH isoflavone supplement and additional repeated measures ANOVA analysis was 
run for differences in concentrations between baseline and 2 h time point. 
 
4.3 Results  
 
At baseline, there were no significant differences in all assessed clinical vascular 
measurements (Table 4.4).  
 
4.3.1 Isoflavone concentrations in the plasma samples  
 
As expected, plasma concentrations of equol (post-hydrolysis quantified as aglycones) 
significantly (P<0.001) increased 2 h after SE5OH intake in the non-equol producers: at 
baseline plasma concentrations of S-equol were below the detection limit versus a mean± 
SEM of 3.22±0.47 µmol/L (Range: 1.77-7.9 µmol/L) at 2 h (Table 4.3). 
 
 
Table 4.3 Plasma concentrations of total isoflavone at baseline and 2 h post-
intervention in non-equol producers (n=14) after intake of SE5OH intervention 





(nmol/L) BL  2 h P value 
Non-equol producers Genistein 4±3 137±15     <0.001 
40mg S-equol Daidzein 4±2 29±7       0.005 
 S-equol ND 3217±469   <0.001 
 Glycitein 21±7 192±28 <0.001 
All values presented as mean±SEM. Univariate analysis was used. Presented P value is for 
differences from baseline in plasma concentrations of isoflavone and equol in non-equol producers 
2 h after consuming SE5OH. BL, Baseline; ND, non-detectable or below limit of detection. 
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4.3.2 The acute effects of equol supplements on vascular and hemodynamic function in non-equol producers 
 
There was no significant acute effects on any of the assessed hemodynamic and vascular measures in the non-equol producers 2 h after SE5OH 
supplement consumption (Table 4.4).   
 
Table 4.4 Acute effect of SE5OH supplement consumption after 2 h on hemodynamic and vascular measures in non-equol 
producers. 







CO (L/min) AI (%) PWV (m/s) 
Placebo 
0 2.57±0.15 76±2 129±2 4.30±0.18 26±2 9.9±0.2 
2 2.87±0.27 79±2 132±4 4.31±0.20 24±2 9.9±0.3 
2-0* 0.20±0.25 3±2 3±4 0.01±0.15 -2±1 -0.1±0.2 
40 mg SE5OH 
0 2.78±0.14 80±2 134±3 4.60±0.25 24±1 9.8±0.3 
2 3.17±0.18 81±2 135±3 4.46±0.21 24±1 9.9±0.3 
2-0* 0.43±0.20 1±2 1±2 -0.14±0.19 0±1 0.1±0.2 
P value   0.205 0.627 0.665 0.593 0.936 0.804 
Data presented as Mean±SEM.*Adjusted means, age used as covariate. Total n=28 except for RHI* n=27. P values for repeated ANOVA for 
intervention effect. There were not significant differences in the vascular measurements at baseline between equol and non-equol producers 
(P> 0.05). AI, Augmentation index; BP, Blood pressure; CO, Cardiac output; PWV, Pulse wave velocity; RHI, Reaction hyperaemia index.  
 





This study suggests that acute intake of 40 mg S-equol (SE5OH) supplement did not have 
significant acute effects on vascular function, in particular endothelial function, arterial 
stiffness and blood pressure in non-equol producer males at elevated CVD risk.  
A previous crossover RCT provided a lower dose of S-equol supplements (SE5OH) 
(10 mg) to 54 overweight or obese subjects (16 men and 38 women having a mean age of 
59.4 years) for 12 weeks [168] and in contrast to our results, observed benefits of S-equol 
supplements on glycaemic control (assessed from HbA1c levels, the change from baseline 
was -0.2±0.1 mmol/L), blood lipids (low density lipoprotein (LDL), the change from 
baseline was -0.2±0.1 mmol/L) and arterial stiffness measured by CAVI score (the change 
from baseline was -0.2±0.1 m/s). However, after stratification based on gender and equol 
producer phenotype, their analysis showed that these effects were only statistically 
significant in non-equol producer women. The observed lack of effect in males suggests 
that equol supplements may exert greater benefits for vascular function in women more 
than in men. This phenomenon might be due to the suggested selective oestrogen receptor 
modulator (SERM) activity of equol [64] and potential gender-dependent differences in 
protein expression of oestrogen receptor (ER) subtypes [255]. An in vitro study has shown 
up-regulated protein expression of both ER subtypes ERα and ERβ in isolated neutrophils 
from women in response to incubation with 17β-oestradiol, while only ERα expression 
was up-regulated in isolated neutrophils from men [255] and this is of particular interest 
as S-equol possesses higher binding affinity to ERβ than ERα [129]. Similarly, 
Diarylpropionitrile is a synthetic SERM that causes rapid NO-dependent vasodilation and 
possesses 30 to 70-fold agonist activity to ERβ than ERα [259].  
Another factor could be gender differences in isoflavone metabolism. Watanabe et al [260] 
reported maximum plasma concentrations of 1.4 µmol/L in males and 2.5 µmol/L  in 
females 1 h after  ingestion of 30 mg of  S-equol (as SE5OH supplements) and Setchell et 
al [19] showed average levels of around 3 µmol/L at 2 h after ingestion of  the same dose 
and supplement (30 mg) in postmenopausal women. Our plasma analysis of total equol 
concentrations showed mean concentrations of 3.2 µmol/L (1.8-7.9 µmol/L) in non-equol 
producer males 2 h after intake of 40 mg SE5OH supplement (Table 4.3). These figures 
are comparable with the previously reported pharmacokinetic data [19, 149, 260] but there 




is an assumption that higher levels could have been achieved in female participants and 
this might be worth to investigate in future studies.  
It has been shown previously that S-equol at 0.1-10 µmol/L can induce vasodilation in an 
in vitro model [93],  and 3 µmol/L of an isoflavone metabolite (potential precursor of equol 
found in human urine [261], dehydro-equol) significantly increased forearm blood flow in 
humans [156]. In this study, infusion of dehydro-equol into the brachial artery at an 
increasing dose of 0.1-3 µmol L-1 min-1 resulted in a dose-dependent increase in 
vasodilation of the forearm arteries (i.e. forearm blood flow after occlusion) in six healthy 
men. The vasodilation response was inhibited by the use of LNAME (an eNOS inhibitor) 
indicating that the underlying mechanism for dehydro-equol-induced vasodilation was 
mediated by an increase in endogenous NO [156]. This latter study confirms the 
importance of investigating potential dose-response relationships for the vascular effects 
of equol to investigate an efficient dose of S-equol and it also highlights the need for further 
research work on bioactivity of equol related metabolites in vitro and in vivo. These 
findings also relate to previous in vitro work on isolated rat aortic rings where it was shown 
that dehydro-equol was the most potent vasodilator compared to other daidzein metabolites 
and its bioactivity was comparable to that of 17β-oestradiol [262]. 
In our previous study, we have shown that equol producers had reduced arterial stiffness 
(assessed by c-f PWV) after isoflavone intake and this effect correlated positively with the 
plasma concentrations of equol (Chapter 3). This subsequent study now suggests no 
benefits of feeding equol supplements to non-equol producers for arterial stiffness.  
These contradictory findings might be explained by higher bioactivity of the endogenously 
produced S-equol. It is found that the endogenously produced S-equol shows much slower 
clearance rate from the body compared to that of the supplemented S-equol (see Figure 
1.10). Alternatively, it is likely that other features of the equol producer phenotype may 
also contribute to the observed effects on vascular function.  
It has been proposed that the inter-individual differences in intestinal microflora species 
may contribute to variation in disease vulnerability through effects on metabolism and 
subsequent exposure to isoflavones or equol [172]. In addition, single nucleotide 
polymorphisms (SNPs) were suggested to be linked to the equol producer phenotype: a 
genome-wide association study in a Korean population has identified an association 
between 5 SNPs in HACE1 (a gene related to immune responses) and equol 
production[28]. One of the SNPs in HACE1 (rs17065302 C > G) has been proposed to 
modulate the expression of HACE1 in the gut, which might lead to changes in the host 




immune responses in the colon. The resulting intestinal environment might more suitable 
to sustain equol-producing microbiota [28]. This study also reported statistically 
significant lower diastolic blood pressure and non-statistically significant lower systolic 
blood pressure in equol producers compared to non-equol producers. Further analysis 
showed an interaction effect between the equol producer phenotype and one of the 
aforementioned HACE1 SNPs (rs6927608 A>C, located in an intron) on blood pressure 
(both diastolic and systolic). This interaction effect was stronger than the effect of equol 
producer phenotype alone. For instance, equol producers who had major allele 
homozygotes (AA) of rs6927608, showed significantly lower systolic blood pressure than 
non-equol producers. It is unknown why the association between SNP rs6927608, blood 
pressure and equol producer phenotype occurred and further investigations are needed.  
The association between isoflavone intakes, equol producer phenotype and potential 
vascular benefits could also involve direct or indirect regulation of the expression levels 
of genes related to CVD development. A recent study has shown that isoflavone 
supplement intake (94 mg/d for 8 weeks, compared to a placebo) significantly altered gene 
expression of 357 genes in white blood cells isolated from equol producers. In particular, 
gene sets related to inflammation and oxidative phosphorylation, that might be involved in 
atherosclerosis development, were down-regulated [263].  
 
The limitations of our study included the measurement of endothelial function by 
EndoPAT that might have weakened our observation of improved endothelial function 
(assessed by EndoPAT, described in detail in section 3.4) and the recent publication 
regarding its lack of power to assess acute changes in endothelial function in relatively 
healthy populations [258]. The use of ultrasound flow mediated dilatation (FMD) (the most 
used non-invasive method for measurement of endothelial function) would have been more 
senstive but this method was not available to us at the time of the study. Our study could 
be also underpowered because of our sample size calculations as discussed in Chapter 3  
(page 86). Additionally, this study arm would have benefited from more frequent 
measurements to coincide with published pharmacokinetics of equol. [19, 149, 260]. 
Especially, an earlier endpoint measurement 1 h after S-equol intake would have been 
useful as a range between 1 to 1.5 h has been reported to be the peak time of S-equol in 
plasma [141]. However, this was not possible due to the time restrictions on use of clinical 
equipment and research unit facility (the time required for conduction of vascular 
measurements was around 60-90 min to complete each test battery, for more details refer 




to page 131).  And maybe another endpoint measurement at 4 h when S-equol levels 
decreases in the blood, would be done to investigate any potential time course for 
bioactivity.  
In addition, our selection of the dose of S-equol (40 mg) was based on bioactivity in 
reducing postmenopausal symptoms in an 8 week intervention unlike our acute phase trial 
in men [167]. However, this was the available literature at the time of the study design. 
  
4.5 Conclusion   
In this study arm we showed that feeding a single dose of equol supplements (40 mg) did 
not have a significant impact on vascular responses in non-equol producers. Although this 
is an acute feeding study, assessing vascular and hemodynamic function only at two time 
points (baseline and 2 h post-intake), the results suggest that the endogenous capacity to 
produce equol may have an important role on vascular benefits beyond the production of 
equol.  
These study findings could have been affected by limitations such as the use of EndoPAT 
for endothelial function assessment, the small sample size, the selected dose and measured 
time points (as discussed previously). Yet, the investigation of the benefits of natural equol 
(SE5OH) supplements on vascular markers in non-equol producers is novel and our study 
followed a hypothesis driven design, prospectively recruiting non-equol producers using a 
standard methodology.  
Further studies on dose-response and/or time-course relationship, and larger long term 
trials are required to establish the influence of equol supplement intake on arterial stiffness 
in equol producers versus non-equol producers including males and females. In summary, 
future human trials may investigate the potential effect of equol producer phenotype on 
bioavailability of equol supplements and subsequent vascular function, in addition to the 












Chapter 5 Main discussion and future work 
 
5.1 Main discussion  
Cardiovascular disease is a major public health burden and nutrition plays an important  
role in the prevention and treatment of cardiovascular disease (CVD) [29]. Clinical 
nutrition and dietary strategies have been shown to modify the development of CVD.  
Dietary constituents such as soy isoflavones were suggested to lower CVD risk factors, 
although the evidence is inconsistent [5-16]. This thesis focused on the potential 
importance of the ability to produce the isoflavone metabolite equol in explaining the 
benefits of soy isoflavones on reducing major CVD risk factors such as endothelial 
dysfunction, arterial stiffness, and hypertension.  Additionally, we examined the vascular 
effects of a single dose of S-equol containing supplements in subjects who lack the 
endogenous capacity to produce the gut metabolite equol.   
Equol producers had significant improvements in arterial stiffness and blood pressure, 
compared with non-equol producers, following 1-year of an isoflavone containing 
intervention (assessed through a retrospective analysis approach (Chapter 2)). Our acute 
study, which prospectively recruited equol producers, has further substantiated 
improvements in arterial stiffness following a single dose of an isoflavone supplement at 
the expected peak time of plasma equol (Chapter 3). These data suggest a higher vascular 
bioactivity of equol, than the parent compound daidzein. However, no significant vascular 
benefits were shown by non-equol producers following single-dose intake of an S-equol 
supplement (Chapter 4), which suggests that the endogenous equol producer phenotype 
may contribute more than equol per se in explaining the efficacy of isoflavone intake on 
vascular function.  
 
Our first analysis (Chapter 2) included type-2 diabetic population that may have a 2 to 4 
fold higher risk of CVD mortality relative to non-diabetics [217]. In particular, the benefits 
of lowering blood pressure in type 2 diabetic patients on cardiovascular mortality have 
been established in human studies [264] and it has been estimated that a 2-3 mmHg 
reduction of diastolic blood pressure (BP) in 50–69 years old subjects, would reduce the 
risk of coronary artery disease and stroke by 10%-20% [58]. Therefore, the observed 




reductions of - 2.4±1.3 mmHg in diastolic BP in our analysis could result in an estimated 
decrease of 14% in CVD risk.  
We also found positive effects on an important predictor of CVD, arterial stiffness assessed 
by the gold standard method PWV [35]. It has been estimated that an elevation of PWV of 
1 m/s would result in a substantial increase of 14-15% in CVD risk  [50]. Our findings also 
suggest that isoflavone interventions in equol producers might be associated with 
decreased carotid-femoral PWV and the observed reductions (-0.7 m/s in postmenopausal 
women (Chapter 3) and -0.8 m/s in males at elevated CVD risk (Chapter 4), respectively) 
could be of clinical importance leading to 10-12% decrease in CVD risk if sustained.  
Our findings could be therefore clinically relevant; however, they are influenced by the 
limitations of our studies as discussed earlier (in Chapters 2, 3, and 4). Further studies are 
required to confirm benefits of the isoflavone intake and equol producer phenotype on 
reducing CVD disease risk factors. Subsequently, if evidence is established, further public 
health research could investigate dietary recommendations of soy isoflavone intake. 
  
As our knowledge about the interaction of nutrition, genetics, metabolism, gut microflora 
profile and other environmental factors increases, the tendency is for clinical nutrition to 
move from an old paradigm of rigid guidelines to a new paradigm where nutritional 
indications are custom-designed according to individual characteristics to promote health. 
In fact, dietary recommendations are already established for specific group of populations 
with different age, gender and health status [265]. In addition, nutrition research has 
suggested a concept called ‘nutritional profile’, which is a combined set of genetic, 
metabolic, proteomic, behavioural and functional factors that are studied to assess the 
interaction between diet and other factors, to affect  health/disease status. This concept is 
considered as a good start to the intervention of personalised nutrition [266].  
Our current knowledge about equol producer phenotype suggests that it is a metabolic 
profile defined by isoflavone intake and could be influenced by the gut bacterial 
community. In addition, it is known that human capability to produce equol varies between 
different populations and the frequency of equol producers in Asian populations is much 
higher than in Western populations [139]. However, the biological and environmental 
explanations for this metabolic phenotype are still lacking, all related microbiota profiles 
are yet to be identified and any associated genetic variation or interaction. Interestingly, 
two previous studies have shown that equol producer phenotype was associated with some 
genetic alterations [267] and variations [28]. Given all the available information on the 




equol producer phenotype, we envisage that it might become an integral part of the 
nutritional profiles and further developments on personalised/stratified dietary 
recommendations for optimal health.  
Interestingly, equol per se has already attracted the attention of supplements industry and 
research has been conducted for almost 18 years to produce S-equol supplement. In 2002, 
Otsuka Pharmaceutical Co., Ltd has managed to develop a natural S-equol supplement 
(SE5-OH) by fermentation of a soy germ solution with the lactic acid bacterium 
Lactococcus garvieae (20-92 strain). Afterwards, few human studies and clinical trials 
have been conducted to confirm its safety and usefulness for women health. In 2014, SE5-
OH supplements have been launched by Otsuka Pharmaceutical Co., Ltd and it is currently 
being advertised as a natural supplement for menopausal and postmenopausal women 
(http://www.otsuka.co.jp/en/company/globalnews/2014/0402_01.html). However, this 
supplement is directed towards women during or post-menopause because of its 
oestrogenic bioactivity. Potentially, the synthesised equol supplements could also target 
different population subgroups such as non-equol producer men at high CVD risk. 
However, further clinical trials investigating effects of equol supplements on 
cardiovascular health are still required. If more evidence becomes available, there could 
be also an interest from food industries to develop different types of supplements 
associated with greater equol production such as probiotics of equol producing bacteria.   
Overall, this thesis supports the potential importance of equol producer phenotype on the 
effectiveness of soy isoflavone interventions to improve arterial stiffness, and 
hemodynamic function. However, further evidence is still needed to elucidate the relative 










5.2 Research gaps and future work 
Previous RCTs have shown that longer term interventions with isoflavones e.g. 12 months, 
may be required to elicit cardiovascular improvements, [15, 171, 220]); studies which 
assess vascular function in equol producers compared to nonproducers would therefore 
benefit from such a longer-term intervention. There is also a need for assessment of the 
vascular function using multiple robust techniques, in particular, for assessments of 
endothelial function and arterial stiffness. Regarding endothelial function, ultrasound FMD 
at brachial artery is considered the most robust non-invasive method, which has been 
shown to be associated with the Framingham risk score in predicting CVD risk, and is 
thought to provide more sensitive assessment of endothelial function than that of  
EndoPAT [43, 257]. In addition, it would be interesting to further confirm our positive 
PWV findings in equol producers, by methods other than c-f PWV. Whilst aortic PWV is 
the non-invasive gold standard method, and estimating it between carotid to femoral is still 
the most accepted approach [38], there are other techniques such as MRI measurements of 
aorta PWV which have been shown to be associated with c-f PWV [268]. As MRI 
technologies might provide more insights regarding the structural and/or functional 
changes associated with improved arterial stiffness, then this technique could be an 
informative target for future research.  
 
It is also suggested that different isoflavone metabolites have different bioactivities; for 
instance dehydro-equol, the potential precursor of S-equol found in human urine [261] has 
been shown to significantly increase forearm blood flow in humans [156]. Therefore, 
establishing the differential bioactivity of isoflavone metabolites, and determining the 
compounds, which have the greatest impact on vascular health, is worth further 
investigation. 
 
Regarding the benefits of S-equol per se on vascular function, there is also a need for 
further human interventions of S-equol supplements that investigate dose-response 
relationship, gender-dependent responses and long-term exposures. Although, in vitro 
work has shown that S-equol at 0.1-10 µmol/L can induce vasodilation [93], the in vivo 
dose of S-equol that induces vascular-related benefits is unknown. In a previous study, 
women showed significantly decreased arterial stiffness (measured via a CAVI device) 
after 12 week, daily intake of 10 mg S-equol containing (SE5OH) supplements [168]; there 




was, however, no effect in males. There is, therefore, a possibility that females might 
benefit more from S-equol intake than males and further studies are required to elucidate 
gender related variations. In addition, previous cross-sectional studies in Asian populations 
with habitual intakes of  25- 50 mg soy isoflavone/ day, have shown equol producers to 
have a better cardio-metabolic profile than non-equol producers (as reviewed in Chapter 
1, Table 1.5, page 39). The findings of this thesis support the latter data in part and there 
might be beneficial features of the endogenous equol producer phenotype which could be 
related to health benefits of specific intestinal microflora, and/or genetic factors that are 
associated with the endogenous equol producer phenotype (Figure 5.1). Previous studies 
have shown that the ability to produce equol could be determined by specific intestinal 
microflora (Table 1.5) and it has been proposed that inter-individual differences in 
intestinal microflora species may contribute to variations in disease vulnerability [125, 
269]. Faecal microbiota extracted from equol producers were able to produce equol from 
incubated daidzein in vitro [176, 186], however it is still unknown if the ability to produce 
equol could be acquired by faecal infusions in vivo and if the changed capability is related 
to any benefits on vascular health. Alternatively, or in combination with a specific 
microbiota profile, genetic variations might contribute to equol producer phenotype and 
interact with equol to improve vascular function. In particular genetic differences (5 SNPs) 
in the human genome were found to be associated with the equol producer phenotype by a 
GWAS study in a Korean population [28].  However, research in this area is at a very early 
stage and further genetic studies are required in other Asian and Western populations to 
identify potential SNPs related to the ability to produce equol and search for any 
interactions with specific microbiota profiles and vascular health. A strategic plan of future 




























Figure 5.1  Illustration of the interactions between gut microflora, and human 
health and the potential role for intestinal metabolite equol. 
Human health is influenced by many environmental and genetic factors. One of the major 
environmental contributors is food. Another factor within the human body is the gut microbiota 
that affects the physiology and metabolism. Recently, it has been suggested that the intestinal 
microbiota plays a role in the development of diseases such as CVD. The intestinal microflora is 
responsible for the production of several metabolites from food sources such as equol from the 
ingested soy isoflavone that is shown to possess vascular bioactivity. In addition, the host genotype 
might interact with diet to contribute to human health and susceptibility to CVD disease (figure 
adapted from Zhao et al., 2013 [269]). 
Supra-organism  




































1) Long term isoflavone intervention that prospectively recruiting equol and non-equol producers to elicit if extended exposure 
to isoflavones exert greater benefits of isoflavone intake on vascular function in equol producers compared to nonproducers 
and confirm  
the potential role of equol producer phenotype in the effectiveness of isoflavone intake on vascular health 
 
2) Dose-response study prospectively 
recruiting EPs and non-EPs to further 
study the vascular effects of S-equol 
supplements and EP phenotype, identify 
the most efficient dose of S-equol 
supplement on vascular function, effects 
of long-term intake, and any gender-




3) Pilot human trial infusing microbiota 
species (faecal transplant) from equol 
producers into non-equol producers to 
investigate if equol producer phenotype could 
be acquired and subsequent RCT to study the 
vascular benefits of isoflavone intake after 
acquiring microbiotic equol producer 
phenotype.  
4) GWAS and intestinal microbiome 
observational studies in Asian and Western 
populations to study the biological 
explanations and factors that may contribute 
to ability to produce equol. 
Figure 5.2 Plan for future research directions and approaches  
Future research could include 1) large long term trials to establish the role of equol producer phenotype in the benefits of isoflavone intake on vascular function 2) human 
studies feeding S-equol supplements to investigate dose-response relationships, if more evidence has become available, 3) faecal infusion studies to transfer equol 
producing bacteria into the gut of non-equol producers, 4) GWAS and observational studies to investigate association between equol producer capacity and genetic 
variations. EP, Equol producer. 









1. Long term isoflavone intervention with prospectively recruited equol and non-
equol producers, in order to elicit if extended exposure to isoflavones exert greater 
benefits of isoflavone intake on vascular function in equol producers compared to 
nonproducers. 
 
1.1 This trial would be a long term parallel-designed RCT in individuals prospectively 
recruited as equol producers and non-producers. Populations at elevated risk of CVD, such 
as postmenopausal women and prehypertensive men could be selected, as previous data 
suggests ‘at-risk’ groups may gain clinical benefits from isoflavone intervention [2]. Based 
on previous evidence of cardiovascular benefits [15, 161, 171, 220], participants would be 
supplemented with a dose of 80-100 mg/day (as isoflavone aglycones equivalents). The 
vascular measurements would include blood pressure; endothelial function measured by 
brachial ultrasound FMD and arterial stiffness by c-f PWV and MRI-derived PWV taken 
at baseline, 3 months and 12 months. To elucidate the plausible biological mechanisms by 
which isoflavones or equol induce improvements on arterial stiffness and hemodynamic 
function, biological analyses could include plasma lipids (Total cholesterol, HDL-
cholesterol, LDL- cholesterol [6, 161, 171] and biomarkers of vascular function. In 
particular, analyses of plasma levels of NO and other modulators of vaso-reactivity 
produced by endothelial cells such as ET-1 [98], prostacyclin/TXA2 [24] and NADPH 
oxidase activity [20]  (see rationale, section 1.3.4, page 21) would help in developing 
further insight into the mechanisms of action. Effects on plasma levels of hydrogen 
sulphide that is also known to induce relaxation of vascular smooth muscles in the 
endothelium [270]) could also be determined. The collected blood samples could be 
analysed for different isoflavone and equol metabolites and these compounds could be 
investigated for significant correlations with vascular benefits. 
 
1.2 Complementary in vitro bioactivity assays in aortic rings or endothelial cell lines 
could be done to identify isoflavones or equol metabolites with the highest bioactivity on 
vascular-related biomarkers such eNOS and /or NADPH oxidase expression and activity.  
 








Collectively, these studies could confirm the role of the equol producer phenotype in the 
effectiveness of isoflavone intake on cardiovascular health, particularly in long term 
inteventions reflecting effects of habitual intakes. In adidition,  this work might identify 
biological mechanisms of action and help establish the relative bioactivity of various 
isoflavone metabolites.  
 
2. Assessing the cardiovascular effects and dose-response relationship of 
providing exogenously produced S-equol to non-equol producers  
 
2.1    A dose-response pilot study would assign participants (including postmenopausal 
women and prehypertensive men) to one of five treatments: 2.5, 5, 20, 40, 60 mg S-
equol/day (i.e. the anticipated range for plasma levels of S-equol following these doses 
would range from 0.125 M to 11 M [93]). The low S-equol doses are expected to attain 
similar plasma levels to the ones reported in previous studies that have shown 
cardiovascular benefits in equol producers. Particularly, these studies have shown mean 
plasma concentrations of S-equol of 0.24 µmol (our acute study, Chapter 3), 0.11 µmol/L 
[6] and 0.19 µmol/L [171] after consumption of 80 mg (50% daidzein), 33 mg (50% 
daidzein), and 105 mg (daidzein content was not defined) of total isoflavones (as aglycone 
units), respectively. Vascular function measurements including endothelial function (ultra-
sound brachial FMD) and arterial stiffness (c-f PWV) would be employed. Blood samples 
would be collected for analysing levels of S-equol and plasma biomarkers of vascular 
function such as NO, ET-1 [98], NADPH oxidase activity [20] that might explain 
mechanisms of bioactivity. In term of endpoint time collections, they should be at 1, 2, 4 
h after dose ingestions, to cover the anticipated pharmacokinetics of S-equol [19]. 
 
2.2  If the suggested study identifies an optimal efficient dose, a subsequent larger 
parallel design RCTs would investigate vascular responses to S-equol intake (longer term, 
i.e. 12 months, rationale in page 146), isoflavone intake (daidzein-rich supplements, 80-
100 mg, same rationale as in approach 1, page 146), or matched placebo in prospectively 
recruited equol producers and non-producers.  








These planned studies would provide data about effects of S-equol intakes on 
cardiovascular function, and help establish differential effects of S-equol as endogenously 
produced or supplements.  
 
3. Faecal infusion approach to transfer equol producing bacteria into the gut of 
non-equol producers, in order to determine the ability to aquire the equol producer 
phenotype  and its associated vascular benefits.  
3.1      A human study could investigate if infusing microbiota species (faecal transplant) 
from equol producers into non-equol producers would induce the ability to produce equol 
in non-producers. Briefly, this future RCT would prospectively recruit non-equol and 
equol producers; the non-producers would be blinded to treatment, and would be randomly 
allocated to a single faecal infusion of microbiota either collected from equol producers 
(allogenic microbiota infusion refers to transplant of microbiota to a non-identical recipient 
from the same species) or collected from own faeces (autologous microbiota infusion 
means transplant of microbiota to a genetically identical recipient). These infusions could 
be done through a gastro-duodenal tube or colonoscopy into the intestine. Faecal samples 
will be collected at baseline and 6 weeks after infusion to compare changes in microbiota 
compositions after both infusions (previously research has shown that the colonic 
microflora is capable of significant changes at 6 weeks after a single faecal infusion [271]. 
The soy challenge would be repeated at 6 weeks to assess if the equol producer capacity is 
acquired in the subjects undergoing the allogenic microbiota infusion.  
3.2        A follow-up RCT could investigate vascular responses to isoflavone intake in non-
equol producers who have had a microbiota transfer from an equol producer donor. This 
study would include a cross-over randomisation to an intervention with isoflavones (80-
100 mg isoflavone aglycones equivalents, same rationale as in approach 1, page 146) or 
matched placebo for 6 weeks. Vascular functions (endothelial function (ultrasound FMD) 
and arterial stiffness (c-f PWV)) would be assessed at baseline and 6 weeks after 
intervention. Previously, 6 weeks have shown induced changes in the intestinal microflora 
profile after a single allogeneic microbiota infusion in vivo. This change was also 








associated with cardio-metabolic benefits and according to previous isoflavone 
intervention, short term studies would be still sufficient to improve vascular reactivity in 
equol producers [6, 161] and it would be a good start for such primary research in this area, 
Figure 5.3. 
These study approaches would elucidate if equol ability could be acquired in the intestine 
of non-equol producers and subsequently if there is any interactive role between equol 









Figure 5.3 Study design for a suggested future isoflavone intervention to investigate 
the importance of the endogenous microbiota profile of equol producer phenotype 
on vascular function. 
If strong evidence for benefits of the equol producer phenotype on cardiovascular health become 
available, an interesting future research would be a human study that investigates if infusing 
microbiota species (faecal transplant) from equol producers into non-equol producers would induce 
the ability to produce equol in non-producers, and if vascular benefits will be associated with this 
transplant.  
 
Faecal microbiota transplant procedures are used in clinical practice as a useful treatment for 
treating infections such as Clostridium difficile [272] and also faecal transplant from lean 
donors has shown improvements on insulin sensitivity in subjects with metabolic syndrome 
[271]. Even though serious side events in faecal microbiota transplant are unusual, it is an 
invasive operation that has risks associated with the administration methods (such as 
colonoscopy) and the screening tests for pathogens before transplant [272, 273]. In 
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conclusion, the proposed study above would be worthwhile only following strong evidence 
for benefits of the equol producer phenotype on cardiovascular health. 
4. Understanding the association between equol producer capacity and genetic 
variation, in order to investigate any genetic variations, and / or specific intestinal 
microbiota which are associated with the equol producer phenotype.  
 
One suggestion would be to conduct good quality observational GWAS studies with large 
sample sizes in Asian and/or Western populations (e.g. at least 1000 paticipants per study 
to end up with the minimum required numbers for valid GWAS analysis, [28]). These 
studies could be done as parts of on-going cohorts. Participants would undergo a soy 
challenge to identify their equol producer phenotype as part of the screening procedure and 
then they would attend one assessment visit where blood and faceal samples would be 
collected for genotyping for GWAS analysis and pyrosequencing for intestinal bacteria 
analysis. It would be interesting if a comparative analysis could be conducted in Asian and 
Western subjects to investigate any genetic and /or microbiotic differences between the 
two populations where equol producer phenotype are different (50-60% and 20-30%, 
respectively).  
 
These observational studies might be able to identify genetic factors, and potentially 
specific intestinal microflora that are associated with equol producer phenotype and any 














5.3 Conclusion  
The data in this thesis contributes to the literature research gap regarding the potential 
effect of the equol producer phenotype in modulating the impact of dietary isoflavones 
intake on vascular health. First our retrospecive analysis was conducted on a large double-
blinded randomised design with a long term (12 months) intervention and the assessd 
outcomes included robust clinical markers of hemodynamic and vascular function 
(ambulatory blood pressure and carotid-femoral PWV). Second, our acute study is one of 
the first human studies that prospectively recruit based on the equol producer phenotype. 
In addition, equol and non-equol producers were matched based on high priority CVD 
predictors (blood pressure and BMI) and the method used to identify their equol producer 
phenotype was a validated standard method. This study was also well-designed as a double 
blinded randomised placebo-controlled cross over intervention trial and included dietary 
restrictions on flavonoid and dietary nitrate intake, as well as restrictions for strenuous 
physical activity that might affect vascular function, on the days prior to the clinical visit. 
Finally, we were the first to investigate the vascular responses on feeding synthetic S-equol 
(SE5OH) supplements to non-equol producers and to suggest a potentially important role 
for the equol phenotype rather than equol per se in the vascular reponses to isoflavone 
intake.  
The limitation in the research of this thesis include assessment of endothelial function 
using EndoPAT, which recently has been reviewed to have limitations [257, 258]. In 
addition, the isoflavone content in the provided treatment bars was not independently 
confirmed prior to commencing the trial, resulting in that arm feeding negligible levels of 
isoflavones and therefore hampering our ability to compare the effects of different matrices 
of isoflavones on vascular function which we had set out to do. This research question is 
yet to be investigated in future studies.  
In conclusion, equol producers had significant benefits on blood pressure and arterial 
stiffness after long-term intake of an isoflavone intervention; and improvements in arterial 
stiffness (assessed by the gold standard method, carotid-femoral PWV) after acute intake 
of isoflavones. The latter coincided with increased equol concentrations in plasma and was 
not observed when synthetic S-equol (SE5OH) supplements were provided to non-equol 








producers. Our findings suggest that equol might be more effective on vascular function 
than the isoflavone parent compounds and the endogenous capacity to produce equol might 
be more important than equol per se in explaining the effectiveness of soy isoflavones on 
arterial stiffness. In contrast, we did not observe significant benefits on endothelial 
function as assessed by EndoPAT after single intake of isoflavones in equol producers and 
this finding needs further verification using the most common used method of brachial 
FMD.  
Overall, this thesis work supports the hypothesis that equol producer phenotype may partly 
explain the effectiveness of isoflavone interventions on arterial stiffness. Further longer-
term interventions are still required to elucidate the relative benefits of the equol producer 
phenotype on efficacy of isoflavone intake on vascular function and how to achieve similar 
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Appendix A Scientific contribution and acknowledgments 
A.1 Scientist contribution for retrospective analysis (covered in 
Chapter 2) 
 
Trial was designed, conducted, completed by Prof. Aedin Cassidy and Dr. Peter Curtis. 
Urinary isoflavone and equol was quantified externally in institute of food research, 
Norwich, UK. During the 1st Phd year, Phd student Sara Hazim prepared a scientific 
rationale to the retrospective analysis including clinical vascular endpoints, biomarkers, 
and statistical methods to be used with guidance of supervisors. SH and PC conducted the 
laboratory analysis for the analysed biomarkers for insulin, ET-1, ACE and resistin.  
 
A.2 Scientist contribution for acute studies (parts of the 
FASTCHECK study that are covered in Chapter 3 and 4) 
 
During 1st year, supervisory team with PhD student SH did study concept and design. PC, 
Manuel Schaer (MS) and SH prepared FASTCHECK study protocol, mainly SH provided 
the scientific rationale for study design of the acute studies providing isoflavone and S-
equol. Prof John Potter provided guidance on the selection of clinical measurements for 
the study, sample size calculations, and clinical judgment for screening results and 
eligibility of participants. During the 2nd PhD year, PC, MS and SH prepared ethics 
documents including poster, participant information sheet, and filling IRAS except 
submission of IRAS documents were done by PC &MS. During the 2nd and 3rd PhD years, 
the Fastcheck team PC, SH, MS, Luisa Ostertag (LO) and Kathleen McGrath (KM) 
recruited the volunteers and conducted the trial (SH conducted most of the vascular 
function assessment for the acute studies feeding isoflavone and S-equol). Colin Kay (CK) 








did the treatment randomisation.  During first half of the 4th PhD year, SH did the 
laboratory analyses with guidance on LCMS method by CK, Rachel De Ferras (RF), LO 
and PC. SH and placement students (KM, and Esme Ward) did food data entry and analysis 
for the FASTCHECK study. SH performed statistical analysis with guidance of PC. 
  








Appendix B Statistical analyses: supplementary data  
 
Table I. Effect of flavonoid supplementation on the vascular function in equol 
producers and non-equol producers 
Outcome  Non equol producers (N1) Equol producers (N2) P 
value 






















58.3±1.8 60.2±2.0 60.8±1.8 56.4±2.2 56.8±2.8 59.1±2.6 0.66 
*NO (M)  43.0±4.2 43.9±3.4 40.7±3.3 61.1±6.5 43.3±4.0 53.5±5.4    <0.01 


















*Outcome  Non equol producers (N1) Equol producers (N2) P 
value 


































The number of participants in the analysis was: N1=30, N2=17 for AMBP systolic and diastolic 
BP, N1=30, N2=16 for PP, N1=29, N2=17 for MAP, N1=29, N2=16 for resistin, insulin and 
HOMA-IR; N1=8, N2=5 for ACE; N1=19, N2=13 for ET-1 and NO/ET-1. Data presented as 
mean±SEM (Standard Error of the Mean). P values represent the significance of the repeated 
measures ANOVA for effect of flavonoid treatment over time accounting for an interaction of time 
and equol production status. *data for outcomes was log-transformed to achieve normality. ACE, 
angiotensin converting enzyme; AMBP, Ambulatory blood pressure; BP; Blood pressure; ET-1, 
Endothelin-1; HOMA-IR, Homeostatic model assessment of insulin resistance, MAP, Mean 

















Table II. Plasma concentrations of isoflavones at baseline, 6 h and 24 h in non-equol 
and equol producers (n=28) after intake of placebo 






BL 6 h 24 h P value P value 
(6 h vs BL)  (24 h vs BL)  
Non-equol  Genistein 4±3 15±9 7±5 0.21 0.51 
producers Daidzein 4±2 16±7 8±4 0.08 0.38 
(n=14) S-equol ND ND ND NA NA 
 Glycitein 21±7 20±13 3±2 0.95 0.02 
Equol  Genistein ND ND 3±3 NA 0.33 
producers Daidzein 1±1 3±2 4±2 0.19 0.21 
(n=14) S-equol ND ND ND NA NA 
  Glycitein 19±6 7±4 6±4 0.14 0.12 
All values presented as mean±SEM. Univaraite analysis used. Presented P value for difference 
from baseline in plasma isoflavone concentrations for both equol and non-equol producers at 6 h 
and 24 h after consumption of placebo. BL, Baseline; NA: Not applicable; ND, non-detectable 
or below limit of detection.  
 
Table III. Plasma concentrations of isoflavones at baseline, 6 h and 24 h in non-
equol and equol producers (n=28) after intake of isoflavone intervention (80 mg 
isoflavone as aglycone equivalents) 





 BL 6 h 24 h  
P value P value 
(6 h vs BL)  (24 h vs BL)  
Non-equol  Genistein 4±3 301±40 72±37 <0.001 0.08 
producers Daidzein 4±2 1692±269 170±46 <0.001 <0.001 
(n=14) S-equol ND ND ND NA NA 
 Glycitein 21±7 291±48 54±12 <0.001 0.02 
Equol  Genistein ND 200±33 28±15 <0.001 0.08 
producers Daidzein 1±1 1688±215 190±31 <0.001 <0.001 
(n=14) S-equol ND ND 236±81 NA 0.007 
  Glycitein 19±6 237±36 35±9 <0.001 0.15 
All values presented as mean±SEM. Univariate analysis used. Presented P value for difference 
from baseline in plasma isoflavone concentrations in both equol and non-equol producers at 6 h 
or 24 h after consumption of isoflavone supplement. BL, Baseline; NA: Not applicable; ND, 
non-detectable or below limit of detection.








Table IV. Plasma concentrations of isoflavones at baseline, 6 h and 24 h in non-equol and equol producers (n=28) after intake of 
placebo or isoflavone enriched cereal bar  
  Treatment     




(nmol/L)  BL 6 h 24 h   BL 6 h 24 h  
P value P value 
(6 h) (24 h)  
Non-equol  Genistein 4±3 15±9 7±5 4±3 45±17 1±1 0.71 0.98 
producers Daidzein 4±2 16±7 8±4 4±2 54±16 6±4 0.99 1.00 
(n=14) S-equol ND ND ND ND ND ND NA NA 
 Glycitein 21±7 20±13 3±2 21±7 28±10 ND 0.98 0.96 
Equol  Genistein ND ND 3±3 ND 7±3 ND 0.97 0.98 
producers Daidzein 1±1 3±2 4±2 ND 39±11 4±2 1.00 0.98 
(n=14) S-equol ND ND ND ND ND 11±5 ND 0.99 
  Glycitein 19±6 7±4 6±4 18±6 23±7 2±2 0.85 0.87 
All values presented as mean±SEM. Univariate analysis used. Presented P value for difference in plasma concentrations of isoflavones and equol 
between placebo and isoflavone enriched cereal bar intervention at 6 h timepoint (6 h), and at 24 h timepoint (24 h). BL, Baseline; NA: Not applicable; 
ND, non-detectable or below limit of detection.  
 












Intervention Time (h) RHI* Diastolic 
BP  
(mm Hg) 
Systolic BP  
(mm Hg) 
CO (L/min)  AI (%)  PWV (m/s)  
 Equol  
Placebo 
0 2.72±0.16 82±3 122±6 3.92±0.21 24±1 9.9±0.3 
producers 2 2.59±0.13 84±4 126±5 4.31±0.35 23±1 10.2±0.5 
(n=14) 2-0* -0.02±0.25 2±2 4±3 0.45±0.19 -1±1  0.4±0.2 
 
80 mg isoflavone 
supplement 
0 2.62±0.17 83±3 123±6 4.09±0.21 25±1 10.0±0.3 
 2 2.53±0.15 82.9±3.9 124±5 3.93±0.23 23±1 10.0±0.3 
  2-0* -0.11±0.24 1±2 2±3 -0.14±0.13 -2±1 0.2±0.2 
Non-equol 
Placebo 
0 2.57±0.15 76±2 129±2 4.30±0.18 26±2 9.9±0.2 
producers 2 2.87±0.26 79±2 132±4 4.31±0.20 24±2 9.9±0.3 
(n=14) 2-0* -0.02±0.24 3±2 3±3 -0.05±0.19 -3±1 -0.2±0.2 
 
80 mg isoflavone 
supplement 
0 2.58±0.15 76±2 128±3 4.32±0.17 26±1 9.7±0.3 
 2 2.84±0.01 75±2 127±4 4.32±0.20 24±2 9.9±0.3 
 2-0* 0.01±0.23 -1±2 -2±3 -0.03±0.13 -2±1 -0.0±0.2 
P value     0.761 0.355 0.472 0.58 0.68 0.33 
Data presented as Mean±SEM. *Adjusted means, age used as covariate. For RHI*, equol producers (n=13), and Non-equol producers (n=14). P value for 
mixed general linear model, repeated ANOVA for intervention. AI, Augmentation index; BP, Blood pressure; CO, Cardiac output; PWV, Pulse wave 
velocity; RHI, Reaction hyperaemia index.
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INVITATION TO PARTICIPATE IN A RESEARCH PROJECT 
 
Short title: Flavonoids, blood pressure control and 
blood vessel function 
 
You are being invited to take part in a research study. Before you decide, it is important 
for you to understand why the research is being done and what it will involve. Please 
take time to read the following information carefully and discuss it with others if you 
wish. Ask us if there is anything that is not clear or if you would like more information. 
 
This study has been approved by the NRES Committee East of England – Norfolk and 
the Research Governance Committee at the Norfolk & Norwich University Hospitals 
NHS foundation trust. 
 
The Chief investigator of the study is: 
Professor Aedín Cassidy 
 
The scientists in charge of the study can be contacted at: 
 
Dr. Peter Curtis: Research Fellow (P.Curtis@uea.ac.uk) 
Dr. Luisa Ostertag: Senior Research Associate (L.Ostertag@uea.ac.uk) 
Ms. Sara Hazim: PhD Student (S.Hazim@uea.ac.uk) 
Mr. Manuel Schär: PhD Student (M.Schar@uea.ac.uk) 
Study e-mail: fastcheck@uea.ac.uk 
Telephone number: 01603 591063 
 
 08/AUG/2013 Version 5 
    185 
What is the study about? 
As we age our risk of heart disease 
increases, with 1 in 3 men over the age 
of 75 in the UK suffering from heart 
disease. The result of this is often 
ongoing illness or premature death. 
 
Diet and cardiovascular disease 
 
It is well known that what we eat and 
drink can have a major role in protecting 
us from disease. In particular, eating 
more plant based foods e.g. fruits, 
vegetables and cereals appear to reduce 
the risk of heart disease. This may be, in 
part, due to natural elements in these 
types of food, such as a group of natural 




Research to date, has shown that after 
eating ‘flavonoids’, or the foods that 
they are found in (for example 
chocolate, berries, orange and soy food), 
the blood vessels in our system can 
become more ‘relaxed’ which helps the 
blood flow more freely. This could help 
lower blood pressure which in turn 
might lower the risk of damage to our 
major organs (e.g. heart). 
 
Lots of research now shows that blood 
pressure benefits can be achieved by 
eating more of these compounds (and 
the foods they are found in), and they 
may be even more effective if your 
blood pressure is a little higher than 
ideal.  
 
What’s still not clear, however, is:  
 
 HOW these benefits occur?  
 
 HOW the body makes changes to 
our blood pressure control when 
we eat these food components?  
 
 WHETHER different types of 
flavonoids are more effective 
than others? 
 
We’d like your help to find this out. 
 
Which type of flavonoids is this study 
interested in?  
We are interested in four types of 
flavonoids that are part of the UK diet:  
 
 A: ‘anthocyanins’ (found in 
berries and other fruits and 
vegetables) 
 
 B: ‘flavan-3-ols’ (found in 
grapes, wine, cocoa and apples) 
 
 C: ‘flavanones’ (found in citrus 
fruits) 
 
 D: ‘isoflavones’ (found in 
soybeans). 
 
We’ve chosen these types of flavonoids 
because they have been shown to have 
an effect on blood pressure after 
consuming them regularly. 
 
What do we aim to do? 
We plan to study the effects of eating a 
single portion of flavonoids on blood 
vessel activity (e.g. how relaxed the 
vessel is) and blood pressure control. We 
would also like to find out if these 
effects differ when the flavonoids are 
taken as supplements (e.g. in a capsule) 
or as part of a food (e.g. berries, orange 
juice or soy snack bar (like a cereal bar)) 
or in a supplement containing all the 
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To do this, we will ask all 
volunteers to visit us on 3 
test-days, as shown below  
 
(1) to eat a flavonoid food 
(or for the ‘chocolate’ 
group; consume a 
chocolate based 
supplement containing all 
the flavonoids found in 
chocolate)  
 
(2) to consume a capsule 
with the same amount of 
flavonoid as the food ((or 
for the ‘chocolate’ group; 
consume a chocolate based 




(3) to consume items without flavonoids 
in them (placebo test) 
 
In addition, volunteers in the soy snack 
bar group will be asked to attend a 4th 
test day;  
 
(4) at which  (a) volunteers who do not 
naturally produce a compound called 
‘equol’*,  when they eat soy, will 
consume a capsule containing natural 
equol* from soy-germ based ingredients 
and (b) volunteers who do produce 
‘equol’*, will consume a capsule 
containing no equol. 
 
The test foods and capsules will be 
prepared so that the researchers and the 
subjects will find it difficult to tell 
whether they contain flavonoids. 
Initially, volunteers will be placed in  
one of the four groups and the foods 
(*or food based supplements) we 
 
 
will test are: 
 
 A: A glass of blackberry drink  
 B: *A chocolate based 
supplement  
 C: A glass of Orange juice 
 D: A soy snack bar (approx.. 
40g) 
This will be done at random and 
unfortunately, you will be unable to 
request which group to belong to. If 
interested, volunteers can participate 
in a second group after a minimum of 
1-month break. 
 
* Equol is a natural compound that 
 is produced by the body after eating soy, 
in around 1/3rd of the UK population. So 
far, research has suggested that people 
who produce this compound may have 
better blood vessel function. We’d like to 
work out if giving this compound to 
people who do not naturally produce it, 
can help heart health. The equol 
supplement is produced by Otsuka Japan 
and the natural S-equol is produced by 
fermenting an isoflavone compound 
found in soy called ‘daidzein’ (using 
fermenting bacteria from the same family 
used in the dairy industry to manufacture 
cheese). After S-Equol is produced, the 
fermenting bacteria are deactivated by 
heat, which also sterilises the product. 
 
What do I have to do? 
During the study, which lasts at least 20 
to 31 days, there are times when you 
will be asked to stop eating dark 
** flavonoids in ‘chocolate’ will be provided as a 
supplement ONLY 
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chocolate, berries, citrus fruits and soy 
products and to eat less of some other 
foods and drinks (depending on your 
normal eating habits) as these might 
affect our results. You will be asked to 
follow these instructions for 3 days 
before each test-day (see Table 1 for 
details (on page 195). 
 
We strongly recommend that you 
consider these dietary restrictions before 
volunteering for this study. Some 
examples of food and drink that can be 
consumed during the study are included 
in Table 1 and more advice will be given 
upon request. 
 
What will be measured? 
Three or four times during the study (at 
visit 1, 2, 3 and 4), we will do 
measurements that are linked to blood 
pressure control and we will also collect 
blood samples at times when the tested 
compound is thought to appear in the 
blood.  
 
The blood pressure measures will tell us 























pumps each minute, and how much your 
blood vessels are able to relax. We’ll 
also be able to measure how flexible 
your arteries are (the blood vessels 
carrying oxygen rich blood) and how 
signals from the brain can control your 
blood pressure. All of these measures are 
non-invasive (which means they do not 
enter the body).  
 
The blood samples will be taken by 
qualified nurses and from these 
important samples we will be able to 
measure substances which show how 
blood pressure is controlled by the body. 
We will also use the blood to look for 
non-disease related genetic differences 
which might explain why some people 
naturally produce equol or seem to have 
better blood vessel responses after eating 
flavonoids.  
 
Each test day will start in the morning 
and, as shown below, will last between 6 
and 8 hrs. After taking our fasted set of 
measures, we’ll ask you to eat the test 
food (or supplement) and then we’ll 
repeat our measures to see how things 
change. The number of times we do this 
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In the orange juice and soy bar 
groups, participants will only be 
required periodically during the 10 hour 
visits and may leave the facility for up to 
4 hours at a time (advice will be 
provided on what activities are permitted 
during this time). A packed lunch will be 
provided for volunteers in these groups. 
 
For ALL subjects other than the orange 
juice group, you will ALSO need to 
return (fasted, e.g. consuming only water 
that we will provide for 10 hours) on the 
next morning for another 2 hours 
assessment at the Clinical Research and 
Trials Unit (CRTU) in the UEA. 
 
For all groups, we’ll provide you with a 
meal to eat after the visit.  
  
How much blood and other samples 
will I provide? 
At each visit, you will provide up to 
104ml of blood (this is around 6 
tablespoons). Over the three to four 
visits (during the 20 to 31 days you are 
taking part) you will give up to 377ml. 
This is less than a pint and is around the 
amount generally provided at a single 
blood donor session (470ml; source: The 
National Blood Service). We will 
endeavour to make your stay as 
comfortable as possible. 
 
Who can enter this study? 
We are aiming to recruit men who are 50 
to 75, who are generally healthy. 
 
At our health check visit, we’ll use your 
blood pressure and blood fat results (and 
your age) to work out if you fall into our 
target group of men who are at mild to 
moderate risk of heart disease over the 
next 10 years. 
 
 
You will NOT be able to volunteer if: 
 
 You smoke (or have stopped smoking 
within 3 months) 
 
 
 If your GP has told you that you have 
a disease related to your heart, liver, 
kidney, gut, blood, brain, cancer or 
diabetes 
 
 You are allergic to chocolate, milk, 
blackberries, orange juice or soy food 
 
 You are having vaccinations 
(including the flu vaccination) or 
antibiotics 3 months prior to and 
during the trial 
 
 Your GP has prescribed you 
medication for high cholesterol or 
high blood pressure 
 
 You wish to take flavonoid-
containing dietary supplements or are 
taking part in another study 
 
 
If you are in doubt about whether or 
not you are suitable to volunteer 
please do not hesitate in contacting the 
research scientists listed on the front 
page. 
 
Do I have to take part? 
It is up to you to decide whether or not 
to take part. If you decide to take part 
you are still free to withdraw at any time 
and without giving a reason. 
 
If you chose not to take part in the study, 
or withdraw from the study at any time, 
this will not affect your future 
healthcare. 
An expression of interest does not 
commit you to participation. 
What happens next? 
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*UEA, University of East Anglia. 
 
Step 1: Register an interest 
Please complete the form at the back of 
this leaflet and return it in the pre-paid 
envelope (enclosed).  
 
Step 2: We’ll call you! 
One of the study scientists will contact 
you (by telephone, or e-mail) to ask 
some general questions about your 
health and lifestyle (i.e. smoking, 
drinking, food habits) and will answer 
any questions you may have.   
 
Step 3: Ready to proceed? 
If you’re eligible for our study, and 
happy to proceed, we’ll arrange a visit 
to our research facility at the University 





Don’t worry if you’re unsure how to find 
us, we’ll send you a map and reimburse 
your travelling expenses. 
 
At the consent visit, we’ll explain the 
study in greater detail and answer any 
questions you may have. If you then 
wish to volunteer for the study, we’ll ask 
you to fill in a consent form. A signed 
consent form allows us to proceed with 
the study. 
 
We won’t take any samples (e.g. blood 
or urine) at this visit and we’ll give you 
time (at least 3 days) to think about 
whether you still want to take part after 




What am I consenting to? 
As part of the consent process, you will 
confirm that you wish to take part in the 
present research study, having read and 
understood the study information and 
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having had any questions satisfactorily 
answered by the research team. You will 
also confirm that we can inform your GP 
that you are taking part. 
 
Please be aware that you consent to 
participate in ANY of the 4 intervention 
groups (i.e. chocolate based 
supplement, milk-based blackberry 
drink, orange juice or soy snack bar). 
Additionally, the consent form will ask 
whether you consent to your samples 
and / or data being available for 
inclusion in research studies in the 
future, which relate to nutrition and heart 
health. You are free to decide whether to 
give this consent and you can still take 
part in the present study if you decide 
NOT to give consent for your samples to 
be used in future research. 
 
Step 4: Complete a health check 
Before coming to have a health check, 
we’ll ask you to; 
 
a) eat 1 soy protein bar (each day) for 
the 3 days before the health check 
 
b) collect some urine on the morning of 
your health check.  
 
We’ll give you instructions and a 
specimen pot, along with the soy bars. 
From your urine sample we can tell if 
your gut produces equol, the compound 
derived from eating soy. 
 
Before coming to the health check, we 
will need you to not eat or drink 
anything other than water for 10 hours, 
as this can affect the blood results.  
 
Health check: During this visit at the 
research facility at the UEA, the research 
team will test your urine sample, 
measure your blood pressure and your 
heart rate and also measure your body 
size. A qualified nurse will then take a 
small FASTED blood sample (between 
2 and 3 teaspoons) to make sure that you 
are healthy. 
 
From your blood sample we’ll be able to 
check some basic blood chemistry e.g. 
whether you are anaemic, and we’ll also 
measure your blood fats (e.g. your 
cholesterol level), and see if your 
kidneys and liver are functioning 
properly. 
 
Finally, once we have collected your 






Step 5: Waiting for the results  
It may take 1-2 weeks for the results of 
the blood test to become available. 
Sometimes blood results can fall outside 
the anticipated range. This does not 
mean you are unwell, it may be perfectly 
normal for you. With our clinical 
adviser, we will discuss the study results 
and whether we need to repeat any tests. 
If our clinical adviser has any concerns 
about your blood results, and thinks that 
your health might be affected by taking 
part, then we will not be able to recruit 
you to the study. 
 
The same will apply if the clinical 
advisor feels that the results of the urine 
test are unusual or if your blood pressure 
needs looking at by your GP. 
 
Notification that you have volunteered 
for this study and all blood and urine 
results will be forwarded to your GP 
(with your consent). 
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From your blood pressure and 
cholesterol we will calculate your future 
heart risk according to the British 
Hypertension Society risk assessment. 
Men who are at mild to moderate risk of 
heart disease over the next 10 years are 
eligible to take part. 
 
What happens if I am eligible? 
You will be invited to take part in this 
study if the screening results are within 
an acceptable range and you meet all the 
listed criteria to take part.  
 
If you accept our invitation to take part, 
we will arrange for you to attend the 
same research facility at the UEA for 3 























by at least 1 week), where our blood 
vessel function measures are made. 
 
Again, we will reimburse your travel 
expenses. 
 
An overview of the measurements that 




Preparing for the trial 
For 3 days before each test-day, we will 
ask you to follow our diet guidelines in 
Table 1 which involves stopping eating 
certain foods (like dark chocolate, 
berries, citrus fruits and soy) and 
limiting the intake of some other food 
and drinks. Our diet guidelines (Table 1) 
include examples of foods and drinks 
you can continue to eat. We can give 






























During the 3 days before your 
assessment visit, we’ll call you to ask  
 
some questions about the food that you 
have eaten the day before and about your 
health. 
  
For 48-hrs before your assessment 
visit, we’ll ask you to avoid strenuous 
exercise (e.g. competitive sports). 
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For 24-hrs before your assessment 
visit, we’ll ask you not to drink alcohol 
and foods that contain caffeine (such as 
tea, coffee, coke, energy drink, hot 
chocolate) and some other foods that 
could interfere with our measures (e.g. 
such as leafy green vegetables, broccoli, 
radishes, carrots, sausages, other 
processed and cured meats and some 
varieties of bottled water); see Table 2 
for details. We’ll provide you with 
bottled water (Buxton) to drink during 
the 24hrs before you attend an 
assessment.   
 
The evening before, we’ll provide you 
with a low flavonoid evening meal 
which you will need to eat at least 10 hrs 
before your appointment. You will then 
be unable to have food or drink 
thereafter, except water (which we will 
provide for you). 
 
Are there any side effects or risks of 
taking part in the study? 
The ‘flavonoid’ compounds in our study 
are found in many foods and products 
(like cocoa, berries, oranges and 
soybeans), that are commonly consumed 
in the UK, and we are providing them in 
doses that you could get from your 
normal diet. The flavonoid supplements 
that we will use are commercially 
sourced food ingredients / plant-based 
food compounds that are fit for human 
consumption. In this respect, we do not 
anticipate any side effects. 
 
It is normal that you may feel some 
discomfort whilst a blood sample is 
taken and there is a slight risk of 
bruising. Using experienced nursing 
staff and trained research scientists 
minimises these risks. 
 
In addition, one of our measures of your 
blood vessel function will involve 
temporarily stopping the flow of blood 
in one arm (for a 5 minute period); 
whilst this test is harmless, it may cause 
some discomfort and tingling in the 
fingers and there is a chance of some 
bruising. 
 
What are the possible benefits of taking 
part? 
There will be no direct benefit to you in 
taking part in this research study. 
However, our results will help increase 
our understanding of flavonoids affect 
blood pressure control. This could help 
design better studies in the future to test 
if these compounds can improve heart 
health.  
 
Will my details be confidential? 
Any personal information (e.g. name, 
address, contact details) supplied by you 
during the study, will be handled by 
trained research staff and will be treated 
as strictly confidential (e.g. stored in 
locked filing cabinets, within a room 
with restricted access). All volunteers 
will be assigned a random 3 digit code 
number when they enrol into the study, 
and all paperwork, samples and results 
will be coded with this number to protect 
their identity. Any documents that link 
your name to this code will be stored 
securely in locked filing cabinets which 
are only accessible to the Chief 
investigator; delegated members of the 
research team and regulatory bodies for 
audit/monitoring purposes. Personally 
identifiable information and study 
results (coded with a 3 digit number) 
will be held in separate locations (so that 
you cannot be linked to the results). Any 
transfer of raw data from our tests, 
which may be provided to our product 
suppliers to establish product 
effectiveness, will be fully anonymised 
(e.g. not be traceable to volunteers). Any 
data we hold, or results we generate 
from your involvement during the study 
will be used for the purpose of this study 
and only the averaged results across 
participants will be reported (protecting 
your identity). The biological samples 
we collect will be analysed within 5 
years from collection and disposed 
safely within this time. Data from the 
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study will be used for up to 10 years 
after collection and disposed of 
according to UEA confidential 
information disposal routes.  
 
For those also consenting to the future 
use of their samples and / or data, 
appropriate ethics committee approval 
will be sought prior to use of these 
resources.  
 
Is there any insurance arranged? 
Yes, if you are harmed by the negligence 
of anyone in the research team.  
 
What will happen to the results of the 
research study? 
The results of this research study will be 
published in scientific journals and 
presented at national and international 
scientific meetings.  
 
It is our policy to provide the volunteers 
who take part in the study a summary of 
our findings for the whole study 
population. We do not report on the 
findings of individuals alone. 
 
Who has reviewed the study? 
The research study has been approved 
by the Research Governance Committee 
at the Norfolk & Norwich University 
Hospitals NHS foundation trust and the 
NRES Committee East of England - 
Norfolk ethics committee. 
 
Expense Payments 
You will be reimbursed for travel 
expenses incurred as part of the study. 
Expenses include travel to and from 
UEA on production of a receipt or at 
45p/mile for private cars (up to a 25 mile 




Please be aware that travel payments are 
liable to tax, and the University of East 
Anglia is not responsible for informing 
the Inland Revenue. 
 
Contact for further information 
If you would like further information 
about the study then you can contact the 
study team at: 
 
fastcheck@uea.ac.uk 
Tel: 01603 591063 
 
Please complete the reply slip overleaf 
(p13.) and return it in the PRE-PAID 
envelope provided if you wish to take 
part in this study. 
 
Thank you for showing interest in 
this study. 
 
An expression of interest does not 
commit you to take part! 
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Foods to avoid Restrict 
Alternatives (*see table 2, for foods to be 
avoided 24hr before assessment)  
Fruit: including fruit juices and products (e.g. desserts, jams, yoghurts) containing: 
Citrus fruit – for example: oranges and 
tangerine / satsuma, grapefruit, lemon, lime 
and mixed tropical fruit items 
Berry fruit – for example blackberry, 
blueberry, strawberry, raspberry, 
cranberry, blackcurrant, redcurrant  
Other fruit -  Black / red grapes, raisins, 
plum, prune, cherry, pomegranate  
Apple 
Nectarine 
Nuts (e.g. almond, hazelnut, 
peanut, macadamia nut, 
walnut, cashew nut, chestnut, 
pecan nut) 
1 per 3 days 
2 per 3 days 
2 handful per 3 days 
 
Mango, banana, melon, pineapple, kiwi, pear, peach apricot, 
green grapes, fig, date gooseberry, avocado 
Vegetables, salad and products (e.g. quiche, pizza, casserole) containing: 
Broad bean, red onion, aubergine, red 
cabbage, red skinned potatoes, purple 
carrot 
Black bean and black olives 
Kidney beans 
Garlic cloves 
2 handful per 3 days 
1 handful per 3 days 
4 per 3 days 
Onion (excluding red), shallot, green bean, tomato, broccoli*, 
carrot*, cauliflower*, celery*, cucumber*, peas, leek, 
green/white cabbage*, potato (excluding red skinned)*, 
pumpkin, radish*, parsnip, pepper, beetroot*, lentil, sweet 
corn, lettuce*, Brussels sprouts*, green olive 
Other foods: including products (e.g. drinks, desserts, vegetarian meat alternatives) containing the following: 
Dark chocolate, baking chocolate and cocoa 
products 
Soy, soy milk and soy containing products 
(e.g. quorn, tofu) 
Cider, red wine 
 
White or milk chocolate 
Oily fish (e.g. tuna, 
mackerel, kippers, salmon, 
sardines, herring) 
2 chunks per 3 days 
1 portion per 3 days 
Sugar based and/or dairy desserts and snacks, egg based 
desserts (e.g. plain biscuits, cereal bar, ice cream, custard) 
Milk and milk containing products (e.g. non berry fruit 
yoghurt, cheese) 
Water, carbonated drinks (e.g. coca-cola, sprite), beer, white 
wine, spirits 
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Table 2: Further food restriction 24 hrs prior to each assessment visit 
Foods to avoid for 24hr (*In addition to Table 1) Alternatives 
Vegetables, salad and products (e.g. quiche, pizza, casserole) containing: 
Beetroot, broccoli, cabbage, carrot, cauliflower, celery, 
cucumber, lettuce, Brussels sprouts, parsley, potato, radish, 
spinach 
Onion (excluding red), shallot, green bean, tomato, peas, leek, 
pumpkin, parsnip, pepper, lentil, sweet corn, green olive 
Other foods: including products (e.g. roll, sandwich) containing the following: 
Drinks containing caffeine e.g. tea, coffee, hot chocolate, coke, 
energy drinks (such as RedBull)  
Drinks containing berry fruit and citrus fruit (including 
cordials) 
Bottled water (excluding Buxton mineral water)  
Drinks / foods containing alcohol 
Cured and canned meat (e.g. bacon, ham, sausages, corned 
beef) 
Smoked fish 
Milk (excluding soya milk), Buxton water (provided by the 
researchers for the 24hr before you attend an assessment visit) 
Fresh meat (e.g. chicken, turkey, beef, pork, lamb) 
Fresh fish (excluding oily fish) 
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Are the cardiovascular responses of participants at 
mild to moderate cardiovascular risk influenced by 
dietary flavonoid sub-class and dietary form? 
 
I am interested in taking part and/ or finding out more information about this study 







Date of Birth: 
 
  
  Can we contact you this 
way? (please tick) 
 
 
 YES NO 
 
Daytime telephone no: 
 
   
 
Evening telephone no: 
 
   
 
Mobile phone no: 
(if applicable) 




   
Please return this form in the pre-paid envelope provided to: 
Peter Curtis – Flavonoids, blood pressure control and blood vessel function  
Clinical Research and Trials Unit 
MED2 building 
Chancellors Drive 
University of East Anglia 
NR4 7TJ 
Expressing an interest does not commit you to taking part in the study! 
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C.3 List of prohibited medications during the trial 
 















































































































































































































































maleate)    
 






























































      
 




Fluvastatin Lescol XL 
(Fluvastatin) 






Zocor (Simvastatin)         
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Antibiotics 








Cefazolin Ceftriaxone Cloxacillin Phenoxymethylpenicillin Procaine 
benzylpenicillin 
Cefotaxime 
Ceftazidime Imipenem + 
cilastatin 




Azithromycin Chloramphenicol Ciprofloxacin Doxycycline Erythromycin Metronidazole 
Nitrofurantoin Spectinomycin Sulfamethoxazole 
+ trimethoprim 
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C.4 General health and lifestyle questionnaire (HLQ)  
 
Please fill in the questionnaire below: 
 
 DAY MONTH YEAR 
Date questionnaire 
completed 
         















Daytime telephone no. Evening telephone no. 
Mobile telephone no.  E-mail address: 
Best method (e.g. landline, mobile, e-mail) and time to contact you: 
Date of Birth: Age today 50 - 75yrs? Proceed?           
Yes    /    No 
 Office use only 
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Q: Question, A: Answer 
 
Q. Do you smoke?  
If you are an ex-smoker, when did you stop? 
A. 
BRIEF MEDICAL HISTORY 
Q. Has your doctor told you that you suffer from heart disease (e.g. Angina), stroke or 
any other disease of the circulation (i.e. Reynaud’s disease)? 
A. 
 
Q. Has your doctor diagnosed you as having high blood pressure (hypertension)?  
A. 
 
Q. Has your doctor diagnosed you as having high cholesterol?  
A. 
Q. Has your doctor diagnosed you as having diabetes (either type 1 (insulin dependent) 
or type 2 (age-onset diabetes))?  
A. 
 
Q Has your doctor diagnosed you with cancer? 
A. 
Q. Has your doctor told you that you suffer from any other illness (e.g. illness related 
to kidney, stomach, colon, brain, thyroid, or liver)? 
A. 
Q. Do you have any known food allergies? Any other allergies?  
A. 
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MEDICATIONS 




Q. Have you been prescribed blood pressure medications (e.g. alpha blockers, beta 




Q. Have you taken antibiotics (either oral or topical) within the last 3 months? 
A. 
 
Q. Have you been vaccinated (including the flu vaccination) within the last 3 months? 
A. 
 
Q. Do you have any vaccinations planned (including the flu vaccination)? 




Q. Are you currently on any long-term medication; including aspirin / steroids, 
antihistamines, anti-inflammatory medication, pain relief? 
A. 
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Dietary intake and supplement use 
Q. Do you take minerals/vitamins or ‘dietary’ supplements (containing flavonoids)?  





Q. Do you regularly consume any of the following; 
Dark chocolate, baking chocolate and other rich sources of cocoa (e.g. hot chocolate, 
chocolate desserts), soy food and products? 





Q. Do you regularly consume berries (such as blueberry, raspberry, blackberry, 
black/redcurrant, strawberry, cranberry), and citrus fruits/ juices (such as orange, 
grapefruit, tangerine, satsuma, lemon)? 




Q. Do you regularly consume red wine/cider? 
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Q. Do you regularly consume any of the following;  
Apples, milk and white chocolate, nuts (e.g. almond, hazelnut, pecan nut, peanut, 
macadamia nut, walnut, cashew nut, and chestnut), garlic, black and kidney beans, 
olives, oily fish (e.g. tuna, mackerel, kippers, salmon, sardines, and herring)?  





Q. Do you regularly consume coffee? 
 If so, please estimate how many cups per day. 
A.  
 
Q. Do you regularly consume tea?  
If so, please estimate how many cups per day. 
A.  
 
Q. Do you regularly consume any of the following; 
Broccoli, beet, cabbage, carrot, cauliflower, celery, cucumber, lettuce, brussel sprouts, 
parsley, potato, radish, spinach? 
 If so, please estimate how much you eat, and how often (per week). 
A.  
 
Q. Do you regularly consume canned and cured meats such as sausages, bacon, ham, 
hot dogs, corned beef and smoked fish? 
If so, please estimate how much you eat, and how often (per week). 
A. 
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Q. Do you drink alcohol?     
(how many units per week; see below *for answer) 
A. 
*A unit of alcohol is defined as: about half a pint (300ml) of ordinary-strength (around 3-
4% alcohol) lager, beer or cider,  
 a 25ml pub measure of spirit or a small glass of fortified wine, such as sherry or 
port (17.5% ABV),  
 a small glass (125 ml) of 8% ABV wine.  
NB: Alcohol content has increased in popular drinks; e.g. A typical (175ml) glass of 





Q. Have you been involved in a dietary intervention trial in the last 6 months? Or a 













































Is the volunteer eligible to proceed in the trial? YES    NO  
Name of scientist / research nurse (PRINT): ……………………………………. 
 
 
Signature of the scientist / research nurse: ……………………………………… 
 
 
 D D M M M Y Y Y Y 
DATE:          














Please remember to keep the wrappers from the soy bars, and return 
them to the study team.  
Please collect you’re urine sample ‘mid-stream’ – instructions are 
provided below.  
 
1. Please complete the following by circling the correct answers:  
 
 Task 
Did you consume the 
bar? 
Did you keep 
the wrapper? 








Day 1 Eat Soy 
bar 1 
YES NO   
Day 2 Eat Soy 
bar 2 
YES NO   
Day 3 Eat Soy 
bar 3 
YES NO   
     
 Task 
Did you collect a urine 
sample? 
Was this a 
mid-stream 
collection? 


















REC Study ID: 
11/EE/0233 
 Volunteer 
Study ID:   
   
  
 209 
A mid-stream urine sample is collected as follows: 
Pass 1 to 2 seconds of urine into the toilet as normal, then without stopping the flow of 
urine, catch the rest of the urine into the bottle provided. If you fill the container, finish 
off passing the rest of your urine into the toilet as normal. 
 
Office use:  
 
Name of scientist / research nurse (PRINT): ……………………………………  
 









 D D M M M Y Y Y Y 
DATE:          
E.g. 0 1 J A N 2 0 1 1 
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C.6 24hr dietary recall sheet 
 
 
VOL_ID: Date:                                                                                     Day of week (circle below) Typical? 
(circle) 
Other important detail: 
 








location Food item – identify full description, 
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Instructions to the researcher 
The recall should follow these steps 
1. Snapshot- Volunteer is asked to recall main meals, food and beverages 
consumed the day before the interview (morning to morning).  
2. Playback – recall the foods consumed back to the participant – remembering 
to include time and location; 
a. Look for long gaps between eating events and ask specifically about this 
b. Look for food items that are usually eaten together i.e. toast + fat spread + 
preserve  
c. Drinks, snacks, accompaniments (i.e. sauce, salt, pepper), alcoholic 
beverages are often missed – ask about these if they are not on the list 
3. Detail Cycle - For each food, a detailed description, amount eaten, and additions 
to the food are collected.  
4. Usual dietary practices / forgotten Foods – volunteer is asked about their 
normal eating habits, with the intention to cross-reference normal habits against 
reported 24hr intake. Consumption of foods commonly forgotten during the 
snapshot and probes will be used as time and eating occasion are collected for 
each food (See table 1 below)  
5. Final Probe - Additional foods not remembered earlier are collected (further 
probe questions) 
 
List of questions for further food intake detail: 
Select 
(√)   
List of probes questions (for all questions, cross-check responses against 
reported 24hr intake) 
 Do you normally eat breakfast? Did you do that yesterday? 
 Do you drink hot drinks? If so, what type and how many do you usually have? Did 
you drink that many yesterday?  
 Do you drink milk in hot drinks and / or on cereal? What type?  
 Do you add sugar / artificial sweetener to hot drinks? If so, what type and how 
much? 
 Do you normally have biscuits or snacks with hot drinks? If yes, did you do that 
yesterday? (cross check with dietary restrictions) 
 What fat spread do you use? Do you add this to sandwiches etc.  
 What oils do you cook with? Do you deep fry items? 
 Do you tend to buy full fat, reduced fat or low fat foods? Were any of the foods you 
ate yesterday any of the reduced or low fat type?  
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 Did you drink any alcohol yesterday? Do you usually drink? What kind (e.g. beer, 
red wine)? How much in glasses/ pints? Did you go to bar/café/ pub yesterday?    
 Was the amount of food consumed on the recall day more than usual, usual, or 




Restricted foods cross-check: 




during last 3d 
Berries, berry products (e.g. Blueberry, strawberry, 
raspberry, cranberry, blackcurrant, redcurrant), 
If yes, which; 
 
Or any of the following fruit and vegetables: 
Black / red grapes, raisins, plum, prune, cherry, 
pomegranate, Broad bean, red onion, aubergine, red 
cabbage, red skinned potatoes, purple carrot 














Citrus fruits (e.g. orange, tangerine, satsuma, 
Clementine, grapefruit, lime, lemon) 
If yes, which; 
 
Yes No  
Soy and soy based products (e.g. soya milk, soya 
spreads, tofu, vegetarian meat) 
If yes, which; 
 
Yes No  
Dark chocolate and cocoa products 
If yes, which; 
 








during last 3d 
Red wine or tea? 
If yes, which; 
 
Yes No  
Oily fish (e.g. tuna, kippers, mackerel, salmon, 
sardines, herring) 
If yes; which: 
 
 




Name of scientist / research nurse (PRINT): ……………………………………  
 
Signature of the scientist / research nurse: ……………………………………… 
 D D M M M Y Y Y Y 
DATE:          
E.g. 0 1 J A N 2 0 1 2 
 
 
 
 
 
 
